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Abstract 
 
Society’s strong dependence on fossil fuels and petroleum-based products leads not only to a rapid 
decline of natural oil reserves but contributes massively to global warming and environmental 
damage. This consequently urges society to look into more sustainable alternatives. 
Microorganisms present such sustainable alternative if converted into so-called microbial cell 
factories. Instead of crude oil, cell factories use renewable resources or waste products as source 
material. The challenge is, however, that microbial production needs to be economically feasible 
to compete with the classical chemical production. The development of a microbial cell factory 
typically takes up to 8 years of research and costs over $50 million. The production and selection 
of heterologous pathway proteins are major bottlenecks encountered in the construction of a cell 
factory. Thus, new approaches for the optimization of recombinant protein production and 
screening techniques with high capacity for the identification of the best performing enzymes are 
continually developed. 
 
This thesis aims to equip researchers with a fundamental knowledge about protein biosynthesis 
necessary for the understanding of protein production bottlenecks. Moreover, the thesis guides 
through the possible causes of low protein yields and presents available approaches for 
optimization of the protein and the host.  
 
The main work presented in this thesis provides and applies a new synthetic biology approach for 
the optimization and selection of recombinant proteins. A major bottleneck during production is 
translation initiation. By creating sequence libraries of the translation initiation region, protein 
production can be improved substantially in Gram-negative and Gram-positive bacteria. The 
design of versatile and tuneable translational coupling devices and their fusion to antibiotic 
selection markers enables subsequent selection of high-expressing constructs. The approach is a 
simple and inexpensive alternative to advanced screening techniques. In addition, a second 
synthetic biology approach provides the means for fast and efficient plasmid backbone swapping 
and is a versatile tool for the design and construction of optimal protein production constructs. 
 III 
Dansk resumé 
 
Samfundets stærke afhængighed af fossile brændstoffer og oliebaserede produkter fører ikke kun 
til et hurtigt fald i den naturlige oliereserver, men bidrager også kraftigt til global opvarmning og 
forurening. Dette motiverer derfor forskere til at undersøge mere bæredygtige alternativer. 
Mikroorganismer repræsenterer et sådant bæredygtigt alternativ, når de omdannes til såkaldte 
mikrobielle cellefabrikker. I stedet for råolie bruger cellefabrikker vedvarende ressourcer eller 
affaldsprodukter som udgangsmateriale. Udfordringen er, at mikrobiel produktion skal være 
økonomisk bæredygtig for at konkurrere med den klassiske kemiske produktion. Udviklingen af 
en mikrobiel cellefabrik tager typisk op til 8 år og koster $50 millioner. Produktionen af heterologe 
pathway proteiner samt den efterfølgende udvælgelse af gode kandidater er en flaskehals, der 
opstår ved konstruktionen af en cellefabrik. Nye tilgange til optimering af rekombinante 
proteinproduktions- og screeningsteknikker med høj kapacitet til identifikation af de mest 
effektive enzymer udvikles løbende. 
 
Denne afhandling har til hensigt at give forskeren en grundlæggende viden om proteinbiosyntese, 
der er nødvendig for at forstå flaskehalse i proteinproduktionen. Desuden guider afhandlingen 
gennem de mulige årsager til lave proteinudbytter og præsenterer tilgange til optimering af 
proteinet og værtorganismen. 
 
Hovedarbejdet i denne afhandling giver og anvender en ny syntetisk biologi tilgang til optimering 
og udvælgelse af rekombinante proteiner. En stor flaskehals under produktionen er 
translationsinitiering. Oprettelsen af sekvensbiblioteker kan forbedre proteinproduktionen 
væsentligt i Gram-negative og Gram-positive bakterier. Udformningen af alsidige og tuneable 
translationelle koblingskassette og deres fusion til et antibiotikaresistensgen muliggør 
efterfølgende udvælgelse af konstrukter med højeste ekspression. Tilgangen er et simpelt og billigt 
alternativ til avancerede screeningsteknikker. 
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 1 
Introduction and thesis outline 
In today’s world, the society strongly depends on petroleum-based products. Those are derived 
from crude oil and comprise gasoline, jet fuels and diesel fuels but also daily products, such as 
textiles, medicines and cosmetics1. In the Key World Energy Statistics from 2017 the International 
Energy Agency highlights trends in energy production and use2. They find that crude oil 
production has grown from 2,869 Mt in 1973 to 4,321 Mt in 2016. These numbers are indicative of 
a higher dependency on oil which is accompanied by a decline of natural oil reserves. However, 
dwindling oil supplies are not the sole problem society is facing: a petroleum-based industry also 
produces huge amounts of greenhouse gases contributing to global warming and environmental 
damage. In the same report CO2 emission from fuel combustion increased from 15,458 Mt of CO2 
in 1973 to 32,294 Mt of CO2 in 2016.  
 
These negative consequences of petroleum-based sources are extremely worrying for our planet’s 
future and urge society to look into more sustainable alternatives. This was highlighted at the 
2015‘s General Assembly of the United Nations (UN) where the UN members adopted a set of 
sustainable development goals that should be achieved in the next 15 years3. Sustainable 
development means meeting the needs of today’s society without compromising those of future 
generations4. Among other items, the assembly concluded that we need to ensure “sustainable 
consumption and production patterns” by “encourage[ing] companies […] to adopt sustainable 
practices”3. Here, the focus ought to be bio-based and sustainable production. Sustainable 
production describes a production process that minimizes waste output and pollution, by e.g. 
recycling, that conserves natural resources and minimizes energy input while still being 
economically feasible5. 
 
Among other sectors, pharmaceutical and chemical industries are looking for sustainable 
alternatives to produce medicine and chemicals, respectively6. Microorganisms present such 
sustainable alternatives that show great promise to replace petroleum-based production. Thus, 
dedicated research groups have made it their task to convert microorganisms into so-called cell 
factories for production of high-value compounds, such as medication, but also bulk chemicals, 
biofuels and -plastics, using renewable resources or waste products. For thousands of years, 
microorganisms have already been used in the production of beer, bread and cheese. More recent 
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examples of microbial production include the production of recombinant human insulin in 
Escherichia coli and Saccharomyces cerevisiae7, the production of opioids and the anti-malarial drug 
artemisinin in S. cerevisiae8,9, the production of therapeutical proteins and biofuels in E. coli10,11, the 
production of industrial enzymes in Bacillus subtilis12 or the production of industrial compounds 
or therapeutical proteins in Lactococcus lactis13. 
 
However, the challenge here is that microbial production needs to be economically feasible to 
compete with classical chemical production14. This requires a long process of developing and 
optimizing a microbial cell factory. Optimization and development can be seen as a cycle going 
through analysis and engineering of the strain, which is called metabolic engineering15. Very often 
protein production represents the major bottleneck in this process. 
 
 The work conducted in this PhD thesis aims at optimizing protein production in bacterial cell 
factories by using synthetic biology approaches. For this reason, the thesis focuses on tool 
development for protein production optimization that can be applied in the engineering part of 
the metabolic engineering cycle. The thesis is divided into three introductory chapters, where 
concepts of synthetic biology, cell factory design and engineering and protein production, which 
are important for the understanding of this thesis, and protein production optimization in general, 
are explained.  
 
Chapter 1 gives an introduction to the field of synthetic biology and its impact on recombinant 
protein production. Furthermore, the chapter introduces the concept of a cell factory and the 
metabolic engineering Design-Build-Test paradigm, and shows how protein production 
optimization can be part of it. 
 
Chapter 2 comprises the fundamental biological processes of protein biosynthesis including 
transcription, translation and finally protein folding and targeting. A comprehensive knowledge 
of these fundamental processes is necessary to understand engineering approaches for protein 
production optimization.  
 
In Chapter 3 the importance of recombinant protein production in the creation of cell factories is 
elucidated, its bottlenecks and several techniques and approaches for optimization are introduced. 
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The need for fast and simple universal technologies for the optimization of protein production in 
bacteria fuelled the work presented in this thesis. Papers 1 to 4 detail the work conducted in this 
regard in form of submitted manuscripts or published articles.  
 
In this thesis, an experimental tool for the optimization of protein production was developed. 
Utilizing translation initiation sequence libraries in combination with an antibiotic selection-based 
screening technology, protein production levels have been raised substantially (Paper 1 and 2). 
This method was initially implemented for the Gram-negative bacterium E. coli but in addition was 
successfully applied to the Gram-positive hosts B. subtilis and L. lactis (Paper 3). Paper 4 contains a 
published article introducing a synthetic biology standard for the rapid exchange of parts. This 
tool demonstrates to be a useful for protein production optimization. It allows for an easy exchange 
of elements that affect protein production, such as gene copy number or the burden of an antibiotic 
resistance marker. Two appendices give short insights into the application of the first synbio 
approach for the optimization of expression of an operon and for the optimization of expression 
on the genome of E. coli. 
 4 
Chapter 1: A new era of biotechnology 
Biotechnology is an interdisciplinary field of science that describes the application of engineering 
principles to biological organisms and processes. Biotechnology dates back several thousands of 
years when the yeast Saccharomyces cerevisiae was used in fermentation processes for the production 
of beer, wine and bread, as well as when people produced cheese and yoghurt with the help of 
lactic acid producing bacteria. In the beginning of the 20th century Charles Weizmann established 
the field of industrial biotechnology by producing acetone and butanol at large-scale by 
fermentation of the bacterium Clostridium acetobutylicum16. About 20 years later, in the 1940s, some 
years after its discovery, the mass production of penicillin in microbes demonstrated the potential 
of biotechnology in the medical field. Later on, the production of synthetic human insulin in 
Escherichia coli paved the way for its medical and pharmaceutical application17. In the 1980s 
synthetic human insulin became the first approved genetically engineered pharmaceutical 
product18,19. 
 
Since the beginning of the 21st century the field of biotechnology expanded quickly. 20 years after 
the launch of synthetic human insulin by one of the first biotech companies, Genentech20, more 
than 1500 biotech companies existed in Europe and about 1300 in the US21. The negative 
consequences of the petroleum-based industry, such as global warming and environmental 
damage, urge scientists to focus on more sustainable alternatives. Therefore, modern 
biotechnology branches into many different areas, not only in the before mentioned industrial and 
medical field, but also in the environmental, agricultural and marine area. All fields have a 
common interest in harnessing biological processes to improve living conditions on our planet for 
today’s and future generations. This includes reduction of our environmental footprint, the use of 
clean fossil-independent energy, e.g. biofuels, and the mitigation of the green house effect22,23. It 
also comprehends the cheap production and fast development of efficient medication for 
healthcare improvement, tackling also problems such as antibiotic resistance. It includes ensuring 
sufficient food supply by increasing yield and enhancing nutrition content. The general use of 
renewable resources and waste products for the production of such is anticipated6. 
  
 5 
1.1 A brief history of synthetic biology and its impact on recombinant 
protein production 
Synthetic biology plays an important role in this new era of biotechnology and emerged in parallel 
with the latter. Consensus on a precise definition of synthetic biology has not yet been reached but 
it is generally agreed that it originates from the idea that engineering approaches can be harnessed 
to study and manipulate cellular systems. The study and manipulation of cellular systems has also 
substantially influenced the field of recombinant protein production (Figure 1A)24. And vice versa, 
detailed knowledge about the central processes of protein biosynthesis enabled successful 
manipulation of cellular systems. 
 
The discovery of transcriptional regulation in the lac operon, that was described in detail by Jacob 
and Monod in 196125, pointed towards a possibility of programmed gene expression. With 
inventions such as molecular cloning26–28 and DNA amplification by polymerase chain reaction 
(PCR)29 this vision got closer to reality. In 1977, the first recombinant human protein, somatostatin, 
was synthesized in E. coli30. When in the 1990s, the process of DNA sequencing became automated31 
and together with the development of computational tools enabled whole genome sequencing32,33, 
the potential to manipulate microorganisms and to generate recombinant DNA was obvious34. 
 
Advances in systems biology enabled the examination and engineering of organisms in 
computational networks35,36. Data for those networks was collected with high throughput 
techniques that analyzed protein, lipid, metabolite and RNA content of cells. These studies are 
generally entitled as ‘omics’ studies. ‘omics’ is a neologism that comprises scientific studies ending 
in –omics, such as genomics, proteomics, lipidomics, metabolomics or transcriptomics. Following 
a computational analysis, cellular processes can be rationally manipulated34,37 (Figure 1B). The 
advent of the omics era constituted an equally important driving force for recombinant protein 
production optimization. The sudden availability of thousands of protein sequences with 
unknown function demanded new approaches to produce those proteins in high quantity and 
quality for functional and structural characterization38.  
 
In parallel, standard molecular parts for regulating biological networks were developed34. In the 
beginning of the 21th century, the first synthetic genetic circuits were constructed34,39,40. Those 
circuits were inspired by electronic circuits and were designed to perform logical functions. The 
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workflow to build these circuits became a characteristic feature of synthetic biology tool 
development34: after an initial design phase, the circuit is physically constructed, and following 
experimental measurements, the system is adjusted to fit the hypothesized characteristics. This 
process is similar to the Design-Build-Test engineering paradigm described in section 1.2.1 and 
was applied for the tool development in this PhD thesis.  
 
To simplify the design and evaluate the performance of new circuits a standardized way of storing 
and assembling parts was anticipated34. The Registry of Standard Biological Parts (RSBP) was 
developed to catalogue those genetic parts as ‘BioBricks’34,41,42. However, the development of new 
one-step DNA assembly methodologies, such as Golden Gate cloning43, Gibson assembly44 or 
Uracil Excision Cloning45,46, made standardization of parts assembly difficult, which is the reason 
why part registries such as RSBP now serve more as a sequence databases34. The development of 
new DNA assembly methods also influenced the field of recombinant proteins production 
allowing for more rapid construction and higher throughput. 
 
 
Figure 1: Comparison of the developments in synthetic biology and recombinant protein production judged by 
publication numbers. (A) Developments in synthetic biology are compared with recombinant protein production 
in general and with protein production optimization in specific. (B) The developments in the field of omics and the 
implementation of CRIPSR/Cas9 are compared with the development of synthetic biology. 
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However, synthetic biology anticipated to go beyond circuit engineering and envisioned 
characterization and engineering of whole organisms, to convert them into cellular devices capable 
of diagnosing diseases, fixing genetic defects or cleaning up environmental pollutants34,47. The rise 
of genome engineering technologies48 as well as advanced DNA-assembly techniques43–45 and a 
dramatic price-drop in DNA synthesis and sequencing49, paved the way towards those future 
goals34. The emergence of de novo DNA synthesis also revolutionized recombinant protein 
production. Suddenly, restrictions to source material, such as pre-existing DNA templates, were 
removed and the possibility to synthetically design genes and to create novel functions and circuits 
arose24.  
 
In 2010, Gibson et al., synthesized and assembled a 582 kb genome for a viable Mycoplasma cell50,51. 
In another demonstration of genome-scale synthetic biology, Pósfai et al. reduced the genome of E. 
coli by 15 % resulting in a strain with enhanced electroporation efficiency and plasmid stability52. 
Likewise, the reduction of L. lactis genome had beneficial effects on recombinant protein 
production levels53.  
 
A platform for multiplex automated genome engineering (MAGE), which was developed in the 
Church lab54, forms the basis for rapid and small modification, such as amino acid replacements, 
RBS modifications or promoter exchanges, in multiple loci of the E. coli genome. Homologous 
recombination provides the basis for larger genomic modifications on the genome, however, its 
efficiency is especially low in E. coli, the model bacterium for synthetic biology and recombinant 
protein production. Thus, systems from other organisms, such as  λ-red recombination system, are 
supplied to facilitate engineering efforts in the E. coli genome55,56 (see chapter 3.2). Nevertheless, 
the low efficiency requires the simultaneous insertion of a selectable marker, which cannot be 
removed scarlessly afterwards. Alternatively, Cre recombinase-assisted genome engineering 
(RAGE)57 or I-SceI endonuclease cleavage can be used to enhance site-specific recombination58. Zinc 
finger nucleases (ZFNs)59 and transcription activator-like effector nucleases (TALENs)60 
revolutionized genome editing in mammalian cells61,62. A few years later, the application of the 
CRISPR/Cas9 system for genetic manipulations started a “new era of genome integration”63. 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated 
genes (Cas9) are essential in the bacterial adaptive immunity. The system can be hijacked to achieve 
site-specific DNA recognition and cleavage through the programmable endonuclease Cas964,65. 
CRISPR/Cas9 assisted λ-red recombineering and MAGE enable the construction of desired strains 
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scarlessly and in a very short time frame66–68. Acceleration of genome engineering enabled easy 
manipulation of living cells to optimize protein folding, secretion and enable post-translational 
modifications (see Chapter 3.5). With those new technologies available the construction of a 
minimized genome can be done within months instead of years69. Despite all advances 
contributing to genome engineering, Pines et al. claim that with the decreasing costs of DNA 
synthesis, one may consider synthesizing a complete genome rather than having multiple 
engineering steps70.  
 
In recombinant protein production setups, transcriptional control through transcription factors 
and the use of different promoter sequences preceded the synbio era71, although more recent 
approaches in synthetic biology extent the engineering possibilities to optimize protein 
production24 (Figure 1A). Engineered transcription factors represent useful sensors and switches 
for metabolic engineering and protein production. They facilitate the design of new synthetic gene 
circuits that can e.g. increase population homogeneity in protein production setups. Recently, a 
recombinase feedback loop for robust protein expression was introduced supporting homogenous 
expression in a population72. Additionally, novel synthetic promoters or promoter libraries can be 
designed to control and tune gene expression24. This can also be done using RNA polymerases, so 
that toxic effects are prevented73,74. Toxicity often occurs when the cell cannot handle the protein 
load resulting in aggregation. The Stephanopoulous laboratory demonstrated that engineering of 
the endogenous E. coli RNA polymerase led to higher tolerance and increased protein production 
titers73. In another recent publication, artificial small RNAs regulate the T7 RNA polymerase and 
thus enhance soluble recombinant protein production in E. coli75.  
 
On the level of translation, creating synthetic RBS libraries allows researcher to tune translation 
rates. With this approach, optimal expression constructs could be identified in many cases54,76. 
Apart from that, synthetic biology approaches enable the engineering of the translated content. For 
instance, the engineering of aminoacyl tRNA synthetases allows for the incorporation of unnatural 
amino acids into a protein sequence77,78. Common applications of this synthetically expanded 
genetic code are light-induced crosslinking for protein-protein interactions or conformational 
changes, but also the light-activation of biochemical pathways through photocaged enzymes79. 
Moreover, unnatural amino acids can be incorporated in directed protein evolution experiments 
for novel or enhanced functions and, specifically immunogenic amino acids, in the synthesis of 
therapeutic proteins80. Liu et al. demonstrated the use of unnatural amino acids as transcriptional 
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on- and off-switches in E. coli81, a useful tool for homogenous protein production and regulation of 
metabolic pathways. In general, however, engineering of the ribosome appears to be necessary to 
make incorporation of unnatural amino acids an efficient process. To not interfere with cell 
viability, Rackham and Chin created an orthogonal ribosome which only translates orthogonal 
messenger RNA and does not crosstalk with the native translation processes82. Ribosome 
engineering advances were recently reviewed by Liu et al.83.  
 
1.2 Metabolic engineering 
Metabolic engineering is the science in which the engineering principles of synthetic biology, e.g. 
control circuits, are combined with decades of basic research to enable sustainable production of 
products extending from fuels and chemicals to food, feed and pharmaceuticals34,84. The natural 
metabolic network of a cell is generally not evolved for those practical applications. Therefore, 
cellular processes need to be modified and improved for certain needs15. Engineering of cellular 
processes can be either hypothesis-driven running through a Design-Build-Test cycle, which is 
elaborated on in 1.2.1, or evolution can be harnessed to reach an anticipated goal (section 1.2.2). 
Metabolic engineering of a protein production host, e.g. the regulation of carbon fluxes or the 
prevention of acetate accumulation, has proven to increase protein production levels. The over-
expression of a recombinant protein interferes with the metabolism of a cell, e.g. by over-
consuming the materials and energy coming from the TCA cycle, which finally results in an 
accumulation of acetate85. 
 
1.2.1 Design-Build-Test cycle 
The construction of a cell factory is a time consuming and laborious process that iteratively cycles 
through designing, building and testing a certain metabolic strategy (Figure 2). Despite all 
advances over the years, the development of a new cell factory requires typically 6 to 8 years of 
research and over $50 million84.  
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Figure 2: The Design-Build-Test-Learn cycle. In the design phase, the host, pathway and anticipated modifications 
are defined. In the build phase, the pathway is assembled. With screening approaches and analytical methods, the 
performance of the cell factory is evaluated in the test phase. In the later introduced learn phase, the data is collected 
and evaluated to improve the design process. (inspired by Petzold et al.86) 
 
The design phase 
In the design phase, strategies are developed that can yield in a cell factory process. Here, 
appropriate strains and enzymes are identified. Hosts are usually selected based on required 
process conditions (temperature, pH, salt, solvent, etc.), strain physiology (growth-rate, product 
toxicity, metabolic versatility, etc.), feed stock and the availability of genetic engineering and gene 
expression tools at hand. The latter makes Escherichia coli and Saccharomyces cerevisiae favourite 
hosts, but recent genetic method developments have opened the option to use less studied hosts 
that possess desirable traits, such as product tolerance, or unique metabolic pathways87. Still, we 
are a long way from having synthetic biology tools that performs robustly in non-model 
organisms88.  
 
Similar requirements as for the host apply to the choice of enzymes. Advances in DNA synthesis 
no longer restrict researchers to using genetic material from natural sources, which provides great 
flexibility in the choice of enzymes24. These should perform well under the needed process 
conditions (in terms of temperature, pH, salt concentrations), enable rapid utilization of low-cost 
feedstocks and enable inexpensive product separation through e.g. secretion of the final product88. 
Even the apparent simpler case of enzyme production sometimes requires manipulation of many 
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genes. Identification of suitable proteins is mostly achieved by querying literature and databases 
(e.g. BRENDA, KEGG, EcoCyc or MetaCyc)89,90. Often, complete biosynthetic pathways are 
transferred from the original host to a heterologous host87. This has proven successful for the 
production of complex biochemicals such as opioids and artemisinic acid9,91–93. However, if there 
is not enough information on the biosynthetic pathway enzymes, retro-biosynthesis and pathway 
prediction algorithms, e.g. RetroPath or GEM-Path, can help to bridge the gaps and identify de novo 
production pathways94,95. Nevertheless, retro-biosynthesis is not further elaborated on here as this 
thesis focuses on protein production optimization. Retro-biosynthesis is reviewed in detail 
elsewhere96. To combine variables, e.g. promoter sequences or gene sequences, most efficiently, it 
should be standard practice to implement in silico tools, such as Design of Experiment (DoE) 
methods, in the design phase97. 
 
The use of stoichiometric models, such as genome-scale metabolic models can be very useful in the 
design process. Those models can be used to predict metabolic fluxes and how they are affected by 
genetic manipulation of the host98. Algorithms that predict the effects of gene over-expression, gene 
or reaction knockouts and insertion of heterologous pathways can be combined with genome-scale 
metabolic models99. So-called ME-models (for metabolism and expression) constitute the newest 
generation of stoichiometric models, accounting for protein biosynthesis, e.g. transcription and 
translation processes100,101. Thanks to the on-going development of computational tools, the design 
phase is very efficient and throughput is very high. After the required manipulations to the host 
are identified, the strategies and genetic elements to achieve them need to be designed. The choice 
of DNA assembly techniques and genome-engineering methods will determine the pace of the 
building phase. 
 
The build phase 
In the build phase, the previously identified manipulations, e.g. integration of heterologous 
enzymes, gene knockout or over-expression, are incorporated into the host. Advances in DNA 
synthesis and genome integration allow for the generation of large libraries84,102,103.  
 
Despite the successful integration of heterologous pathways, genes need to be expressed. Gene 
expression can very often be a major bottleneck in metabolic engineering but the development of 
tools for production optimization is progressing. With the ability to vary promoter104–106 and 
translation initiation strength107,108, to optimize stability of the mRNA109,110 and to prevent the 
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resulting protein from aggregating, there are many starting points to alter protein production. 
Chapter 3 discusses in more details the bottlenecks and optimization approaches in protein 
production. Paper 4 of this thesis provides a plasmid backbone series, which allows for fast and 
easy parts exchange and provides the means to optimize production of proteins and biosynthetic 
pathways. We see one application of this toolbox, in the construction of a microbial cell factory. 
 
To overcome physiological limitations, such as product toxicity, enzyme toxicity or insufficient 
substrate utilization, evolutionary approaches show much more capacity than rational 
engineering. Therefore, adaptive laboratory evolution (ALE) can be applied in the build phase. 
ALE is described in more detail in section 1.2.2. 
 
The test phase 
The performance of the constructed strain is evaluated in the test phase. Available screening 
approaches are described in more detail in section 3.6. High-throughput screening approaches are 
preferred to analytical approaches, as the latter are very time-consuming and expensive. 
Furthermore, the relatively low throughput of analytical methods is not applicable for the 
screening of very large libraries. In this thesis, a high-throughput screening tool is developed, 
which provides the means to be applied in the test phase of the construction of a microbial cell 
factory (Paper 1-3). 
 
Apart from protein production and product formation, growth rate, tolerance and mutations will 
be evaluated with the help of omics tools: (i) next-generation sequencing (NGS) permits 
comprehensive validation of the genome of the engineered strain, (ii) RNA-seq analysis can be 
employed to identify up- or down-regulated genes, unintended mutations and other 
transcriptional failures, and (iii)  proteomic assays provide means to quantify of protein levels over 
time, identify pathway bottlenecks and characterize synthetic parts86. 
 
The learn phase 
The learn phase is not always considered a part of the Design-Build-Test cycle. However, it is 
perhaps the most important step to increase the rate of success. With the appearance of efficient 
computational and high-throughput molecular biology techniques, a step needed to be introduced 
to compute the large pool of generated data after each iteration, which can then be used to improve 
the design and build process in the next iteration88,111. It is a robust practise to avoid mistakes or 
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unnecessary steps. Generated omics data can be integrated into genome-scale metabolic models 
and statistical models allow for the analysis of complex data. This data can be used to identify 
trends or patterns that can be helpful for the re-design84. As more and more data is collected, the 
necessity of using sophisticated data-analysis tools, such as machine-learning algorithms for, e.g. 
pathway prediction or automated DoE, becomes more and more important. Being one of the first 
of its kind, a data-driven statistical prediction tool for membrane protein expression levels from 
nucleotide sequence was recently developed112. 
 
1.2.2 Adaptive laboratory evolution (ALE) 
Once a metabolic pathway has been constructed, in most cases further optimization is still 
necessary to increase yield. For this reason, adaptive laboratory evolution (ALE) can be used113. 
Here, the organism adapts to the controlled conditions that it is exposed to. Over time stable 
mutations leading to a beneficial phenotype may accumulate113. NGS can then be used to identify 
which mutations are responsible for the optimal phenotype114. ALE can either be performed in 
serial dilutions or in continuous cultures113. When using serial dilutions, cells are propagated in 
batch cultures. Each time that the culture reaches a certain density, an aliquot is transferred to a 
fresh culture. This iterative process is repeated until cells reach the desired phenotype, e.g. a 
desired growth rate113. Alternatively, chemostat cultures have the advantage that conditions such 
as pH, oxygen levels and cell density are kept constant113. Organisms such as bacteria and yeast 
are normally subjected to ALE as their fast generation time allows for rapid evolution113,115.  
 
ALE has proven to be very efficient for the optimization of growth on non-preferred carbon 
sources, such as glycerol for E. coli116 and xylose and galactose for S. cerevisiae117,118. ALE is also very 
useful in the adaption to environmental stresses such as elevated temperatures119,120 or osmotic 
stress113,121, or in the adaptation to toxic compounds. For example, in the production of biofuels,  E. 
coli needs to obtain tolerance towards organic solvents such as ethanol122,123 or isobutanol124,125. 
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Figure 3: Adaptive Laboratory Evolution (ALE). Strain evolution can either be performed in a serial dilution 
experiment or in a continuous culture in a chemostat. Over time, fitness of the strains will increase as will the 
number of mutations occurring. Evolved clones are isolated and their genome sequenced. Identified mutations will 
be reverse engineered into the original strain to confirm their beneficial effect. (inspired by Dragosits and 
Mattanovich113). 
 
In a recent engineering effort, the tolerance of E. coli towards L-serine was improved by ALE. L-
serine is a very attractive product in fermentation as its theoretical yield from glucose is the highest 
among the amino acids but its high toxicity limits microbial production126,127. The evolved strains 
produced 37 g/L of L-serine, one of the highest reported titers, and improved productivity by 4-
fold compared to the unevolved strain126,127. This tolerant strain was used to further optimize L-
serine production in E. coli by applying an expression library-based optimization and selection 
approach which was developed and applied in Papers 1-3 (see Appendix 1). However, as Atsumi 
et al. previously showed in the case of isobutanol, developing tolerance towards a product does 
not necessarily mean an increase in production titers125. Tolerance could also be achieved by 
degradation of the product.  
 
1.3 Relevant microbial cell factories 
The choice of host is an important step in the development of microbial cell factories as well as for 
protein production setups. Two microbial cell factories dominate the market. Escherichia coli and 
Saccharomyces cerevisiae are by far the most studied organisms with a whole palette of engineering 
tools available and a collection of established products in pharmaceutical, food and 
biotechnological industry. Filamentous fungi, including Aspergillus, Trichoderma, Penicillium and 
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Rhizopus species, are preferred industrial hosts for recombinant protein production. Likewise, 
Bacillus subtilis is a profitable industrial host for protein production thanks to its ability to secrete 
large amounts of proteins. Lactococcus lactis is an increasingly attractive host for the production of 
plant-based proteins, secondary metabolites and membrane proteins. As E. coli and the latter two 
Gram-positive hosts have been used extensively in the studies included in this thesis, a brief 
description of the three hosts will follow. Other selected hosts are summarized in Table 1.  
 
1.3.1 Escherichia coli 
The Gram-negative, facultatively anaerobic, rod-shaped bacterium E. coli is probably the best 
studied and most widely used organism128. E. coli seems to be the ideal candidate for metabolic 
engineering as it has a fast doubling time, possesses metabolic versatility, both, a well-
characterized genome and metabolism and plenty of genetic tools for strain manipulation128. 
Altogether, E. coli has a very long history of use and is a very cheap host for production. Even 
though some E. coli strains might be pathogenic, most are part of the natural human gut flora and 
its products are regarded as safe10. About 30% of recombinant biologics on the market are 
manufactured in E. coli10,128. FDA approved recombinant protein drugs, such as the interferon β-1b 
Extavia (Novartis, 2009) used in multiple sclerosis treatment10, amino acids, bio fuels, organic 
solvents and polymers are produced in E. coli11. Some major drawbacks are the lack of post-
translational modification machineries which carry out common modifications to human 
proteins129, its poor secretion capacity130 and the production of endotoxins128. Endotoxins trigger a 
strong immune response in mammals. They are as relatively thermostable lipopolysaccharides part 
of the cell envelope and are mostly released upon cell lysis.  
 
1.3.2 Bacillus subtilis 
Bacillus subtilis is a Gram-positive, facultatively anaerobic, rod-shaped bacterium found mostly in 
soil12. Some genus can form endospores and thus survive in extreme environmental conditions131. 
B. subtilis is non-pathogenic and does not produce any endotoxin leading to the GRAS status by 
the FDA, which means that B. subtilis can be used during food production12. Currently, B. subtilis 
is the best-characterized Gram-positive bacterium. It is a very attractive organism for protein 
production for several reasons. First of all, Gram-positives contain only one membrane, which 
simplifies protein secretion132. Secondly, due to an intermediate G/C-content, there is no 
pronounced codon bias. And lastly, towards the end of exponential phase B. subtilis becomes 
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naturally competent and generally performs well in homologous recombination, which facilitates 
genome engineering133. Similar to E. coli, B. subtilis has a fast doubling time, possesses metabolic 
versatility and a well-characterized genome and metabolism134. Despite the recent development of 
engineering tools like CRIPSR/Cas9 systems and expression platforms106,135,136 there is still a distinct 
lack of genetic tools for strain manipulation.  
 
1.3.3 Lactococcus lactis 
Lactococcus lactis is a Gram-positive, facultatively anaerobic, spherical-shaped, non-sporulating 
bacterium that was originally isolated from plant13. However, it is mostly associated with dairy 
products13. L. lactis has been used for centuries in food fermentations, especially cheese, yoghurt, 
pickled vegetables and the like. Because of this, L. lactis has GRAS status13. Over the past decades, 
L. lactis has become the model lactic acid bacteria when it comes to expression systems and genomic 
engineering137. Consequently, the application of L. lactis has been expanded from the food industry 
to being a successful microbial cell factory. Currently, the use of L. lactis presents an alternative for 
membrane protein production138, protein secretion139,140 and plant-based protein and secondary 
metabolite production141–143. However, as for B. subtilis, there is a need for more genetic tools for 
strain manipulation. 
 
 
Table 1: Other microbial cell factories 
Organism Characteristics Ref. 
Saccharomyces 
cerevisiae 
• unicellular eukaryote with long history in brewing and baking 
• fast growing organism, well-characterized 
• whole catalogue of engineering tools is available 
• tolerant to high ethanol concentration and low pH 
• complex cellular structure that allows for compartmentalization and is 
able to perform post-translational modifications 
• production of pharmaceuticals (e.g. insulin, vaccinations and growth 
hormones), food additives (e.g. vanillin, steviol glycosides) and 
complex molecules (e.g. polyketides, isoprenoids and opiates 
9,144–
147 
Aspergillus 
spp. 
 
• filamentous fungi, multicellular eukaryote 
• tolerant to wide range of temperature and osmolarity 
• high capacity for secreting homologous and heterologous proteins 
• is able to perform post-translational modifications 
• high proteolytic activity 
• engineering and expression tool are available 
• production of amylases, lipases and cellulases, therapeutic proteins 
(e.g. interleukins, antibodies), organic acids (e.g. citric or malic acid), 
complex compounds (polyketides, isoprenoids), used in 
bioremediation 
148,149 
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Continuation of Table 1: Other microbial cell factories 
Streptomyces 
spp. 
• Gram-positive, filamentous bacteria 
• GC-rich genome, versatile metabolism 
• high secretion capacity and low level of extracellular proteases 
(especially S. lividans) 
• produce most antibiotics of natural origin (e.g. neomycin, tetracycline, 
chloramphenicol) and other bioactive compounds 
• limited availability of  engineering and expression tool 
148,150 
Pseudomonas 
putida 
• Gram-negative soil bacterium 
• versatile metabolism, increased tolerance to oxidative stress and high 
tolerance to chemical compounds 
• development of expression tools, such as the SEVA collection, and 
genetic tools for engineering 
• used in industrial biocatalysis, bioremediation and bioplastic 
production 
151–
157 
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Chapter 2: Introduction to protein biosynthesis 
An understanding of the underlying molecular mechanisms involved in protein biosynthesis is 
required to address protein production bottlenecks in microbial cell factories. Protein biosynthesis 
describes the cellular production of new proteins. It comprises central processes in which (i) the 
DNA is transcribed into messenger RNA (mRNA), (ii) the mRNA is subsequently translated into 
a polypeptide chain with an amino acid sequence characteristic for each protein, and (iii) the 
polypeptide chain is folded and transported to the cellular compartment where the protein is 
supposed to act. Translation, folding and transport can happen simultaneously. 
 
2.1 Transcription in prokaryotes 
Transcription is the first step in protein biosynthesis. Here, mRNA is synthetized from a DNA 
template in three stages: initiation, elongation and termination.  
2.1.1 Transcription initiation and regulation 
The DNA-dependent RNA polymerase (RNAP) synthesizes mRNA. The bacterial RNAP core 
enzyme consists of five subunits encoded by rpoA, rpoB and rpoC in E. coli. The α subunits bind to 
the template DNA and serve a regulatory158 and structural function being chiefly involved in the 
assembly of the core complex159. The β and β’ subunit form the catalytic center of RNA synthesis 
and ensure the binding of the DNA/RNA hybrid formed during transcription. The ω subunit 
stabilizes the core complex.  
 
A σ factor transiently associates with the core complex and is responsible for recognizing a 
promoter sequence to orchestrate transcription initiation160. In E. coli, rpoD encodes for the sigma 
factor σ70, which keeps essential genes and metabolic pathways operating. The σ factor recognizes 
a consensus promoter sequence that consists of two parts, known as the -10 and -35 sites161 (Figure 
4). The numbers correspond to the approximate distance in nucleotides from the transcription start 
site (TSS). Compilation of 168 E. coli promoter regions found a conserved motive in the -35 
(TTGACA) and -10 (TATAAT) regions162 (Figure 4). Upstream of the promoter core region, 
promoters can contain an AT-rich sequence, the UP element, which elevates the transcription rate 
through binding of the α subunits of the RNAP. Together, these characteristics essentially guide 
the design of synthetic promoters163. 
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Figure 4: Schematic representation of a prokaryotic promoter. The transcription start site (TSS, +1) is shown in 
orange. The -10 and -35 sites are shown in blue and located 10 nt and 35 nt upstream of the translational start site, 
respectively. Promoters can contain an AT-rich UP element (grey). (adapted from Gilman and Love, 2016163) 
 
Alternative sigma factors get activated during specific stress conditions, such as σ38/σS (rpoS) in 
starvation and stationary phase164, which is often found to be mutated in ALE experiments (see 
Chapter 1)165,166, σ32 (rpoH) upon heat exposure which controls chaperones such as GroEL and DnaK 
and also the Lon and Clp proteases167 (see section 2.3), or σ24/σE (rpoE) in extreme heat stress and 
cell envelope stress168,169. E. coli has a total of six different sigma factors at its disposal together with 
more than 300 transcription factors (half of which are only predicted) which together fine tune 
transcription170. 
 
Having this large number of transcriptional regulators gives E. coli the possibility to respond 
quickly to different environmental conditions. Transcription factors can either turn the 
transcription of genes on (transcriptional activators) or off (transcriptional repressors) by binding 
to specific DNA sequences. Transcriptional repressors mostly bind in the promoter region directly 
interfering with the RNAP, whereas transcriptional activators mostly bind upstream of the 
promoter to support recruitment of the RNAP171. Furthermore, there are transcription factors that 
can act as both, activators and repressors. Many transcription factors contain a so-called helix-turn-
helix motive as DNA binding domain172. Most transcription factors need to be activated by e.g. 
ligand binding or protein-protein interactions. In two component systems, activation is mostly 
linked to phosphorylation173. Transcription factors can play in important role in the development 
of biosensors in the synthetic biology field (see chapter 3.6). 
 
2.1.2 Transcription elongation 
Once transcription is initiated, the RNAP is release from the promoter, which defines the 
transcriptional speed. In this process, the RNAP creates a so-called transcription bubble. It uses the 
non-coding strand as template to construct a 5’ à 3’ mRNA template with a speed of ca. 20 – 40 
nt/s174. During transcription elongation the RNAP is closely followed by a ribosome immediately 
translating the synthesized mRNA transcript. While transcription and translation in eukaryotes 
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take place in different compartments, in prokaryotes transcription rate and translation rate are 
interconnected in prokaryotes174. If translation slows down, the growing gap between polymerase 
and the ribosome gives access to the Rho factor (see 2.1.3), which triggers termination of the 
transcription process. Likewise, a faster ribosome can cause secondary structure changes in the 
mRNA leading to the formation of intrinsic termination hairpins. Conversely, a trailing ribosome 
can restrain the RNAP from spontaneous backtracking and therefore prevents premature 
termination174. 
 
2.1.3 Transcription termination 
Once the mRNA transcript is finalized, transcription needs to be terminated. Here, bacteria use 
two different mechanisms, the Rho-dependent and Rho-independent termination. Rho-
independent termination is determined solely by the DNA sequence. These terminator signals 
contain a ca. 20-nt long GC-rich sequence segment that is followed by a series of adenines. When 
the GC-rich motif is transcribed, the newly synthesized mRNA transcript will form a hairpin 
structure that will stall and destabilize the RNAP. Formation of the hairpin structure also 
destabilizes the RNA-DNA hybrid structure as base pairing between the series of adenines with 
uracil is rather weak175,176. The design of synthetic terminators is based on these principles177. 
 
Rho-dependent termination requires participation of the Rho factor, a protein that exhibits RNA-
DNA-helicase activity. It is deputed whether the protein binds to an unstructured but C-rich 
sequence, the Rho utilization site, downstream from a stop codon and moves along the RNA 
towards RNAP, or whether Rho is already associated with the RNAP during elongation. However, 
it is well established that Rho triggers dissociation of the complex. The trp operon in E. coli contains 
one of the best studied Rho-dependent terminators178,179. 
 
2.2 Translation in prokaryotes 
Translation is the second major step in protein biosynthesis. Here, mRNA is translated into a 
polypeptide chain in three phases: initiation, elongation and termination. Translation initiation 
occurs as soon as the 5' end of a mRNA strand is synthesized. The heart of the translation process 
is the ribosome, which consists of the two ribosomal subunits 30S and 50S, together forming the 
functional 70S ribosome. Both ribosomal subunits are constructed of ribosomal RNA (rRNA) and 
proteins (62% RNA, 38% protein)180. An mRNA can be occupied with several ribosomes, forming 
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a so-called polysome. Both, translation initiation and translation elongation contribute to the 
frequency of ribosome loading in polysomes181,182. 
 
2.2.1 Translation initiation 
As with transcription, the initiation of translation is rate-limiting. Three initiation factors IF1, IF2 
and IF3 are involved in the assembly of the initiation complex. IF1and IF3 prevent the premature 
congregation of the large to the small ribosomal subunit183. IF3 also aids the binding of the new 
mRNA184. The selection of an initiation start site depends on the interaction of mRNA and the 30S 
subunit. The mRNA contains a so-called Shine-Dalgarno (SD) sequence located circa 4 to 14 
nucleotides upstream of the start codon that is recognized by the 30S subunit which contains the 
complementary sequence in the 16S rRNA185 (Figure 5). The 3'-terminal sequence of E. coli 16S 
rRNA was shown to be 3’-AUUCCUCCA-. Thus, the consensus core SD sequence in E. coli is 5’-
AGGAGG-3’. Together, the two sequences form a double stranded RNA structure186. Due to this 
mechanism, proteins with a non-AUG start codon, such as those of the lac operon, can be 
translated33,187,188. Experiences from protein production suggest that the SD sequence and its 
surrounding sequence play a very important role in the efficiency of translation initiation189.  
 
 
Figure 5: Translation initiation in prokaryotes. The 3’-end of the 16S rRNA binds to the Shine-Dalgarno sequence. 
IF1 and IF3 prevent premature assembly of the ribosome. IF2 guides the initiator tRNA to the AUG start codon. 
Upon GTP hydrolysis the initiation factors leave the small subunit and allow the ribosome to assemble and start 
translation. 
 
IF2 binds specifically to the N-formylmethionine-tRNA (fMet-tRNA), also called initiator tRNA, 
and guides it to the ribosome. Thus, independent of the codon utilized as translational start site, 
all proteins start with a methionine. The 30S subunit, mRNA and initiator tRNA form a 
preinitiation complex186,190. IF1, IF2 and IF3 dissociate from the complex after hydrolysis of GTP, 
which allows the 50S subunit to bind to the 30S subunit and to complete the initiation complex. 
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How to optimize and engineer the translation initiation region for most efficient protein 
production is discussed in more detail in Chapter 3.4.4. The optimization of translation initiation 
is subject of two papers in this thesis and led to optimized protein production in Gram-negative 
and Gram-positive hosts (Paper 1 and 3). 
 
2.2.2 Translation elongation  
tRNAs direct the correct amino acid to the given position in the mRNA. Each tRNA contains an 
exposed triplet of nucleotides (anti-codon) that is complementary to the codons of the mRNA191. 
Anti-codon and codon form hydrogen bonds that maximize stability when paired correctly. The 
aminoacyl-tRNA-synthetase catalyses the loading of the tRNA. Under ATP hydrolysis the amino 
acid is attached to the C-terminal adenosine of the acceptor arm191,192. A loaded tRNA is called 
aminoacyl-tRNA. The ribosome contains three active sites, A-, P- and E-site. The A-site is the point 
of entry where each aminoacyl-tRNA arrives. The P-site contains the elongating polypeptide chain, 
bound to a tRNA. Uncharged tRNAs leave the ribosome through the E-site193 (Figure 6). 
 
Three elongation factors (EF) orchestrate the elongation process. EF-Tu, a small GTPase, facilitates 
the binding of an aminoacyl-tRNA to the A-site. If the correct aminoacyl-tRNA is in place, GTP 
hydrolysis by EF-Tu will lead to a large but energetically favourable conformational change in the 
ribosome, which is called conformational proofreading194,195. The elongation factor EF-Ts resets EF-
Tu by exchanging GDP with GTP. Once an aminoacyl-tRNA is bound in the A-site, the polypeptide 
chain is removed from the tRNA in the P-site and its carboxyl group is bound to the amino group 
of the newly arrived amino acid, a process known as peptide bond formation, catalysed by the 23S 
rRNA of the large ribosomal subunit193,196 (Figure 6). For a moment the polypeptide chain is then 
associated with the tRNA at the A-site, but shortly after the translocation of the ribosome relative 
to the mRNA follows, which is catalysed by elongation factor EF-G197 (Figure 6).  
 
The A-site can then be occupied by the next aminoacyl-tRNA assisted by EF-Tu. The binding of a 
new aminoacyl-tRNA leads to the release of the deacylated tRNA in the E-site because of an 
allosteric linkage between the A- and E-site198. This process continues until the ribosome reaches a 
stop codon. The large ribosomal subunit contains a polypeptide exit tunnel through which the 
growing polypeptide chain will leave the ribosome199. The ribosome is able to elongate the 
polypeptide chain by 10 to 20 amino acids per second200. Folded mRNA structures slow down 
elongation, yet the ribosome exhibits helicase activity and is able to quickly unwind these 
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structures201,202. The ribosome’s helicase activity was a decisive factor in the design process of the 
RNA hairpin structures, which are utilized throughout the publications included in this thesis 
(Paper 1-3). 
 
Figure 6: Translation elongation in prokaryotes. After the fMet-tRNA is bound in the P-site, an aminoacyl-tRNA 
can bind to the A-site. EF-Tu facilitates binding and GTP hydrolysis leads to a conformational change. Catalysed 
by the 23S rRNA, a new peptide bond is formed and the polypeptide chain is then associated with the tRNA at the 
A-site and a deacylated tRNA is located at the P-site. The following translocation of the ribosome, catalysed by EF-
G, translocates the polypeptidyl-tRNA to the P-site and the deacylated tRNA to the E-site. The binding of a new 
aminoacyl-tRNA to the A-site, releases the deacylated tRNA at the E-site. This iterative cycle is repeated until the 
stop codon is reached. 
 
2.2.3 Translation termination and ribosome recycling 
A soon as the ribosome reaches a stop codon the termination of the translation process begins. This 
process is orchestrated by three ribosome release factors and assisted by a ribosome recycling factor 
(RRF). Release factor RF1 recognizes all stop codons whereas RF2 recognizes UAA and UAG193,203. 
Both factors trigger the release of the polypeptide chain. RF3 catalyses the release of RF1 and RF2 
by GTP hydrolysis193. After the release of the polypeptide chain the ribosome is left with the 
deacylated tRNA and the mRNA. RRF triggers the ribosomal dissociation into large and small 
subunit together with the elongation factor EF-G193,203. Ribosome disassembly requires the 
hydrolysis of GTP by EF-G204. Subsequently, IF3 is required to replace the deacylated tRNA in the 
P-site, which releases the mRNA. All components are free for a new translation initiation183,205. In 
operons, ribosome re-initiation can occur shortly after termination. Operons are genes that are 
transcribed into one mRNA but are translated individually. Stop and start codons of the coding 
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sequences are in close proximity, which enables the upstream elongating ribosome to dissociate 
and reassemble at the downstream intergenic region, and thereupon initiate translation of the 
downstream coding sequence. However, due to the ribosomes helicase activity, the mRNA 
structure around the translation initiation region of the downstream gene will be in a relaxed state 
when the elongating ribosome reaches the end of the upstream gene. This is favourable for 
ribosome binding and assembly, whereupon de novo initiation of the downstream coding sequence 
can occur206. Efficient translation initiation of the first gene in an operon will lead to accelerated 
translation of the following genes (see Appendix 1). 
 
2.2.4 Protein synthesis inhibitors 
Besides intrinsic regulatory processes controlled by enzymes, small molecules or peptides can 
inhibit protein synthesis. Most inhibitors of protein synthesis are antibiotics and interfere at 
different stages of translation. The antibiotic neomycin prevents the assembly of the ribosome by 
binding to the 30S subunit207. Tetracyclines block the A-site and therefore prevent the binding of 
aminoacyl-tRNAs208,209. Many of the aminoglycosides, such as kanamycin and gentamycin, and the 
aminoglycoside-like spectinomycin intervene in ribosomal translocation and can lead to 
mistranslation by tRNA mismatching210,211. Chloramphenicol blocks the polypeptidyl transfer 
reaction of the 50S subunit212. Macrolides, such as erythromycin, can bind as well to the 50S subunit 
and therefore prevent the peptidyl transfer reaction212. Other macrolides inhibit ribosome 
translocation or cause premature dissociation of the peptidyl-tRNA from the ribosome. Antibiotics 
such as rifamycin or rifampicin are an exception and inhibit transcription by binding to the β-
subunit of the core complex of the RNAP213.  
 
In a protein production project one should therefore carefully evaluate what antibiotic resistance 
gene is best to use. The corresponding antibiotic that needs to be supplemented for plasmid 
selection can interfere with protein production. Antibiotic resistance genes are discussed in greater 
detail in Chapter 3.1.2. 
 
 
2.3 Protein folding and targeting 
Translation transforms genetic information into amino acid sequences but does not produce a 
functional protein. To this end, the polypeptide chain needs to fold into a specific three-
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dimensional conformation. Folding is a spontaneous process that is determined by the formation 
of intramolecular hydrogen bonds, hydrophobic interactions and electrostatic interactions and 
reaches a final native conformation which has the lowest energetic state214. If in a non-native 
conformation, hydrophobic residues are often exposed to the aqueous environment and cause 
aggregation of the protein215. To counteract this effect, many proteins require assistance by 
molecular chaperones to reach their folded states fast and efficiently216. Most chaperones are 
proteins but in some rare cases RNA and lipids can also influence the folding of a protein217,218. 
While a detailed review of protein folding and targeting is well beyond the scope of this thesis, a 
short summary of the chaperones and translocation systems of E. coli is given. 
 
2.3.1 Protein folding in the cytoplasm 
Three chaperones, the trigger factor (TF), DnaKJ/GrpE (Hsp70 system) and GroEL/ES (Hsp60 
system) are the central elements of protein folding and quality control in the cytoplasm of E. 
coli219,220. They work as an interactive network passing unfolded proteins from one to the other221 
(Figure 7).  
 
Figure 7: Cytoplasmic chaperones. The trigger factor (TF) is a ribosome-associated ATP-independent chaperone 
that directly binds to the polypeptide chain leaving the ribosome’s exit tunnel. Upon interaction with TF 65 to 80% 
of total proteins are folded into their native state. DnaJK receive substrates from TF and fold proteins upon ATP 
hydrolysis by GrpE. 10 to 20% of the total proteins are folded into their native state by the DnaJK-GrpE chaperone 
system. The last 10 to 15% are passed on to the GroEL/GroES complex where are folded in an ATP-dependent 
manner. (adapted from Kim et al.219). 
 
The trigger factor is a ribosome-associated chaperone whose role it is to prevent misfolding of 
polypeptide chains leaving the ribosome’s exit tunnel222 (Figure 7). DnaKJ/GrpE, receives 
substrates from TF223 (Figure 7). It assists folding in a co- and post-translational manner in an ATP-
dependent reaction219,221,223. Unfolded proteins will be passed on to the GroEL/ES chaperonin for 
further folding assistance (Figure 7)219. The GroEL/ES chaperonin is required under all growth 
conditions indicating that also essential genes require GroEL/ES folding assistance224,225. Due to its 
distinct architecture (a barrel structure with a lid)226,227, a fully assembled GroEL/ES complex 
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provides protection from the cellular environment225. If the substrate is still not correctly folded 
after release from the chaperonin, it will rebind to GroEL/ES and refold225. 
 
2.3.2 Co-translational translocation and insertion of inner membrane proteins 
The Gram-negative cell envelope contains two membranes, which separate the cell from its 
environment. These biological membranes are dynamic assemblies of lipids and proteins. The 
inner membrane forms a symmetric lipid bilayer consisting of phospholipids and contains integral 
or peripheral membrane proteins. Inner membrane proteins (IMPs) are α-helical proteins. The 
outer membrane is composed of an asymmetric lipid bilayer, since the outer leaflet contains 
glycolipids instead of phospholipids, which mainly serve as a barrier towards external threats. The 
majority of outer membrane proteins (OMPs) are β-barrel proteins. The space between the two 
membranes constitutes the periplasm, which, in contrast to the cytoplasm, is an oxidizing 
environment228. 
 
Most IMPs are inserted into the membrane during translation. This process is called co-
translational insertion and is mostly mediated by the Sec-translocon, a protein-conducting channel, 
which consists of three integral membrane proteins, SecY, SecE and SecG, and the peripheral 
associated ATPase SecA229–231. Co-translational translocation or insertion is mediated via the SRP 
(signal recognition particle) pathway232 (Figure 8). SRP prevents folding before the inner membrane 
is reached and translocation is started232,233. The SRP receptor FtsY mediates the transfer of the 
polypeptide chain chain to the Sec-translocon234–236. The inner membrane protein YidC assists the 
IMP integration process in many cases237. YidC can also promote membrane protein insertion itself 
by functioning as a membrane insertase220,238–240. 
Whether a polypeptide chain emerging from the ribosome is targeted to the inner membrane 
depends on an N-terminal signal or anchor sequence241. Signal peptides typically have an average 
size of 20 amino acids with a tripartite structure: a positively charged N-terminal region (n-region), 
a hydrophobic core (h-region) and a polar C-terminal region (c-region). Signal sequence 
hydrophobicity indicates if a protein is translocated co- or post-translationally229,242,243. Signal 
sequences of post-translationally translocated proteins are less hydrophobic than those targeted by 
SRP. 
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2.3.3 Post-translational translocation 
Most periplasmic and OMPs, are translocated post-translationally244. In these cases, TF competes 
with SRP for binding to the emerging polypeptide chain244,245. Upon binding of TF post-
translationally translocation depends on the cytoplasmic chaperone SecB, which prevents 
premature folding and mediates targeting to the Sec-translocon230 (Figure 8). SecB binds to SecA 
associated to the protein conducting channel246.  
 
Figure 8: Co- and post-translational transport across the inner membrane. Co-translational protein insertion or 
translocation occurs via the SRP-dependent pathway through the SecYEG translocon or the YidC protein. Post-
translational translocation occurs via SecA/B-dependent translocation in an unfolded state through the Sec-
translocon or in a folded state via the Tat complex. 
Besides being targeted to the Sec-translocon, secretory proteins can also be translocated via the 
twin-arginine translocation system (Tat system). The Sec-translocon transports unfolded proteins 
across the inner membrane whereas the Tat system serves to transport folded proteins230,247. Tat-
targeted proteins may bind with cofactors before translocation, an important feature for many 
redox pathways248,249 (Figure 8). Tat substrates use the cytosolic chaperones TF, DnaKJ/GrpE and 
GroEL/ES for folding250. The overall structure of Tat signal peptides is similar to those of Sec signal 
peptides241. However, Tat signal peptides are larger than Sec signal peptides due to an extension 
in the N-terminal region by the consensus motive SRRxFLK, which contains two conserved and 
almost invariant arginine residues251,252. Compared to the Sec-translocon, transport via the TAT 
pathway is slower and less efficient252,253. 
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2.3.4 Protein folding in the periplasm 
Like proteins in the cytoplasm also periplasmic proteins require assistance with folding. YfgM is a 
recently discovered inner membrane protein, which traffics of proteins between the Sec-translocon 
and the periplasmic chaperone machineries DegP, Skp, SurA, FkpA, Spy and PpiD254,255 (Figure 9). 
DegP, Skp and SurA are involved in OMP translocation and folding and will be discussed further 
in section 2.3.5.  
 
The inner membrane chaperone PpiD supports folding of newly translocated polypeptides, 
including periplasmic proteins and OMPs256. Spy is a recently discovered periplasmic chaperone, 
whose function is unknown. It was first believed to interact only with periplasm-destined proteins 
by binding to aggregation-prone regions257 but more recent studies show that it can rescue the loss 
of FkpA and Skp, two chaperones involved in guiding OMPs to the β-barrel assembly machinery258. 
FkpA is another periplasmic chaperone with cis/trans peptidyl-prolyl isomerase (PPIase) activity 
that has been shown to mediate the folding of periplasmic and outer membrane proteins259. 
 
Figure 9: Folding and targeting in the periplasm. YfgM trafficks proteins to the periplasmic chaperones. PpiD 
supports folding of newly translocated peptides. Disulfide bonds are inserted by DsbA and isomerised by DsbC. 
DsbB regenerates DsbA. Spy is a chaperone with unknown function. FkpA is a peptidyl-prolyl isomerase. SurA 
and Skp are involved in the folding and trafficking of outer membrane proteins to the BAM complex. DegP is a 
periplasmic protease involved in the degradation of misfolded outer membrane proteins. 
In E. coli about 300 proteins are estimated to contain at least one disulfide bond260. Disulfide bonds 
can be important for the stability and function of a protein and their formation is only stable in the 
oxidizing environment of the periplasm261. The soluble oxidoreductase DsbA generates disulfide 
bonds (Figure 9). DsbA is then regenerated by DsbB. DsbB is an IMP which transports the electrons 
to the Q-cycle of the respiratory chain220,261. A third component in the system is DsbC, a disulfide 
bond isomerase262,263.  
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2.3.5 Folding and insertion of outer membrane proteins 
The chaperones SurA, Skp and DegP are involved in the trafficking of OMPs through the periplasm 
to prevent misfolding and keep the peptide chain partly unfolded until the β-barrel assembly 
machinery (BAM) complex is reached264 (Figure 9).  
 
The PPIase SurA is the main periplasmic chaperone in E. coli involved in OMP biosynthesis265,266. 
It is the only chaperone that has been shown to interact with the BAM complex267. SurA is also 
involved in targeting Tat substrates to the outer membrane268. Skp is a holdase chaperone, which 
binds hydrophobic patches of substrates with its hydrophobic cavity, and keeps them from folding, 
while simultaneously allowing hydrophilic patches to fold. The OMP OmpA is the most prominent 
substrate of Skp269,270. It is believed that Skp can target the BAM complex but experimental evidence 
is not available220. DegP was previously believed to show chaperone activity in the periplasm, but 
more recent discoveries suggest that DegP mainly functions as a protease and degrades misfolded 
OMPs which cannot be rescued168,271. The BAM complex, consisting of five subunits, assists the 
insertion of OMPs272,273 (Figure 9). Several structures of the BAM complex and mechanisms for 
OMP insertion have been described274–276. However, the exact mechanism remains elusive. 
Under normal conditions E. coli only secretes very few proteins into the extracellular space. A 
review by Costa et al. gives a comprehensive overview of all secretory systems277. 
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Chapter 3: Recombinant protein production in bacterial cell 
factories 
Equipped with a comprehensive overview and understanding of protein biosynthesis one can then 
proceed to design, build and test, and optimize, recombinant protein production in microbial cell 
factories. The emergence of recombinant protein production has revolutionized scientific research 
and industrial biotechnology. The possibility to produce proteins in suitable host organisms 
enabled characterization, functional and structural studies of many unknown proteins and brought 
many therapeutic proteins into clinical application10. Moreover, recombinant protein production 
allows for engineering of proteins with improved characteristics such as solubility, activity or 
affinity and enables tagging of proteins for detection and purification129,278. As more explicitly 
discussed in Chapter 1.1, the emergence of synthetic biology impacted the rapid development of 
recombinant protein production.  
 
Despite all advances, however, bottlenecks in recombinant protein production are encountered 
regularly. Production of insoluble aggregated forms, degradation, low yields and toxicity limit the 
success of recombinant protein production. This chapter focusses mainly on overcoming 
bottlenecks and optimizing recombinant protein production in Escherichia coli by engineering gene, 
vector and strain (Figure 10), but also gives a brief insight into the increasingly popular hosts 
Lactococcus lactis and Bacillus subtilis. The choice of the production host, some of which are reviewed 
in more detail in section 1.3.,  is the first and very important step in a protein production project.  
 
 
Figure 10: Optimization variables for protein production. Engineering at gene, vector and strain level can benefit 
protein production. Finally, it is crucial to define optimal fermentation conditions for large-scale protein production 
for industrial or pharmaceutical applications. (adapted from Gustafsson et al. 201297). 
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3.1 Bacterial expression vectors and their design 
Besides the choice of expression host, the choice of an expression vector is a decisive factor for 
successful protein production. In addition to the multiple cloning site, where the gene of interest 
is cloned into, an expression vector consists of three major parts – the promoter, driving expression 
of the target gene, the origin of replication, determining the copy number and the antibiotic 
resistance marker, needed to maintain the plasmid in the cell (Figure 11). 
 
 
Figure 11: General structure of a prokaryotic expression vector. A promoter (P) drives the expression of a gene of 
interest (goi), which can be cloned into the vector with different cloning techniques. The ribosome binding site 
(RBS) is a decisive factor for translation efficiency. The antibiotic resistance marker (AbR) is used for selection and 
maintenance of the plasmid. The origin of replication (ori) determines the copy number of a vector. Examples for 
promoter, origin of replication, antibiotic selection marker and cloning methods are listed in the boxes. 
 
3.1.1 Promoter systems 
Apart from the in section 2.1. mentioned RNAP binding motives, located 10 and 35 nucleotides 
upstream of the transcription start site162, strength and regulation of a promoter depend on distinct 
regulatory elements71 that react to specific factors, such as small molecules or increased 
temperature279–282. Promoters in an expression vector can either be derived from the expression 
host, e.g. from operons involved in sugar utilization, or can be rationally, synthetically designed279–
281,283. Here, the promoters used in the studies of this thesis are described in more detail. Other 
promoter systems that are frequently used in protein production setups are listed in Table 2. 
 
The rhaBAD promoter 
The rhaBAD promoter is originally driving the expression of the L-rhamnose metabolizing 
pathway RhaBAD. Apart from that, the rhamnose utilization system encodes the rhamnose 
transporter RhaT and the regulatory proteins RhaS and RhaR (Figure 12). All three promoters are 
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activated upon addition of L-rhamnose. In the presence of L-rhamnose RhaR activates 
transcription of rhaSR. Production of RhaS leads to the activation of the rhaT and rhaBAD 
promoter284–286. In a protein production set-up the rhaBAD promoter drives expression of the gene 
of interest. The regulators RhaR and RhaS are normally co-expressed from the expression plasmid 
(Figure 12). The rhamnose inducible promoter system is extremely tight and highly tunable, which 
makes it very attractive for the expression of toxic proteins287. In this thesis, the tunability of the 
PrhaBAD promoter system was exploited to invest the dynamic range of several commonly used 
antibiotic resistance markers and to validate the translational coupling devices that were 
developed in the course of Paper 1. 
 
As so often for sugar-inducible promoter systems, PrhaBAD is susceptible to carbon catabolite 
repression284,288. Carbon catabolite repression enables bacteria to utilize sugars in a sequential 
order289. The cyclic AMP receptor protein (CRP) binds upstream of the polymerase binding site to 
a so called CRP binding site290 functioning as a transcriptional activator. CRP is activated upon 
binding of cyclic AMP (cAMP). cAMP levels are elevated if no glucose is available and vice versa289.  
 
Figure 12: The rhaBAD promoter system. In the presence of L-rhamnose RhaS activates PrhaBAD, which encodes the 
enzymes RhaBAD for rhamnose untilization, and PrhaT, which encodes the rhamnose transporter RhaT. RhaR 
activates PrhaSR, which encodes the two regulators RhaR and RhaS and, thus amplifies the inducing effect. (inspired 
by Hjelm220) 
 
In general, sugar-inducible promoters have the drawback that the cell can metabolize the inducer 
over time. Therefore, inducers need to be supplied regularly in large-scale fermentation processes. 
A recent study demonstrated that the tunability of the rhaBAD promoter is caused by consumption 
of L-rhamnose rather than by regulation of protein production rates. Inactivation of the rhamnose-
utilizing enzyme RhaB led to these findings. An additional knockout of the rhamnose transporter 
RhaT restored a tunable phenotype and varying the concentration of L-rhamnose could precisely 
set protein production rates and the system was stable over time291. Another study used the L-
rhamnose analogue L-mannose, which cannot be catabolized by E. coli, for more controlled protein 
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production by PrhaBAD. L-mannose can only be used for induction when simultaneously the 
regulator RhaS is constitutively over-expressed292. 
 
The T7 promoter 
Despite the necessity of the bacteriophage T7 RNAP being encoded in the host cell, either on the 
genome or supplemented on a plasmid, the T7 expression system is one of the most popular 
expression systems for protein production since it was introduced in the 1980s. The T7 RNAP is 
highly active and very selective for its own promoter, which does not naturally occur in E. coli293. 
E. coli BL21(DE3) is the most common strain used for T7-based expression. In addition to carrying 
the bacteriophage DE3 gene encoding for the T7 RNAP on its genome, BL21(DE3) lacks the lon 
protease and is deficient in the ompT outer membrane protease which degrade proteins during 
purification294.  
 
Figure 13: The T7 expression system. The T7 RNAP is under control of PlacUV5, which is recognized by the 
endogenous RNAP of E. coli. T7 RNAP recognizes only the T7 promoter, which controls expression of the gene of 
interest (goi). (inspired by Hjelm 220). 
 
The T7 RNAP is controlled by a strong lac derived lacUV5 promoter, which itself is recognized by 
endogenous E. coli RNAP295. The lacUV5 promoter is commonly induced with the metabolically 
inactive lactose analogue isopropyl β-D-1- thiogalactopyranoside (IPTG). In the absence of IPTG, 
the repressor LacI occupies the operator site (lacO) and prevents expression of the T7 RNAP 
(Figure 13). LacI is only removed when the binding of IPTG induces a conformational change of 
the repressor. For recombinant protein production a T7-lac hybrid promoter, which also contains 
the LacO operator site, drives the expression of the target gene. Thus, LacI represses both, 
expression of the T7 RNAP and expression of the target gene296 (Figure 13). Due to its high 
transcription rate, T7 RNAP produces large amounts of mRNA resulting in large amounts of 
protein297. However, this turns out to be problematic for membrane or secreted proteins, which 
then encounter saturation of the secretion machinery. Reduction of mRNA levels can be achieved 
by expressing a gene encoding the T7 lysozyme, a natural inhibitor of the T7 RNAP. The T7 
lysozyme is encoded on the plasmids pLysS and pLysE providing low and high levels of T7 
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lysozyme, respectively. As a consequences of this, co-expression of T7 lysozyme also prevents 
leaky expression of the target gene298,299. Throughout this thesis, the T7 expression system is used 
for protein production in E. coli BL21(DE3) (Paper 1, Paper 2 and Paper 4). 
 
Table 2: Commonly used promoter systems for protein production in E. coli. 
Promoter Inducer Characteristics Ref. 
Plac lactose, IPTG • Best studied promoter system 
• Weak promoter, can be used for low level production of 
toxic proteins or membrane proteins 
• repressed by LacI, which binds to a specific operator site 
in the promoter region (lacO) and is only removed when 
the binding of lactose induces a conformational 
• is controlled by carbon catabolite repression 
25,289,290,300 
Ptac, Ptrc lactose, IPTG • hybrids of the tryptophan (trp) promoter and Plac 
• vary in their spacing between the -10 and -35 region 
• three times stronger than the trp promoter and ten times 
stronger than the lac promoter 
• repressed by LacI 
301,302 
ParaBAD L-arabinose • tight promoter, limited titratability, as increasing the 
arabinose concentrations mostly shortens the delay time 
until expression but does not substantially increase 
production 
• repressed by AraC in the absence of arabinose, activated 
by AraC in the presence of arabinose 
• pBAD vectors are a commercial vector series with the 
araBAD promoter 
• can lead to mixed expression populations, constitutive 
expression of the transporter AraE results in homogenous 
cultures 
• is controlled by carbon catabolite repression 
280,303–307 
PtetA tetracycline, 
anhydro-
tetracycline 
(aTc) 
• tight, strain independent promoter 
• repressed by TetR in the absence of tetracycline 
• self-repressing system, which makes it capable of fast and 
efficient response to tetracycline and very attractive for 
recombinant protein production 
• independent of carbon catabolite repression 
• use of an antibiotic as inducer can lead to growth 
interference problems, use of the non-toxic tetracycline 
derivative anhydrotetracycline (aTc) recommended 
308–312 
PL, PR Temperatures 
above 37°C 
• λ phage promoter systems  
• regulated by the heat-sensitive cI repressor 
• great alternatives in cases where the addition of a 
chemical compound as inducer is not desire 
282,313 
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3.1.2 Selection marker 
Transforming a vector into bacterial cells is an inefficient process. In order to get and maintain a 
vector in the cell, an expression vector needs to encode a selection marker. Generally antibiotic 
resistance genes are used as selection markers in bacteria. By adding the respective antibiotic to the 
culture one makes sure that only the cells carrying the expression vector will survive. Without 
selection pressure, cells not containing the vector will have growth advantages and overgrow the 
plasmid carriers.  
 
The most common antibiotic resistance markers in E. coli confer resistance to ampicillin, kanamycin 
and chloramphenicol; spectinomycin, tetracycline and gentamycin are also used frequently. 
Resistance to kanamycin, chloramphenicol and spectinomycin is conferred by three cytosolic 
transferases. Ampicillin acts in the periplasm, which is the reason why the ampicillin resistance 
protein β-lactamase likewise is secreted into the periplasm where it degrades the β-lactam 
antibiotic. It is therefore possible that β-lactamase competes with membrane and secretory proteins 
for the secretion machinery. In a study conducted in the course of Paper 1, we saw elevated 
membrane protein expression levels, when the co-expressed ampicillin resistance marker was 
replaced with a spectinomycin resistance marker (see Paper 1, Supplementary Figure 2). 
Tetracycline resistance is transferred by the efflux pump TetA which catalyzes an energy-
dependent export of tetracycline, causing similar competition for secretion resources314. As already 
mentioned in section 2.2.4 most antibiotics act on the ribosome and might therefore interfere with 
protein biosynthesis. In a study by Kim et al., included as a publication in this thesis (Paper 4), 122-
fold differences in protein production were found by just exchanging the antibiotic resistance 
marker315. These production differences most likely arise from the fitness costs, the metabolic 
burden and physiological changes of the cell caused by antibiotic selection316–318.  
 
Problems of using antibiotics in large-scale recombinant protein production have long been 
recognized, but only few alternative methods for selections have been developed. Here, essential 
genes and toxin-antitoxin systems have been proven to be alternative methods resulting in very 
stable plasmid system319,320. Both approaches come with the disadvantage that they rely on a 
genomic modification in the expression strain prior to its use for protein production.  
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3.1.3 Origin of replication 
Different expression vectors are maintained at different copy numbers in the cell depending on 
their origin of replication. Vectors are divided into high, medium and low copy plasmids. For 
cloning and DNA amplification purposes high copy plasmids, such as ColE1 based replicons, are 
preferable. The native ColE1 origin can be found in 20 to 30 copies in a cell321,322 but mutants such 
as in the pUC vector series produce between 500 and 700 copies per cell323–326. The frequently used 
pBluescript plasmid is derived from the pUC vector series327. A high copy number is not always 
desirable and can cause problems when producing toxic proteins and membrane proteins in 
particular. In the case of a high copy plasmid, the slightest leakiness of the promoter will already 
lead to protein accumulation. In these cases, medium copy number plasmids, such as the pBR322 
and p15A replicon can be used. The pBR322 replicon originates from the ColE1-like replicon pMB1 
with a copy number of 15 to 20328,329. The p15A origin can be found in the pACYC vector series and 
has around 10 to 12 copies per cell129,278,330. Plasmids with the pSC101 origin count as low copy 
plasmids with less than 5 copies per cell26,331. The pSC101-derived plasmid pSC101-ts has a point 
mutation in an essential replication protein, which makes replication temperature- sensitive332. 
Plasmids with similar origins of replication are unable to coexist in the same cell. This phenomenon 
is called plasmid incompatibility. If two plasmids require the same functions and machineries for 
replication upon partitioning into daughter cells one plasmid can be lost over time278.  
 
The ColE1, p15A and pSC101 replicons only function in E. coli and some other Enterobacteriaceae333. 
If working in another organism than E. coli, one can exploit vectors for broad host range, such as 
pBBR1334,335, RK2336, RSF1010337 or pRO1600338. Many of those broad host range vectors are shuttle 
vectors that can also replicate in E. coli. Often plasmid manipulations can be accomplished much 
easier in E. coli and the vector is subsequently transferred to the host organism339. Vectors 
encompassing the R6K replicon are often used as suicide vectors155. The replication mechanism of 
R6KoriV requires the π protein for initiation of replication, which is not supplemented in a suicide 
vector340. 
 
In a study by Kim et al., included as a publication in this thesis (Paper 4), 49-fold differences in 
protein production were found by just exchanging the origin of replication315. 
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3.1.4 Gene expression systems for Lactococcus lactis 
The comprehensive knowledge about its genome341 does not only encourage general interest in 
Lactococcus lactis, but greatly simplifies the development of gene expression systems. Various 
constitutive and inducible expression systems have been developed in the last years. Available 
promoter systems are listed in Table 3. High-level production of heterologous proteins has been 
achieved using constitutive or inducible promoters. Nevertheless, inducible promoters are 
generally desired for protein production13,342. 
 
The nisin-inducible controlled gene expression (NICE) system is probably the most widely used 
inducible system for expression in L. lactis. Nisin is an antimicrobial peptide produced in some 
strains of L. lactis. The two-component system NisRK is triggered by nisin and consequently acts 
as transcriptional activator of the nisA and nisF promoter343. In the NICE system constructed by de 
Ruyter et al. in 1996, the nisA promoter is used to drive expression of the target gene while the 
genes nisR and nisK need to be integrated into the genome of the host strain344,345. Induction can be 
achieved with nisin or its analogs, and even with culture supernatant of nisin producing 
Lactococcus strains. This system is tightly controlled and provides relatively high protein expression 
levels343,346. The NICE system was used in the L. lactis study  in Paper 3. 
 
Table 3: Promoter systems used in Lactococcus lactis 
Type Promoter Description Ref. 
Constitutive 
promoter 
P32 medium 347 
P21, P45 strong 348 
P8 very strong 342 
NICE expression 
system 
PnisA nisin inducible, titratable, can only be used in strains 
with nisKR 
344,345 
Induction under 
environmental 
changes and stress 
conditions 
P170 auto-induction during transition to stationary phase, 
pH shift 
349 
PRro12 temperature shift, works optimal at 42 °C 350 
P15A10 phage attack 351 
PpstF phosphate starvation 352 
Sugar-inducible 
promoters 
PxylT xylose inducible, high expression levels 353 
Plac lactose inducible 354 
Zinc-dependent 
promoters 
PZn suppressed by zinc, triggered by EDTA or zinc 
starvation 
355 
PczcD activated in the presence of zinc, titratable 356 
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3.1.5 Gene expression systems for Bacillus subtilis 
Being one of the most frequently used Gram-positive bacteria for protein production in 
biotechnology357, the molecular toolbox for Bacillus subtilis and thereupon its expression systems 
have grown over the last years. The available promoter systems are summarized in Table 4. 
 
Originally many constitutive promoters encoded on the genome of B. subtilis were used for 
recombinant protein production. Since the genome sequence of several B. subtilis species is 
available, promoter sequences can easily be identified134,358 and can, after testing, be categorized in 
strong106,359–361 and weak constitutive promoters362. Synthetic constitutive promoter, such as the 
Anderson promoter collection, have been proven to work in Bacillus subtilis361. Furthermore, 
promoter library approaches helped to extend the spectrum of promoter strength106. In this thesis 
protein production in B. subtilis was studied using the constitutive promoters PJ23100, PliaG, PlepA, Pveg 
and P32, the latter of which is derived from L. lactis (Paper 3). 
 
Inducible expressions systems with application in B. subtilis do exist. The SURE expression system 
(SUbtilin Regulated gene Expression) is regulated by subtilin, which exhibits homology to the well-
characterised nisin used in the NICE expression system (see 3.1.4). Similarly, the lantibiotic triggers 
a two-component system, SpaKR, in B. subtilis363. Several strains containing the SpaKR system have 
been constructed for the SURE system363,364. However, the system is not as frequently used as the 
NICE system, because its inducer subtilin is not commercially available364.  
 
Similar to L. lactis, expression systems that respond to environmental changes have been developed 
for B. subtilis365–368. A cold-shock inducible system is especially interesting for protein production 
as expression at 25 °C has shown to be beneficial for protein production369. High expression levels 
can be achieved using a xylose inducible expression system. Xylose inducible expression systems 
are most frequently used for recombinant protein production in B. subtilis 370–372. Other sugar-
inducible systems exist. Two T7 expression systems have been rebuild in B. subtilis, one is IPTG 
inducible373 whereas the second one responds to xylose374.  
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Table 4: Promoter systems used in Bacillus subtilis 
Type Promoter Description Ref. 
Constitutive 
promoter 
PJ23101 very weak 361 
PliaG weak 362 
PserA, PlepA strong 106,360 
Pveg very strong 359 
SURE expression 
system 
PspaS subtilin inducible, titratable, can only be used in strains 
with spaKR 
363 
PspaSmut subtilin inducible, can only be used in strains with 
spaKR, less titratable, higher expression compared to PspaS 
363 
LIKE expression 
system 
PliaI(opt) bacitracin inducible, titratable 375 
Inducible 
expression 
system 
Pxyl-tet tetracycline inducible, very tight, medium expression 
level 
376 
PliaI bacitracin inducible, titratable, nisin and vancomycin can 
also be used for induction 
361,377 
Induction under 
environmental 
changes and 
stress conditions 
P2, P7 temperature shift, works optimal at 45 °C 368 
Pdes cold-shock inducible, works optimal at 25 °C 369 
PgsiB induced under glucose starvation, heat, low pH 365 
PAPaseI repressed by high phosphate concentration 366 
P23S dependent on osmolarity, inducible with 2.5 % NaCl 367 
Sugar-inducible 
promoters 
PxylA xylose inducible, high expression levels, sensitive to 
carbon catabolite repression 
370 
PsacB sucrose inducible, sensitive to carbon catabolite 
repression 
378 
PmtlA mannitol inducible, strongly regulated by carbon 
catabolite repression 
379 
PglvA maltose inducible, high expression levels, strongly 
regulated by carbon catabolite repression, a mutant 
version that is less susceptible to carbon catabolite 
repression exists 
380,381 
PT7 T7 RNAP under control of PxylA, xylose inducible 374 
IPTG-inducible 
promoters 
Pspac IPTG inducible, co-expression of lacI for tight regualtion 382 
Pgrac IPTG inducible, higher expression levels compared to 
Pspac 
372 
PN25/O IPTG inducible, co-expression of lacI for tight regualtion 383 
PT7 T7 RNAP under control of Pspac, titratable up to 0.5 mM 
IPTG 
373 
 
3.2 Genome integration and genomic expression 
With the advent of precise and efficient genome integration technologies, genomic-based protein 
production has gained attention. Compared to vector-based expression systems, expression of 
genome-integrated proteins reduces metabolic burden and provides genetic stability. In large-scale 
fermentation set-ups, genomic expression is more suitable and cheaper, as no antibiotics need to 
be supplemented to the culture medium63. Figure 14 illustrates the most commonly used genome 
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integration technologies for recombinant protein production in E. coli. Here, a comprehensive 
overview of these technologies is given. More detailed reviews about genome engineering 
technologies can be found elsewhere384.  
 
 
Figure 14: Genome integration techniques for chromosomal protein production. λ-Red recombineering is based 
on homologous recombination. The phage proteins Beta, Gam and Exo mediate and facilitate the integration 
process. Successful integrants can be selected by antibiotic resistance or by CIRSPR/Cas9 counter selection. The 
antibiotic resistance cassette can be removed via FRT/Flp or Cre/loxP-mediated excision. Clonetegration is a one-
step cloning and integration approach. Integration can happen in six phage integration sites located on the E. coli 
genome. Successful integrants are selected on antibiotics. The antibiotic resistance marker and the integrase are 
excised by Flp. 
 
λ-Red recombineering is a homologous recombination-mediated technique for genetic engineering 
used in prokaryotes. Recombineering can be carried out using either double-stranded DNA 
(dsDNA) or single-stranded DNA (ssDNA) templates. The system relies on three components, the 
Exo, Beta and Gam protein. Exo is a dsDNA-dependent endonuclease, which produces a single-
stranded product for recombination. The single-stranded product is then protected from 
degradation by the Beta protein385. Thus, only Beta is needed for recombineering with single-
stranded products54. The Gam protein inhibits the endogenous nucleases RecBCD and SbcCD, 
which degrade linear DNA fragments55 (Figure 14). A publication by Mosberg et al. nicely describes 
the mechanisms behind λ-Red recombineering385. Generally, an antibiotic resistance gene is 
inserted simultaneously, to simplify the identification of recombinant clones after recombination. 
Selection on the respective antibiotic will reveal successful integrants. However, the selection 
marker needs to be removed after selection. This can happen via the Flp/FRT system from 
 41 
Saccharomyces cerevisisae386 (Figure 14). Alternatively, the Cre/loxP system from the bacteriophage 
P1 can be used387 (Figure 14). However, both systems leave a scar in the genome which can prove 
problematic if several rounds of recombineering are performed in one strain resulting in false 
recombination events. Recent advances in CRISPR/Cas9-coupled recombineering, allow for 
markerless integration into the prokaryotic genome68.  
 
A simultaneous cloning and integration approach (clonetegration) was developed for integration 
into six phage sites located on the E. coli chromosome388 (Figure 14). Clonetegration has been 
proven to be a fast and efficient integration method. However, antibiotic-based selection and 
subsequent Flp-mediated excision of an antibiotic resistance marker is required as well.  
 
The antibiotic selection system developed in this thesis (Paper 1), can be employed to optimize 
protein production and to select for highly expressed gene variants on the genome of E. coli (see 
Appendix 2) using either λ-Red recombineering or clonetegration. The first one provides the means 
to select for optimized endogenous proteins. 
 
3.3 Factors affecting recombinant protein production 
E. coli is the most preferred and extensively studied system for the production of recombinant 
proteins in bacteria. Nevertheless, there are certain limitations for protein production that make 
expression of complex proteins a major challenge. For example, an average E. coli protein comes at 
a size of 300 amino acids, corresponding to about 33 kDa389. Proteins above 100 kDa can often not 
be expressed properly390 and are secreted poorly391 (Figure 15). Similarly, small proteins are often 
subject to proteolytic degradation392. In addition, many eukaryotic proteins frequently encompass 
codons that are rarely used in E. coli and thus slow down translation processes393 (Figure 15).  
 
Besides size and codon usage, toxicity presents a major problem. Many recombinant proteins need 
to be secreted to the periplasm for post-translational modifications but secretory and membrane 
proteins then often become toxic to the host cell (Figure 15). First of all, translocation of high levels 
of recombinant proteins hinders the translocation of endogenous proteins394–397. As a consequence 
of this, the respiratory capacity is reduced, which leads to a decrease in oxygen consumption rates 
and activates the ArcAB two-component system that mediates the transition from respiratory to 
fermentative metabolism395,398. Additionally, the accumulation of proteins in the cell’s membrane 
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system has a toxic effect. However, the major problem presents the saturation of the membrane 
translocation machinery, which, firstly, causes aggregation of the proteins in the cytoplasm and 
their subsequent degradation. Proteins aggregate when hydrophobic side chains get exposed to 
the aqueous environment and interact with other hydrophobic residues on neighbouring chains to 
form non-functional aggregates. Logically, proteins with highly hydrophobic domains, such as 
membrane proteins, are more prone to aggregate. Aggregation is accompanied by changes in the 
protein structure therefore resulting in inactive proteins399 (Figure 15). Large amounts of 
aggregates are sequestered as inclusion bodies. The latter are not necessarily unwanted, as they are 
usually highly homogeneous and can easily be separated from other cellular components400. 
Several protocols for inclusion body purification have been developed401,402. The aggregated 
proteins can be renaturated and solubilized to restore their activity403,404. However, protein 
extraction from inclusion bodies is a time consuming and tedious process, and soluble protein 
production is preferred. 
 
 
Figure 15: Reason for and solutions to low protein yields in recombinant protein production. Reasons for low 
protein yields are listed. Below possible solutions are provided. The grey bar on the left indicates in which chapter 
detailed information about particular solutions can be found. 
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3.4 Approaches for protein production optimization 
Proteins can be engineered and modified to overcome the bottlenecks presented in section 3.3. The 
approaches presented below are connected with the protein production optimization tools that are 
developed in this thesis.  
 
3.4.1 Protein engineering 
Directed evolution 
Modifying the nucleotide and amino acid sequence of a target gene has proven to be a successful 
approach to improve protein production. But in many cases the lack of pre-existing knowledge 
makes it impossible to predict which nucleotide and amino acid modifications in a target protein 
might have a positive effect on protein production220. Hence, optimized protein variants are often 
identified from sequence libraries. This approach is called directed evolution405. The generation of 
large sequence libraries can be achieved using error-prone PCR, gene shuffling or chemical 
mutagenesis405–407. The key goal with these approaches is to create great sequence diversity406. 
However, the application of directed evolution is not only limited to protein production 
optimization, including solubility and folding, it is also a powerful method for evolving single 
proteins with altered substrate specificity, enhanced activity and optimized functionality. Here, 
gene shuffling strategies have driven the success of directed evolution in the last decades resulting 
in hybrid enzymes, enzymes with altered or broadened substrate specificity and pH stable protein 
variants, just to name a few408–414. More targeted approaches can be employed by using algorithms 
that design shuffled libraries from non-homologous genes in silico, e.g. the SCHEMA or SCOPE 
algorithm415–418. 
 
A screening and selection method is required to efficiently identify the optimized mutant from 
these large libraries. Commonly, fusions to the green fluorescent protein (GFP) are used419. In this 
thesis, we developed a selection system with a huge screening capacity due to a growth-based 
assay that could be implemented as a screening tool for directed evolution of proteins for 
production optimization (Paper 1 and 2).  
 
Codon adaptation index (CAI) 
It is also possible to engineer the DNA coding sequence of a protein without actually changing the 
amino acid sequence. There is a repertoire of codons for each amino acid and certain codons are 
typically more frequently used than others. The codon adaptation index (CAI) is the most 
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widespread technique to score the abundance of a codon but other techniques exist420. CAI 
calculates the statistical codon usage relative to the codon usage in highly expressed genes to 
predict protein expression levels421. Hence, proteins that use abundant codons score highly in the 
CAI whereas those that use rare codons will score low in the CAI. The CAI can affect translation 
elongation. Introducing more abundant synonymous codons can increase production by up to 
1000-fold422 but can also alter protein folding and therefore activity421,423,424. Questioning this 
common understanding of codon bias, Kudla et al. engineered a synthetic library of 154 gfp genes 
that varied randomly at synonymous sites. When expressed, protein production varied by 250-fold 
but no correlation between CAI and expression level was found. The effect of CAI seems to play a 
role in global fitness rather than in production optimization. Those findings were confirmed in 
later studies425–427. Goodman et al. even found that rare codons at the 5’ have a beneficial effect on 
expression426. More recent studies, using ribosome profiling techniques, uncovered some 
relationship between internal Shine-Dalgarno sequences and ribosome pausing. For this reason, 
the exclusion of SD-like codons can be beneficial for protein production428. Gene libraries that vary 
at synonymous sites can be screened with the here developed antibiotic selection system for their 
expression performance (Paper 1). 
 
3.4.2 Protein fusions 
Fusing the target protein to another soluble protein can increase folding and solubility390. This way, 
one can protect small proteins from proteolysis and large proteins from aggregation429–431. Fusion 
proteins or fusion tags can also facilitate protein purification432, and some fusion proteins can be 
used as expression reporters. Nevertheless, fusion proteins must be chosen and engineered 
carefully. For instance, secretory and membrane proteins contain information in the N-termini that 
is required for correct targeting. Although there are trends that some fusion partners are on average 
performing better than others, there is no guarantee that a given tag will work with a protein of 
interest. 
 
Green fluorescent protein (GFP) 
The green fluorescent protein (GFP) is commonly used in molecular biology as it is a stable protein 
that can easily be monitored in whole cells. GFP is used as fusion reporter for monitoring 
expression levels, protein folding, localization and membrane protein topology. Further, fusions 
to GFP were found to improve the solubility of a protein and protein purification strategies433,434. 
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Waldo and co-workers developed a folding reporter-vector in which a target protein is expressed 
with GFP as a C-terminal fusion. Conveniently, it was shown that the GFP reporter does not fold 
properly if the target protein aggregates. As a result GFP does not fluoresce. The reporter can be 
used to assay, for example, the solubility after directed evolution experiments435. In addition, the 
GFP folding reporter does not fluoresce upon secretion into the periplasm, and can thus be used 
as a reporter for protein localization436. Building on these findings, Drew et al. employed the GFP 
folding reporter for mapping the topology of membrane proteins437 and to monitor membrane 
protein expression levels438. As a continuation of the platform developed by Drew and colleagues, 
the GFP folding reporter was applied to 601 inner membrane proteins of E. coli and their membrane 
topology was analyzed439. Split-GFP variants present good alternatives for topology mapping and 
protein tagging in general440. Commonly the protein is split between the tenth and eleventh β-
strand. The resulting GFP1-10 fragment remains non-fluorescent until complementation. The 
resulting GFP11 fragment constitutes a 16 amino acid short peptide, which can easily be fused to a 
target protein. Besides split-GFP, different variants of GFP with enhanced properties were 
developed. Superfolder GFP, which is a very stable version that also folds properly in the 
periplasm presents here the most prominent example441. 
 
The implementation of fluorescent proteins has also enabled the use of fluorescence-detection size-
exclusion chromatography to evaluate the quality of purified proteins, e.g. as a result of different 
detergents used for solubilisation, and to track higher order structures in purification 
processes442,443. Moreover, the combination of GFP-fusions and fluorescence activated cell sorting 
(FACS) enables the selection of high producing variants from expression libraries. Skretas and 
Georgiou screened an E. coli transposon library with the latter approach and identified a variant 
with substantially increased production of the membrane-integrated human central cannabinoid 
receptor (CB1) 444. 
 
In this thesis, we made use of the various benefits of membrane protein-GFP fusions. Two 
membrane proteins of the GFP platform445 were used to test and characterize the tunable antibiotic 
selection system TARSyn, developed in Paper 1. Additionally, a protein from the GFP platform 
was used to characterize the impact of all SEVA-Linker plasmid backbones on protein production, 
shown in Paper 4. 
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β-lactamase 
The ampicillin resistance-conferring protein β-lactamase can also be employed as a protein fusion. 
Although a fusion with β-lactamase may not improve protein production as such, it is a useful 
screening tool for optimized production. Skretas and Georgiou used membrane proteins fusions 
to β-lactamase to find enhanced production of membrane proteins when screening the ASKA 
library, a plasmid library encoding all known E. coli open reading frames446. As β-lactamase only 
acts in the periplasm, screening for optimized secretion is another possible application. The 
laboratory of DeLisa recently showed that β-lactamase can be used to screen for optimized 
extracellular secretion through strain engineering447. This thesis exploits extensively the use of β-
lactamase as a reporter for protein translation in the antibiotic selection system. However, we did 
not use β-lactamase as a direct fusion partner, instead we translationally coupled the gene of 
interest with the reporter.  
 
Other examples of fusion partners, which mostly support solubilization and folding of the target 
protein, are listed in Table 5.  
 
Table 5: Fusion proteins for recombinant protein production in E. coli and their characteristics 
Fusion protein Characteristics Ref. 
Maltose 
binding protein 
(MBP) 
• very big (42 kDa) addition to the target protein 
• translocation of the target protein into periplasm (due to malE-SP) 
• increases solubility of target protein 
• has intrinsic chaperone activity, reduces toxicity of target protein 
• prevents degradation of target protein 
• serves as affinity tag for purification via amylose 
448–457 
 
Glutathione S-
transferase 
(GST) 
• smaller (26 kDa) addition to the target protein 
• rather poor solubility enhancer 
• serves as affinity tag for purification via glutathione 
458–461 
 
Ubiquitin and 
small ubiquitin-
like modifier 
(SUMO) 
• small addition to the target protein 
• increases solubility of target protein 
• increases stability of target protein 
• additional Histidine-tag needed for purification 
461–465 
 
N-utilizing 
substance A 
(NusA) 
• very big (55 kDa) addition to the target protein 
• increases solubility of target protein (best soluble protein of E. coli) 
• "attracts" chaperones for proper folding 
• slows down translation for proper folding 
466–469 
 
Thioredoxin A 
(TrxA) 
• increases solubility of target protein 
• good fusion partner for crystallographic studies, as it tends to form 
crystals itself 
460,461,467,
470,471 
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Affinity tags for purification 
Smaller peptide tags are probably less likely to interfere with protein structure, activity and 
characteristics and therefore do not necessarily need to be removed. On the other hand, they mostly 
serve for purification purposes and likely do not support solubilization. They are listed here, as the 
choice of affinity tag can greatly influence the protein yield after purification. An optimal 
production scenario includes optimal purification conditions for the process to be economically 
viable. The most frequently used affinity tags are listed below (Table 6), but many other fusion 
partners, such as the calmodulin-binding protein, the chitin-binding domain or the cellulose-
binding domain exist and were nicely reviewed by Terpe432. In the studies presented in this thesis 
we employed fusions to His-tag and Strep-tag for successful protein detection and purification.  
 
 
Table 6: Commonly used affinity tags for protein detection and purification 
Affinity tag Characteristics Ref. 
poly-histidine tag 
(6xHis-/ 8xHis-tag) 
• Affinity purification through Ni2+-NTA resin or immobilized 
metal-affinity chromatography (IMAC) 
459,472,473 
 
Strep-tag • Affinity purification through binding to strepavidin and elution 
with biotin 
474–479 
FLAG-tag • artificial designed peptide, very hydrophilic 
• through internal cleavage site elution under non-denaturating 
conditions possible 
• affinity purification through FLAG-antibody binding 
• affinity pull-down 
480–483 
HA-tag • used for coimmunoprecipitation (co-IP) 
• especially strong epitope for purification and detection 
484 
cMyc-tag • used for coimmunoprecipitation (co-IP) 
• used for immunofuorescence assays 
• can interfere with protein translocation 
459,485 
 
Despite all their advantages fusion proteins can compromise the expression, solubility and 
bioactivity of a protein and should be only sensible when the protein fusion itself constitutes the 
desired product. In industrial applications fusion proteins are usually avoided due to additional 
costs and time required for removal of the fusion partner. Further, for pharmaceutical applications 
additional sequences are unwanted due to safety regulations486. Tags can be removed by e.g. 
protease cleavage, but most proteases leave a few residues behind. Last but not least, one risks with 
the cleavage of a fusion partner the loss of solubility of the target protein487.  
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3.4.3 Optimization of protein secretion 
Secretion of recombinant proteins to the periplasmic space of E. coli has several advantages over 
intracellular production. This includes a higher solubility, stability and enhanced activity, if 
disulfide bonds need to be formed, and easier downstream processing, as proteins can simply be 
obtained by osmotic shock or permeabilization of the cell wall253,261,263,488,489. However, the choice of 
signal sequence (ss) impacts greatly the efficiency of secretion and decides via which route a 
proteins gets translocated (see Chapter 2). In the model organism E. coli, the route for many 
endogenous periplasmic proteins is known, which simplifies the selection of a signal peptide242,243. 
Often post-translational translocation is preferred as the risk for aggregation and misfolding is 
lower130,490. However, for other applications, e.g. phage display, co-translational translocation has 
proven to be most efficient242. Commonly used signal sequence (ss) are PelBss, MalEss, PhoAss and 
signal sequences of the Omp proteins that mediate post-translational translocation, whereas 
DsbAss, TolBss and TorTss drive co-translational translocation244. Proteins utilizing the TorAss will 
be translocated via the Tat pathway130 (Figure 16). Direct protein fusions to a leaderless β-lactamase 
gene can be employed to identify optimal signal sequences in a growth-based selection assay, 
similar to the selection assay that was developed in this thesis (Paper 2). Additionally, the TIR 
optimization approach that is employed in Paper 1-3 will, when applied to signal sequences, result 
in universal optimized scaffolds for periplasmic protein production. 
 
 
Figure 16: Coding sequences for commonly used signal sequences (ss). Signal sequences contain three regions, 
the n-region (blue), the h-region (black) and the c-region (light blue), and are fused to the N-terminal of a gene of 
interest (orange). Signal sequences encode whether a protein will be translocated co- or post-translationally via 
SRP-dependent, SecB-dependent or the Tat pathway. (Figure adapted from Steiner et al.242 and Choi et al.130) 
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3.4.4 Optimization of translation initiation 
It has been shown that the rate-controlling step in protein synthesis is translation initiation 129,491,492. 
The nucleotide sequence central for this process is the so-called translation initiation region (TIR) 
that comprises the Shine-Dalgarno (SD) sequence, a linker region between the SD sequence and 
the translational start site and approximately the first five codons of the gene coding sequence and 
optional translational enhancers such as A/U-rich sequences189,493,494. Details about the mechanisms 
behind translation initiation can be found in Chapter 2.2.1. The efficiency of translation initiation 
mostly depends on four factors (Figure 17): The nature of the SD sequence, the start codon for 
translation, the length and sequence of the linker region between SD sequence and the start codon, 
and the free energy (∆G) of folding of the mRNA corresponding to its secondary structure around 
the translation start site. 
 
Figure 17: The translation initiation region. The translation initiation region (light grey) spans from the SD 
sequence to the 5th or 6th codon of the gene. The efficiency of translation initiation depends on the Shine-Dalgarno 
sequence (SD sequence, orange), which needs to be recognized by the 16S rRNA, the linker region between SD and 
start codon (black), the start codon (turquoise) and the secondary structure of the mRNA which needs to be resolved 
(ΔG). (adapted from Reeve et al.493). 
 
All four points have extensively been studied in the last decade and many approaches have been 
developed that optimize translation initiation and therefore protein production levels. One of the 
most important steps in translation initiation is the binding of the 30S ribosomal subunit to the 
mRNA, where the 16S rRNA pairs with the SD sequence of the mRNA185,495. Nucleotide changes in 
the SD can therefore affect protein production levels by as much as 600-fold496 and up to 100,000-
fold (personal communication). Vimberg et al. tested the effect of SD variation on the level of 
protein synthesis. They found that at 37 °C the consensus SD sequence AGGAGG performed best 
in E. coli189. Most commercially available expression vectors contain this consensus SD sequence, 
hence it is difficult to improve translation by changing it. Nevertheless, for metabolic engineering 
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applications a reduction in expression levels is sometimes favoured. To predict the performance of 
weaker SD sequences, one can make use of the prediction software EMOPEC497. However, as 
translation efficiency does not only depend on the SD sequence it is hard to gauge whether a 
construct with altered SD will perform as predicted. To address this problem, Mutalik and co-
wokers developed a standardized bicistronic design (BCD), comprising a small peptide that can 
easily be incorporated in front of any gene of interest. The BCD contains two SD motifs, one driving 
translation of the small peptide and a second SD, encoded in the small peptide sequence, driving 
translation of the target gene. Variation was introduced in the second SD and selected BCD 
sequences showed a 600-fold variation in expression496. Using such BCD elements makes 
translation initiation rates reliable and transferable between target genes. Our own experience 
taught us that expression levels of already optimized constructs could still be doubled by utilizing 
the best-performing BCD sequence (unpublished data). Marino et al. tried a similar approach by 
designing transcriptional fusions of target gene and the proteins Mistic and YebL. Expression was 
enhanced but not comparable to the biscistronic design of Mutalik and co-workers498. 
 
The second factor influencing translation initiation is the initiator codon. Most commonly the start 
codon is AUG but sometimes GUG and UUG and rather rarely CUG or AUU are used33,499–502. The 
use of AUG is most efficient for translation initiation as all three nucleotides base pair with the 
initiator fMet-tRNA503. A recent study by Hecht and colleagues showed that in theory all 64 codon 
can serve as an initiator codon in translation initiation, as long as a strong SD sequence is used188. 
A study in this thesis makes use of the non-canonical AUU start codon to down-regulate expression 
of a translationally-coupled reporter gene, which can be useful if a gene of interest is already highly 
expressed and the detection range of the reporter is already saturated (See Paper 1). 
 
The region between the SD sequence and the AUG start codon was long thought not to play an 
important role in translation initiation. However, Egbert and Klavins showed that by varying the 
length of this region, gene expression levels varied over a 1,000-fold range504. The optimal spacer 
length was shown to be 5 nucleotides505 but can vary with the context of the SD sequence494. When 
expressing a gene of interest, the construct is often assembled on an expression vector using 
various cloning techniques. Independent from which cloning technique is used, an arbitrary 
junction will be created between the vector backbone and the coding sequence, exactly the 
sequence between the SD sequence and the start codon, the context of which will influence 
expression levels107,506. Modifications applied to this region might also change the secondary 
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structure of the mRNA. An algorithm to predict mRNA folding around translation start site has 
been developed507, however, it was shown that expression variability cannot completely be 
explained by the free energy associated with mRNA folding and seems to be context specific in a 
way that is not completely computationally predictable107.  
 
The creation of sequences libraries, can help to find the optimal TIR sequence for high-level 
expression of a gene directly under the conditions in which it will be expressed. Sampling from 
TIR libraries yields clones with very large differences in expression. However, the specific 
randomized region decides on whether experimental evaluation is possible (Figure 18). In so-called 
RBS libraries, variation is introduced in the SD sequence and its direct surroundings. The resulting 
library includes a high frequency of poorly performing constructs, due to suboptimal SD 
sequences508 (Figure 18).  When only manipulating the region downstream of the SD sequence and 
sampling all synonymous combinations for the second and third codon, the library size is reduced 
and experimental evaluation possible (Figure 18).  
 
 
 
Figure 18: Different DNA sequence libraries for the optimization of translation initiation. So-called RBS libraries 
generally introduce variation in the SD sequence and its surroundings, creating numerous variants with low 
expression levels (left). If 10 nucleotides (x=10) are randomized completely, 1,048,576 expression variants are 
created. Screening capacity needs to be high to be able to identify the good candidates. The presented data is 
imaginary but resembles observations by Jeschek et al.508. When only a part of the translation initiation region (TIR) 
but the SD sequence is kept optimal, the library size and the frequency of bad solutions is reduced (right). Mirzadeh 
et al. introduce variation in the 6 nucleotides (x=6) upstream of the start codon. The second and the third codon is 
changed to all possible combinations (y=4, z=2). The presented data is imaginary but resembles observations by 
Mirzadeh et al. 107. 
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The latter approach was described by Mirzadeh et al. The authors found that protein production 
levels were affected by up to 1000-fold107. In this thesis TIR sequence libraries as described by 
Mirzadeh et al. have been utilized to optimize protein production. These libraries were constructed 
to apply TARSyn, a synthetic biology approach for selection of highly expressed gene variants 
developed and applied in Paper 1 to 3. However, due to its high screening capacity, we are 
confident that TARSyn can be used to screen degenerated RBS libraries.  
 
Supporting the previous example, other studies found synonymous codon substitutions in the 
second and third codons of the target gene to have a large effect on protein production levels509–512. 
However, it is not clear whether those codon substitutions affect mRNA folding around the 
translational start site426,513,514 and therefore translation initiation, or the ribosomal speed and would 
therefore affect translation elongation515,516. Most likely, both processes are affected. Cheong and 
co-workers enhanced expression levels by creating an expression library where the first ten codons 
of a gene of interest were substituted by all possible combinations of synonymous codons. This 
approach resulted in up to 530-fold increase in expression517. Nørholm at al. concluded that the 5’-
coding region is the major region of the protein coding sequence that influences translation 
efficiency. Their conclusion is based on a study of two difficult-to-express membrane proteins. 
Codon optimized sequences of both genes were compared to variants where the codons close to 
the AUG start codon were substituted with synonymous codons. The latter showed a substantial 
improvement in production512.  
 
Very importantly, this thesis provides a new comprehensive study that shows that such library 
approaches for translation initiation optimization can also be applied in the Gram-positive hosts 
B. subtilis and L. lactis (Paper 3). 
 
Three different computational tools for the prediction of the translation rate have been developed. 
All of them use biophysical models to calculate and design optimal translation initiation regions. 
The RBS Calculator, launched in 2009, was the first of its kind108. New results and insight in the 
translation initiation mechanism led to an on-going development of the RBS Calculator518,519. The 
latest version, RBS Calculator 2.1, was released in September 2017520. In addition to predicting 
translation rates, the  RBS Calculator offers the means to design RBS libraries, which is mostly 
applied for pathway optimization and less for protein production optimization521–523. The RBS 
Designer and UTR Designer are similar computational tools524,525. However, as this thesis focuses 
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chiefly on experimental approaches for protein production optimization, the reader is referred to 
the thorough review by Reeve et al.493 for further details on the subject matter. 
 
3.5 Optimization of the protein production host  
3.5.1 Codon usage 
In the previous section codon abundance and the use of CAI was discussed. As an alternate 
solution to CAI, tRNAs for rare codons can be co-expressed to circumvent the codon bias problem. 
Usually rare codons correlate with rare tRNAs526. The pR1952 and pSJS1240 plasmids527,528 or the 
pRIG plasmid529, for example, encode two and three rare E. coli tRNA genes, respectively. Those 
plasmids have proven to be useful in the expression of AT-rich genes. Commercially available 
tRNA plasmids include pRARE and pLysSRARE2 from Novagen which can be purchased in the 
Rosetta, and Rosetta2 strain (Novagen) and carry tRNA genes for seven rare codons. The BL21-
CodonPlus strain from Stratagene also supplements rare tRNAs and comes in different variants, 
such as CodonPlus-PL and CodonPlus-RIL that can be used to overcome biases of GC- and AT-
rich genes, respectively390. Both commercial expression platforms have been used successfully, for 
example in the Human Protein Atlas project530. One should, however, be aware, that the presence 
of additional tRNAs can also have a negative effect on recombinant protein production, as reported 
by Søgaard and Nørholm531.  
 
3.5.2 Co-expression of molecular chaperones 
The over-expression of molecular chaperones is another strategy that has been used to improve the 
yield in the production of recombinant proteins. Chaperone functions are described in more detail 
in Chapter 2. Host chaperone accumulation can be induced by heat, osmolytes or membrane 
fluidizers and does not necessarily require plasmid-mediated over-expression488,532. Recent 
experiments indicate that the optimization and selection approach that is applied in this thesis, can 
also be used to optimize translation initiation of the chaperones on the genome of E. coli, which 
results in elevated levels when production is induced.  
 
Over-expression of the cytoplasmic chaperones DnaKJ-GrpE, GroEL/GroES and TF has been used 
in several studies to enhance yield and solubility of several human proteins, including the very 
difficult-to-express class of GPCRs533–535. Opposing these previous studies, Skretas and Georgiou 
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found that the disruption of DnaJ substantially increased production of another GPCR444. Similarly, 
Nannenga and Baneyx found that the deletion of TF tripled production of two membrane 
proteins536. However, the involvement of DnaKJ in protein degradation, and competition of TF and 
SRP for binding to the emerging polypeptide chains, can provide reasonable explanations. 
Nevertheless, this demonstrates that co-expression of chaperones requires specific testing for each 
target protein. Unfortunately, no screening platform for such purpose exists. A few pACYCDuet-
1 derivatives for the co-expression of chaperones are available via Addgene. Those plasmids 
originate from a study for soluble production of human lysozyme in E. coli537. At this point, it is 
important to mention that the antibiotic selection system developed in this thesis, monitors the 
translation rate and cannot distinguish between correctly folded and misfolded, aggreagated 
proteins. The implementation of a simultaneous folding reporter would be of high interest for the 
screening of chaperone co-expression. 
 
As controversial as the results are for cytoplasmic and membrane proteins, they appear to be quite 
consistent for the optimization of periplasmic proteins. The co-production of FkpA, Skp and SurA 
can substantially improve production yields of secretory proteins, such as antibodies and scFv 
antibody fragments but also other protein classes490,538–540. Yields were improved up to 36-fold in 
those studies. The co-production of DsbA and DsbC when producing proteins, which are rich 
disulfide bonds, has led to success541,542543. For example, the production of an IgG antibody was 
enhanced 3-fold, when over-expressing DsbA or DsbC544. Schlapschy et al. constructed a helper 
plasmid that combines all previous efforts and encodes four established periplasmic chaperones, 
DsbA, DsbC, FkpA and SurA. Its positive effect was demonstrated using the human plasma 
retinol-binding protein (RBP) as well as the extracellular carbohydrate recognition domain (CRD) 
of the dendritic cell membrane receptor DC-SIGN545. Nonetheless, co-expression of chaperones can 
also have side effects, such as reduced yield due to reduce solubility or degradation, reduced 
specific activity or growth inhibition. Side effects of chaperone co-expression were nicely reviewed 
by Martinez-Alonso and co-workers546. 
 
In B. subtilis and L. lactis the co-production of chaperones showed a positive effect as well. The 
surface anchored chaperone-like protein PrsA from B. subtilis and the peptidyl-prolyl-cis/trans-
isomerase PmpA from L. lactis both optimized production of secreted proteins when over-
expressed547–549. 
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3.5.3 Strain engineering for a more effective T7 expression system 
The T7 polymerase can be a big bottleneck, especially when produced proteins or compounds tend 
to be toxic for the cell. To test the β-carotene pathway in the SEVA linker series, presented in Paper 
4 of this thesis, we were in need of an optimized T7 system.  The laboratory of Christopher Voigt 
reduced T7 RNAP toxicity by utilizing a weak Shine-Dalgarno sequence and a GTG start codon. 
Additionally, an N-terminal lon-mediated degradation tag was inserted. A spontaneous point 
mutation in the polymerase active site (R632S) occurred and showed a positive effect. The 
engineered T7 RNAP can be obtained on a plasmid74. For our study we successfully integrated the 
mutant T7 RNAP into the genome of E.coli and obtained β-carotene production of about 4 mg/mL.  
  
Alternative strategies have been developed. Lemo21(DE3) is a derivative of BL21(DE3) that has the 
T7 lysozyme expressed under control of the rhamnose inducible PrhaBAD promoter. Thus, the level 
of T7 lysozyme and thereby also the activity of the T7 RNAP can be carefully titrated. By varying 
inducer concentrations, optimal protein production yields can be achieved e.g. by reducing 
toxicity550.  The construction of pLemo was inspired by the Walker strains. Evolved strains such as 
the Walker strains C41(DE3) and C43(DE3) can improve membrane protein production, similar to 
the recently published Mutant56(DE3)550–552. The first two BL21(DE3) derivatives contain, among 
other potential mutations, a mutation in the lacUV5 promoter that decreases the production of T7 
RNAP and therefore leads to decreased transcription rate550. The latter one contains an additional 
deletion in FryA, a putative transporter subunit, which improved strain fitness.  
 
To obtain a similar effect, Kim et al. constructed a titratable T7 system by putting a mutant LacIV192F 
repressor under control of a rhamnose inducible PrhaBAD promoter. The mutant LacI variant binds 
to the lac operator site but does not bind to inducer molecules like IPTG. When LacIV192F binds to 
the operator site, transcription will be blocked. Through this, the activity of T7 RNAP can be 
carefully titrated. It should be noted that the use of the pLemo is limited to T7 RNAP-based 
expression systems whereas the LacI system is applicable to all other lacO-based expression 
systems that use endogenous E. coli RNAP553. The antibiotic selection system that is presented in 
this thesis provides the means to screen for optimal induction of the mutant LacI and of T7 
lysozyme, in the case of pLemo, in liquid culture MIC assays. 
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3.5.4 Strain engineering for post-translational modifications 
Production of a target protein can be optimized by utilizing the synthetic biology approaches 
developed in this thesis. However, sometimes additional post-translational modifications are 
required to obtain an active protein. In those cases, it is necessary to co-express the appropriate 
helper plasmids during the optimization process, or, use the appropriate strain in the optimization 
process (unpublished data). Therefore, a short insight into the options for post-translational 
modifications will be given. 
 
Disulfide bond formation  
If the reductive cytoplasmic environment is transformed into an oxidative environment, disulfide 
bonds can be formed in the cytoplasm and secretion is not necessary. Several E. coli strains have 
been constructed for this purpose. The thioredoxin and glutaredoxin pathway are involved in the 
reduction of disulfide bonds that form in the E. coli cytoplasm554. Its key enzymes, trxB and gor, 
respectively, have been knocked out or mutated in some strains to increase disulfide bond 
formation in the cytoplasm555. Such strains are commercially available, e.g. the Origami or Rosetta-
Origami strains from Novagen. Additionally to the trxB and gor mutations, SHuffle strains, 
available from New England Biolabs,  express a leaderless DsbC protein which thus resides and is 
active in the cytoplasm556. The SHuffle strain was successfully applied to the cytoplasmic 
production of a full-length antibody and various human proteins557,558. Very recently, the 
laboratory of DeLisa successfully transferred the whole periplasmic oxidation pathway into the 
cytoplasm by solubilizing the membrane protein DsbB and co-expressing a leaderless DsbA 
protein559. The system outperformed the SHuffle system in the production of a mouse urokinase 
(uPA) containing 12 disulfide bonds.  
 
Hatahet, Nguyen and colleagues developed a plasmid-based system that allows for the formation 
of disulfide bonds in the cytoplasm without disruption of the reducing pathways. The plasmid 
expresses the yeast mitochondrial protein Erv1p and the mature disulfide isomerase DsbC from a 
pLysS backbone and was later named pCyDisCo (cytoplasmic disulfide bond formation in E. 
coli)560. In contrast to other disulfide bond catalysts, Erv1p is able to function independently of an 
intermediary protein (e.g. DsbA for the disulfide bond catalyst DsbB)561–563. Therefore, co-
expression of Erv1p in the E. coli cytoplasm is sufficient to increase the activity of recombinant 
proteins by 1000-fold. Compared to the ΔtrxB Δgor origami strain the activity was doubled when 
over-expressing Erv1p564,565.  
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Glycosylation 
For a long time, glycosylation was thought to be a solely eukaryotic feature. The discovery of an 
N-linked glycosylation system in the gram negative bacterium Campylobacter jejuni, the pgl gene 
cluster, opened up the possibility to synthesize glycoproteins in prokaryoates566. Expression of the 
system’s oligosaccharyl-transferase PglB in E. coli led to glycosylation of its substrate AcrA567, and 
in a more applied study even to glycosylation of a scFv antibody fragment, which increased 
biophysical and pharmacokinetic properties568. In 2012, the laboratory of DeLisa published a major 
breakthrough in bacterial glycoprotein production. Expression of four yeast-derived enzymes, 
involved in the eukaryote’s glycosylation process Alg1, Alg2, Alg13 and Alg14, and PglB in E. coli 
resulted in the in vivo formation of a Man3GlcNAc2 glycan, the core structure to all human N-
glycans569. However, the subsequent composition of the produced glycan and the efficiency of 
glycan attachment to a protein remain major challenges for glycosylation in prokaryotes. 
Additionally, a difference in the consensus sequence recognized by PglB and the eukaryotic 
consensus sequence presents a bottleneck in the development of E. coli as a glycoprotein 
production host570. An excellent review on the details of protein glycosylation in bacteria was 
published in 2010 by Nothaft and Szymanski571. 
 
3.6 Screening for optimized protein production 
Available screening techniques vary in their capacity, sensitivity and selectivity. The ideal 
screening assay should be (i) highly sensitive, which enables the detection of small differences, (ii) 
should cover a large dynamic range, which prevents saturation of the system, and (iii) should 
respond in a linear range of detection572. The correlation between an input and an output of a 
screening assay is defined in its transfer function (Figure 19). 
 
 
 
 
Figure 19: The transfer function. Correlation between 
the input, i.e. protein concentration, and the output 
response are important. The linear range, the dynamic 
range and the sensitivity (Δoutput/Δinput) define a 
reporter. 
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Construction of the reporter system for protein production 
When optimizing production of a protein of interest, a reporter protein helps to identify the 
optimized candidates in screening assays. The choice of reporter protein decides on which 
screening techniques can be used later on (Table 7). A reporter is not always essential, but often 
enables high throughput. Commonly used reporters are fluorescent proteins, proteins that form or 
bind to pigments, or antibiotic resistance markers. The production of the reporter protein needs to 
be connected with the target protein production. In most cases, the target protein is fused directly 
to a reporter protein or a split-reporter protein as described previously (Figure 20A, B). An 
attractive alternative is the coupling of target and reporter gene on translational level. Translational 
coupling setups avoid the physical fusion of target and reporter protein. Translational coupling is 
a natural phenomenon occurring in prokaryotes, for example in the attenuation of the tryptophan 
operon573. Such setups can be constructed utilizing secondary structure forming RNA devices. 
Masking of the SD sequence of the reporter gene in an mRNA secondary structure, makes 
translation of the reporter gene dependent on the translation of the target gene. Only if the target 
gene is translated, the helicase activity of the ribosome will unwind the secondary structure and 
expose the SD sequence for ribosome binding (Figure 20C).  
 
 
Figure 20: Direct and translationally coupled protein fusions. A gene of interest (goi, blue) can be fused directly 
to a reporter gene (orange) (A). Reporter proteins can be split into two parts, which upon reassembly exhibit the 
same phenotype as their non-split counterparts. The gene of interest can be fused to a split-part of a reporter protein. 
The complementary split-half needs to be supplemented or co-expressed (B). (C) Target gene and reporter gene can 
be translationally coupled. Translation of the reporter depends then on translation of the target gene. 
 
Mendez-Perez et al. designed the first synthetic RNA hairpin structure574. Yet, the target gene needs 
to be C-terminally His-tagged to make use of this coupling device. In the first study of this thesis 
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(Paper 1) an alternative translational coupling device is developed, which no longer requires an 
artificial extension of the target gene. Translationally coupled fusions are especially useful if a 
growth-coupled phenotype, e.g. an antibiotic resistance marker should be utilized for screening. A 
previous study found that many antibiotic resistance marker form oligomeric complexes and as a 
result can drag the target protein in a misfolded state575. Independent of whether direct fusions or 
translationally coupled setups are employed, any reporter proteins with colorimetric or fluorescent 
phenotypes can be used for screenings. 
 
Screening and selection 
Which screening approach can be applied, depends on the phenotype of the reporter. Screening 
approaches are summed up in Table 7. Screening on LB agar plates or in microtiter plates can be 
very time consuming and laborious but is needed in case of a colourimetric phenotype. The 
throughput of manual screening is rather low with less that 105 clones per day. In the presence of 
a fluorescent phenotype, higher throughput can be achieved by using fluorescence-activated cell 
sorting (FACS) (up to 109 cells per day) or droplet micro-fluidics88,576–580. While being extremely 
efficient, FACS and droplet micro-fluidics are expensive platforms to purchase and maintain, and 
specific training is required to operate such platforms. The most powerful screening method in 
terms of throughput is to link protein production to fitness or survival of the cell88. This is an easy 
task if the target is essential for growth. If not, the production of the target protein can be linked to 
a growth-essential factor, such as an auxotrophic marker or an antibiotic resistance gene572,581. The 
drawback of these systems is that selection becomes difficult in strains where the desired protein 
is already produced to decent levels and has to be further improved582. If antibiotics need to be 
supplemented in g/L, screening is not economically feasible anymore. This thesis addresses the 
drawback by outlining the design of novel translational-coupling devices, which tune the coupling 
efficiency, thereby extending the efficacy of the used reporter gene.  
 
Estimating gene expression levels by screening small molecule products 
In the case that the target protein performs an enzymatic reaction and the product can easily be 
measured, the product formation itself can be used to indicate expression levels. Inconspicuous 
small molecules can be converted into a detectable output through transcriptional activation of a 
conspicuous reporter protein or another enzymatic reaction. Similar to before, screening outputs 
can be fluorescent, colorimetric or growth-dependent. If no detectable phenotype can be achieved, 
small molecules can be quantified using analytical methods, such as LC-MS or GC-MS86. 
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Table 7: Screening approaches and their requirements and capacity 
Method Requirements Capacity 
Cell survival Growth-coupled selection system 108 – 1010 per day 
FACS Fluorescent phenotype < 109 per day 
Colony picking Fluorescent/ colourimetric phenotype < 105 per day 
Enzyme assay Target protein performs an enzymatic 
reaction, which results in an easily 
detectable phenotype 
< 105 per day 
Analytical methods Chromatography standards must be 
available 
< 103 per day 
 
Expression of a reporter with a conspicuous phenotype is mediated by transcription factors (Figure 
21A) or riboswitches (Figure 21B), which are activated upon binding of the small molecule product. 
Transcription factors act on transcriptional level by binding to a specific DNA sequence close to 
the promoter171. They are described in more detail in section 2.1.1. In comparison, riboswitches act 
mostly on translational level. The core of the riboswitch contains a so-called aptamer, which binds 
the small molecule. Upon binding the ligand, riboswitches induce changes in the mRNA folding, 
which controls translation, yet some control on transcriptional level is also possible583–585.  
 
 
Figure 21: Inconspicuous small molecules can be converted into a detectable output. (A) Small molecules can 
bind to a transcription factor, which thereupon activates expression of a conspicuous reporter gene. (B) A small 
molecule can bind to the aptamer of a riboswitch, which thereupon induces conformational changes in the mRNA 
structure, resulting in the translation of a conspicuous reporter gene. (C) Inconspicuous small molecules can be 
converted into conspicuous small molecules in an enzymatic reaction. 
 
However, the development of a specific sensor is time-consuming, as no fully generalizable 
methods to develop such sensors are available yet582,586. Enzymatic reactions that convert the 
inconspicuous small molecule into a conspicuous phenotype are rare but have been applied, e.g. 
in the detection of L-tyrosine which can be converted to the pigment melanin587 (Figure 21C). If a 
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product is secreted into the medium, a chemical reaction with a supplemented compound can 
result in a detectable phenotype.  
 
Screening capacity is generally the major bottleneck in many experiments. The development of 
new screening approaches is not only worthwhile for protein production optimization but is also 
beneficial for general metabolic engineering. The test phase of the Design-Build-Test cycle can be 
accelerated through the use of advanced screening methods. 
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Concluding remarks and future perspectives 
The development of economically feasible microbial cell factories for cost efficient production of 
chemicals, pharmaceuticals and proteins is still a challenging task. Among others, production and 
screening of pathway enzymes present major bottlenecks. While the final goal might be different, 
here, cell factory development and recombinant protein production face a common problem. Both 
disciplines are confronted with low protein yields caused by insufficient expression, protein 
toxicity and insolubility. To overcome these challenges, different strategies can be pursued. 
 
In this thesis we demonstrate the use of novel and versatile synthetic biology tools that improve 
protein production in Gram-negative and Gram-positive bacterial hosts.  
 
In order to facilitate screening of expression libraries, we developed a set of tuneable antibiotic 
resistance devices that provide a simple and versatile growth-based assay for the selection of high-
expressing variants in libraries with an unprecedented level of diversity. In Paper 1, we used this 
powerful approach to double the yield of an antibody-like protein, which was already produced 
at industrial titres and obtained a 65-fold increase in the yield of another antibody-like protein in 
E. coli. 
 
To provide new tools that facilitate the use of the two Gram-positive hosts B. subtilis and L. lactis 
in protein production projects, we established an expression library-based approach for protein 
production optimization. Hereafter, we implemented a tuneable antibiotic resistance device in B. 
subtilis and L. lactis to select for high expressing variants. In Paper 3, the combined effort of both 
tools resulted in industrial protein titres with 2 g//L culture in B. subtilis. 
 
Because the simple exchange of an antibiotic resistance gene or a reduction in copy number can be 
sufficient to increase protein yields, we developed the SEVA-Linker series, a system that allows 
the fast and easy exchange of plasmid backbones. With this it is possible to combine six antibiotic 
resistance genes and five origins of replication, resulting in 30 different plasmid backbones. The 
SEVA Linker series manifested a 430-fold difference in protein production of a difficult-to-express 
membrane protein (Paper 4). 
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Overall, the tools developed in this thesis facilitate the design, construction, screening and selection 
of gene expression constructs in many different protein production optimization approaches, but 
further development is still required. As an example, the tuneable antibiotic resistance devices are 
indicative of target gene expression levels but fail to give information about protein folding. We 
are considering an extension of the system for such purposes.  
 
With advances in systems biology, researchers have uncovered a long list of unknown enzymes, 
which require suitable expression tools to explore their structure and function. The tools for protein 
production optimization developed herein may support this process. The new information that 
those enzymes will provide might help to understand metabolic regulation in more detail and to 
uncover new targets for the treatment of diseases. As a result of the former, the construction of cell 
factories will be accelerated and, as a result of the latter, new medication can be developed. 
 
In general, there is a lack of adequate screening methods that keep up with the capacity and speed 
of parts assembly. This means that the unprecedented level of diversity that many synthetic 
biology approaches implement, can often not be covered in screenings. We hope that the tuneable 
antibiotic resistance devices, with the help of an available protocol for their use (Paper 2), will 
become a fundamental part of many protein production optimization processes due to being 
universally applicable, simple and inexpensive to use. 
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Abstract 
Evolution can be harnessed to optimize synthetic biology designs. A prominent example is 
recombinant protein production - a dominating theme in biotechnology for more than three 
decades. Typically, a protein coding sequence (cds) is recombined with genetic elements, such as 
promoters, ribosome binding sites and terminators, which control expression in a cell factory. A 
major bottleneck during production is translational initiation. Previously we identified more 
effective translation initiation regions (TIRs) by creating sequence libraries and then selecting for a 
TIR that drives high-level expression – an example of synthetic evolution. However, manual 
screening limits the ability to assay expression levels of all putative sequences in the libraries. Here 
we have solved this bottleneck by designing a collection of translational coupling devices based on 
a RNA secondary structure. Exchange of different sequence elements in this device allows for 
different coupling efficiencies therefore giving the devices a tuneable nature. Sandwiching these 
devices between the cds and a antibiotic selection marker that function over a broad dynamic range 
of antibiotic concentrations, adds to the tunability and allows expression levels in large clone 
libraries to be probed using a simple cell survival assay on the respective antibiotic. The power of 
the approach is demonstrated by substantially increasing production of two commercially 
interesting proteins, a Nanobody® and an Affibody®. The method is a simple and inexpensive 
alternative to advanced screening techniques that can be carried out in any laboratory. 
 
Keywords: protein production, antibiotic resistance, translational coupling, selection system, synthetic 
evolution, translation initiation region 
 
Introduction 
Proteins are essential for many biomedical and biotechnological applications. Most proteins are 
recombinantly produced in a heterologous organism, as their natural sources are impractical for 
high production yields1,2,3. In general, high yields are desirable, as this facilitates downstream 
applications and reduces the production costs. Furthermore, the use of recombinant sources allows 
facile engineering of protein modifications for increasing the activity, solubility4,5,6 or enabling 
purification7,8.  
 
Translation initiation is often the rate-limiting step when it comes to protein production in 
bacteria9,10,11. The efficiency of translation initiation is determined by the nucleotide sequence of the 
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translation initiation region (TIR), which consists of the Shine-Dalgarno (SD) sequence, the region 
upstream of the SD which contains the translational standby site12, and a region that stretches from 
the SD to the 5th codon of the cds13. In clones engineered for protein production, TIR is typically a 
random sequence formed at the junction of the vector and the first five codons of the coding 
sequence14. Such a randomly formed TIR has not co-evolved with the ribosomes of the host cell 
and often does not function efficiently for maximum production. Nucleotide changes in this region 
can affect protein production levels by as much as 1000-fold14,15 as they affect mRNA secondary 
structure and binding of the ribosome – a relaxed mRNA structure being more favourable for 
efficient translation initiation16,17,18,19,20. Computational tools that use thermodynamic principles to 
predict an optimized TIR are available21,22,23,24,25,26, but in the end experimental validation of the 
TIRs is still required. An alternative approach is to experimentally construct a TIR library and 
identify an optimal TIR by screening expression levels. However, the bottle-neck in this approach 
is the experimental evaluation of expression levels in large libraries.  
 
To achieve optimal production yields in a recombinant setting, we have explored a synthetic 
evolution approach, whereby we carry out an in vitro randomisation of the TIR and then 
experimentally select a nucleotide sequence that is compatible with high protein production. In a 
recent study, partial sequence variation was introduced in the TIRs for two difficult-to-express 
membrane proteins that were fused to fluorescent reporters and the plasmid libraries were 
screened by fluorescence activated cell sorting (FACS). In libraries containing approximately 
30,000 TIRs we observed up to 1000-fold variation in expression levels14. Still, identification of the 
highest performing constructs was time consuming and required access to advanced screening 
equipment.  
 
An attractive alternative to screening individual clones in a library is to couple expression of the 
cds to a growth-based selection system.  The ideal selection system is independent of the cds, and 
has a large dynamic screening range so that clones producing at industrially relevant titres can be 
identified. Previous work has used antibiotic selection markers that are either directly fused, or 
translationally-coupled to the gene of interest27,28,29,30. Translational coupling is a naturally 
occurring phenomenon in bacteria and is known to involve translating ribosomes that are able to 
resolve secondary structures that sequester the SD sequence of downstream genes31 (Fig. 1a). 
However, to our knowledge, no previous study has systematically addressed the dynamic range 
of either the antibiotic resistance markers or the translational coupling devices – i.e. to what extend 
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protein production levels correlate with the host resistance to the corresponding antibiotics. Here, 
we explore the concentration range of six antibiotic resistance markers and we design translational 
coupling devices that increase this range for one of the markers. 
 
Results and Discussion 
Probing the tunability of common antibiotic resistance markers 
Our initial aim was to determine which antibiotic resistance markers were suitable to use as reliable 
reporters for protein production. We engineered a series of clones in which a rhamnose-inducible 
promoter (PrhaBAD) controlled the expression of a gene encoding a fluorescent protein (Dasher-GFP), 
a translational coupling device, and one of six commonly used antibiotic resistance markers – 
conferring resistance to ampicillin/carbenicillin, chloramphenicol, spectinomycin, kanamycin, 
gentamicin or tetracycline, respectively (Fig. 1b). The constructs were transformed into Escherichia 
coli MG1655 and expression was induced with different concentrations of rhamnose. The different 
resistance genes were analysed with regards to the correlation between protein production (as 
determined by fluorescence) and resistance to the chosen antibiotic (as determined by the Minimal 
Inhibitory Concentration, MIC) using a fluorescence microplate reader as illustrated in Fig. 1b. Fig. 
1c shows that all constructs expressed Dasher-GFP in a rhamnose-dependent manner. All of the 
resistance markers, except for gentamicin, showed a linear correlation between the MIC and 
fluorescence (R2>0.9) (Fig. 1d-i). However, the ampicillin resistance marker (β-lactamase) 
displayed the largest dynamic range (Fig. 1c, right) and it was therefore selected for further 
characterization. Viable constructs based on the tetracycline resistance marker were only recovered 
at very low concentrations of tetracycline. For the chloramphenicol resistance marker, no linear 
correlation was found above an inducer concentration of 10 mM rhamnose, indicating that the cat 
gene is only tuneable to a certain extent. 
 
Exploration of an alternative translational coupling architecture 
With the coupling device that we used in the previous experiment, the MIC of ampicillin began to 
plateau at 10mM rhamnose (Fig. 1c, right).  Moreover, very high antibiotic concentrations were 
required for selections when expression was induced with more than 10 mM rhamnose, which 
could make downstream applications complicated and expensive. This limits the use of the 
coupling to antibiotic resistance markers when expression levels are high. To extend the selectable 
range of β-lactamase we explored alternative architectures of the translational coupling device.  
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Figure 1. Comparison of different antibiotic resistance genes as translationally coupled expression reporters. (a) 
A cartoon demonstrating the principle of translational coupling. A gene of interest (here dasher-gfp, green) is cloned 
upstream of a translational coupling device and a reporter gene (light red). If the gene of interest is not translated, 
the Shine-Dalgarno (SD) sequence of the reporter gene will be masked by secondary mRNA structure and no 
translation will take place. If the gene of interest is translated, the secondary structure will be unfolded by the 
ribosome’s helicase activity and the SD sequence will be accessible for a ribosome to bind and translate the reporter 
gene. (b) The six different expression constructs used in this study. In these constructs the gene encoding the green 
fluorescent protein Dasher-GFP (green) was translationally coupled with different antibiotic resistance genes and 
expression controlled by a rhamnose inducible promoter (PrhaBAD). Thus expression could be tuned with different 
rhamnose concentrations and followed during growth by simple whole-cell fluorescence in a microplate reader 
(illustrative example in bottom panel).  In minimum inhibitory concentration (MIC) assays different rhamnose 
concentrations were added to simulate different expression levels and growth at different concentrations of 
antibiotics was tested. The investigated antibiotic resistance genes confer resistance to ampicillin (bla, red), 
chloramphenicol (cat, orange), spectinomycin (aadA, yellow), kanamycin (aphA1, light grey), gentamicin (acc3, dark 
grey) and tetracycline (tetC, blue). (c) To assure that induction was similar in all constructs, fluorescence was plotted 
against inducer concentration (rhamnose) (left panel). To analyse the dynamic range of each antibiotic resistance 
gene the obtained MIC values (colour coded for each gene as indicated above) were plotted against inducer 
concentration (rhamnose) (right panel). Finally, the correlation between protein production, determined as 
fluorescence normalized for cell density, with MIC values was determined for ampicillin (d), chloramphenicol (e), 
spectinomycin (f), kanamycin (g), gentamicin (h) and tetracycline (i).  
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Our goal here was to design a device with a weaker output from β-lactamase, so that less ampicillin 
could be used in the selections (Fig. 2a). Since coupling efficiency must be dependent on proximity 
to the upstream gene we rationally designed hairpin structures where the stop codon of the 
upstream gene was located at the base of a hairpin that contained the TIR of the downstream gene 
(Fig. 2b). This way, the two coding sequences were in close vicinity, but the hairpin structure was 
not part of the cds of the upstream gene. The complementary part of the stem region encodes for 
the second amino acid of the downstream gene (Fig. 2b). We chose the UGA stop codon, as the 
ampicillin and kanamycin resistance gene comprise a serine as the second amino acid, encoded by 
UCA, complementary to the UGA stop codon. The addition of serine had no effect on the other 
resistance markers tested. The three nucleotides following the stop codon in the stem region are 
determined by the choice of start codon in the complementary downstream region and two of these 
together with the next seven nucleotides comprise the Shine-Dalgarno (SD) sequence for the 
reporter gene. We chose a SD sequence consisting of the nine nucleotides AUAGGAGGU. The stem 
region was designed to contain 11 nucleotide pairs in total.  
 
To reduce the translation efficiency of β-lactamase whilst preserving the overall hairpin structure, 
we designed two alternative hairpins. In the first we exchanged the AUG start codon with the less 
efficiently translated AUU start codon (Fig. 2b, indicated with an asterisk).  Coupling efficiency is 
not only reduced by using the weaker start codon but potentially also by stronger termination of 
translation of the target gene, due to a simultaneous change of the base following the stop codon 
most likely causing rapid selection and interaction of the release factor with the stop codon 
avoiding frame shifts, as previously shown32. To further reduce coupling efficiency, we 
additionally modified the Shine-Dalgarno sequence so that it was less complementary to the 16S 
rRNA. We changed the very strong sequence to the very weak AUUCCUGGU sequence for the 
most effective reduction of coupling efficiency (Fig. 2b, indicated with an asterisk). 
 
The hairpins were designed with a very small loop region connecting the two halves of the stem. 
The loop region consists of only three nucleotides where two nucleotides are defined by the chosen 
SD sequence. The small loop region was chosen so that the spacing between the SD sequence and 
the start codon of the reporter gene is close to the optimal five nucleotides33. Due to the 
experimentally determined good correlation coefficients between 0.87 and 0.96 that we achieved 
with the small loop region, we preferred to not elongate the loop region. The hairpin folding 
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propensity was tested in silico with the mfold web server34. The ΔG of the hairpins varied between 
-14.5 (strong coupling), -12.4 (weak coupling 1) and -12.3 (weak coupling 2). 
 
Determination of the MICs at different expression levels, confirmed that these designs reduced the 
levels of antibiotic resistance, while preserving high correlation co-efficiency between expression 
of the upstream gene and the MIC (Fig 2c-d). For example, when using the coupling device with 
the AUU start codon, the MIC value was reduced from 3 to 0.2 mg/ml ampicillin with 5 mM 
rhamnose and from 6.5 to 0.5 mg/ml with 40 mM rhamnose. When using the weak coupling device 
with the AUU start codon and the suboptimal Shine-Dalgarno sequence, the MIC value was 
lowered to 0.1 mg/ml ampicillin at 5 mM rhamnose induction and to 0.25 mg/ml ampicillin at 40 
mM rhamnose. The detected fluorescence levels stayed similar in all three coupling set-ups 
indicating that the expression of the upstream gene is unaffected by the use of different coupling 
devices (Fig. 2d). Thus these experiments demonstrate that translational coupling devices can be 
used to tune the range of an antibiotic resistance marker. 
 
Figure 2. Modifying the translational coupling efficiency by rational sequence changes in the predicted RNA 
hairpin structure. (a) DNA sequences with strong and weak coupling efficiencies between the upstream gene (here 
dasher-gfp, green colour) and the downstream selection marker (here the ampicillin resistance gene, red colour) 
were designed to enable selection under different expression regimes. (b) Sequences and predicted structures of 
the strong and weak translational coupling devices. Important features are boxed: stop codon of the upstream gene 
(red), start codons of the downstream genes (AUG or AUU, green) and Shine-Dalgarno (SD) sequences 
(AUAGGAGGU or AUUCCUGGA, grey). Differences are indicated with an asterisk. (c) In MIC assays, different 
inducer concentrations were added to simulate different expression levels of dasherGFP and resistance towards 
different concentrations of ampicillin were tested for the strong (black) and the two weak coupling devices (dark 
and light red). (d) Correlation between protein production, determined as fluorescence normalized for cell density, 
with MIC values was determined for the strong (black) and the two weak translational coupling devices (dark and 
light red). 
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Antibiotic-resistance-based selection of high expressers from TIR variation libraries  
We next explored the combination of a translational coupling devices and β-lactamase in the 
selection of optimal TIRs from sequence-randomized libraries. We focused on two well-studied 
genes, araH and narK, that are highly sensitive to TIR variation and whose expression can be 
estimated by fusions to GFP14,35. The regions encoding NarK-GFP and AraH-GFP were first fused 
to a translational coupling device and β-lactamase (Fig. 3a). Previously characterized NarK-GFP 
and AraH-GFP expression variants were used to validate the use of β-lactamase as an indicator of 
protein production levels (Supplementary Fig. S1a). We then created TIR libraries by randomizing 
the six nucleotides upstream from the start codon and sampling all synonymous codons in the first 
two positions after the start codon as described previously14. These libraries were designed to 
contain circa 30,000 TIR variants. The libraries were transformed into E. coli BL21(DE3) pLysS, 
protein production induced with IPTG and the cultures plated on agar plates with three different 
concentrations of ampicillin (Fig. 3b). This was repeated in parallel cultures with different 
ampicillin concentrations and each culture was analysed by flow cytometry (Fig. 3b). The cell 
library populations exhibited higher average fluorescence intensities as a result of growth in higher 
concentrations of ampicillin (Fig. 3C). When plating the libraries directly on LB agar plates 
containing different concentrations of ampicillin, we observed a decrease in the number of colonies 
but an increase in average colony fluorescence with rising antibiotic concentrations (shown for 
AraH-GFP in Fig. 3d). Individual colonies were picked from these plates and assayed for 
expression levels assessed by fluorescence per cell density. araH-gfp and nark-gfp variants selected 
on the highest antibiotic concentration showed to also be the highest expressing variants with 25-
fold and 10-fold increased expression, respectively (Supplementary Fig. S1b). This demonstrates 
that synthetic evolution of the TIR is resulting in populations enriched in high expressing clones 
and that our tuneable translation coupling devices enable identification of those with substantially 
increased protein production capacities.  
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Figure 3. Enriching populations of highly expressing gene variants from a TIR optimization library by screening 
for resistance to ampicillin. (a) Expression of the two E. coli membrane transporters NarK and AraH is highly 
sensitive to TIR variation and can be followed by direct fusions to GFP. In this study these fusions were 
translationally coupled to β-lactamase. All three proteins use the SecYEG translocon for targeting to the inner 
membrane or the periplasm. (b) NarK-GFP and AraH-GFP TIR libraries were constructed by PCR, transformed 
into BL21(DE3) pLysS and grown with different ampicillin concentrations either directly in liquid culture or on 
agar plates. Expression levels of the different synthetically evolved populations were assayed by flow cytometry 
(c) or by exposing agar plates to UV light (d). Selection on plates is here demonstrated for AraH-GFP.  
 
Optimization of Nanobody® production by synthetic evolution of the TIR 
To demonstrate the effectiveness of the tuneable antibiotic resistance cassettes we used them to 
identify optimal TIRs for commercially interesting proteins. Initially we focussed on a camelide-
derived single chain antibody (also known as a Nanobody®, Fig. 4a) that binds to GFP and 
enhances its fluorescence36,37. To identify a TIR that drove high-level expression of the Nanobody® 
we fused the cds to strong and weak coupling devices and the β-lactamase gene thereby creating 
two parallel constructs (Fig. 4b). As we had no estimate of the initial expression level, we 
hypothesized that the construction and selection of two parallel constructs would increase the odds 
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for identifying optimized TIRs with minimal additional effort. TIR libraries, each containing circa 
30,000 clones, were generated and transformed into BL21(DE3) pLysS, induced with IPTG and 
plated onto LB agar containing increasing concentrations of ampicillin (Fig. 4c). We observed that, 
regardless of the coupling device, the TIR library produced viable colonies at higher ampicillin 
concentrations than the original TIR (Fig. 4d, e). And as expected, the weak coupling device was 
more sensitive to ampicillin. Plasmids were recovered from five different colonies selected on 1.5 
mg/mL and 4 mg/mL of ampicillin for the weak and the strong coupling device, respectively, and 
two unique TIRs were identified – one from each experiment. Western blotting confirmed that the 
increase in antibiotic resistance of the synthetically evolved constructs was paralleled by an 
increase in the production of the Nanobody® (Fig. 4f). Importantly, for both of the synthetically 
optimized clones, the activity of the Nanobody® was preserved as judged by its ability to bind 
GFP (Fig. 4g). Taken together the production of the Nanobody® could be improved 10-fold and 3-
fold using weak and strong coupling devices, respectively. This exemplifies the value of different 
translational coupling devices to tune the resistance of the antibiotic resistance reporter. The yield 
of purified Nanobody®/L of culture was estimated around 986 mg and 86 mg using the weak and 
strong coupling devices, respectively, judged by densiometric analysis in accordance with a 
standard curve of purified protein of known concentration (Supplementary Fig. S3a, b). Sequences 
of the selected TIR variants are shown in Table S4. 
 
Optimization of Affibody® production by synthetic evolution of the TIR 
We also explored the effectiveness of the tuneable antibiotic resistance cassettes for identifying 
optimal TIRs for an Affibody® molecule. Affibody® molecules are small (6.5-kDa) affinity proteins 
based on a three-helix bundle domain framework38. We focussed on an albumin binding domain 
(ABD)-fused dimeric Affibody® molecule (Fig. 5a). This molecule binds to the human epidermal 
growth factor receptor 3 (HER3), which is implicated in a number of different cancers39. In the 
experiment we translationally coupled the cds to the β-lactamase gene and then created a TIR 
library (Fig. 5b). The TIR library contained circa 30,000 clones, which were transformed into 
BL21(DE3) pLysS, induced with IPTG and plated onto LB agar containing increasing 
concentrations of ampicillin. We observed that the TIR library produced viable colonies at higher 
ampicillin concentrations than the original TIR (Fig. 5c). 
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Figure 4. Optimized production of a single chain antibody by synthetic evolution. (a) Nanobodies® are derived 
from the variable domain of camelide heavy chain antibodies. (b) A His-tagged Nanobody®-encoding sequence 
was translationally coupled to the bla gene using both the strong and weak translational coupling hairpins. (c) 
Nanobody® TIR libraries were constructed by PCR, transformed into BL21(DE3) pLysS and grown with different 
ampicillin concentrations on agar plates. (d) Colony forming unit (CFU) counts after plating the TIR libraries with 
the weak coupling to bla (TIRLib1) or (e) with the strong coupling to bla (TIRLib2).  The growth of the original, non-
randomized clones (TIROrig) were included as controls. Concentrations where optimized clones were sampled are 
indicated with an asterisk.  (f) Nanobody® production levels with two different synthetically evolved TIR clones 
were analysed by Western blotting using an antibody against the His-tag. TIRSynEvo1 was selected with the weak 
coupling device and TIRSynEvo2 with the strong coupling device The increase in Nanobody® production was 
analysed by densitometry and plotted as the ratio of protein compared to the original clone (right panel). An 
antibody against Leader Peptidase (LepB) was used as a loading control. (g) The specific Nanobody® binds to GFP 
(illustrated in upper panel) and functionality of the nanobodies produced from the original and from the two 
synthetically evolved clones were assayed by mixing GFP with cell extracts from the different clones and analysed 
by in-gel fluorescence (lower left panel). The activity levels were estimated by densitometry comparing in-gel free 
GFP levels with the larger Nanobody®-bound GFP species (lower right panel).  
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Plasmids were recovered from five different colonies that grew at 400 µg/mL ampicillin, and five 
unique TIRs were identified. Protein production from these TIRs was tested in glucose-limited fed-
batch fermentations, reaching cell concentrations of 200 g/kg wet weight. The resulting product 
concentration was increased from approx. 26 mg/g cells to 50-57 mg/g cells (Fig. 5d). Or calculated 
another way, from 6 g/L to 11-12 g/L, thus approximately doubling the yield. The purified product 
did not show any increase of product related impurities.  
 
Figure 5. Optimized production of an Affibody® in fed-batch fermentation by synthetic evolution. (a) Schematic 
structure of the Affibody® molecule. Two Affibody® units (blue) are fused to an albumin binding domain (ABD, 
grey). The molecule binds bivalently to the human epidermal growth factor receptor 3 (HER3). (b) The Affibody® 
moelcule-encoding sequence was translationally coupled to the bla gene using a strong translational coupling 
hairpin. A TIR library was constructed by PCR and expressed in BL21(DE3) pLysS. Selection was performed on LB 
agar plates with different ampicillin concentrations. Optimized constructs were tested in fed-batch fermentation 
for their improved production. (c) Colony forming unit (CFU) were compared after plating the TIR library (TIRLib) 
and the original construct as control (TIROrig). The concentration used for sampling of optimized variants is 
indicated with an asterisk. (d) Affibody® production levels in fed-batch fermentation were calculated for five 
synthetically evolved library variants (TIRSynEvo1 – TIRSynEvo5) per cell mass and per culture volume in comparison to 
the original construct (TIROrig). 
 
Conclusions 
Previous studies from our laboratories have shown large differences in protein production by 
randomizing a specific region of the TIR14. Possibly, the approach represents a good compromise 
between the extend of sequence variation and library size and this enables isolation of highly 
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expressing clones even by simple colony picking and manual protein production screening by e.g. 
fluorescence or SDS-PAGE. To simplify and speed up identification of the best clones in these TIR 
libraries, we have now developed a selection approach that can replace manual or FACS-based 
screening. By translationally coupling a cds of interest to the cds of ß-lactamase and then plating 
the library on high ampicillin concentrations we could easily select for the best expressing gene 
variants. Formation of satellite colonies is a known issue with using ampicillin, but this was not 
observed under our experimental conditions. If this problem did occur, replacing ampicillin with 
the more stable carbenicillin could solve the issue40. Construction of the TIR library and selection 
of optimal clones can be performed in just a few days, and may be attractive to combine with DNA 
synthesis as a general synthetic biology workflow for simultaneous gene synthesis and expression 
optimization. The selection-based screening may also enable screening of other libraries that 
extend beyond the TIR, such as promoter optimization, or optimization of entire gene coding 
sequences (produced synthetically or by error-prone PCR).  
In the present work, we evaluated the efficacy of six commonly used antibiotic resistance genes, 
revealing important differences in the application of those as reporters. This systematic study 
informs the general use of these antibiotics for any growth-based selection. Secondly, we designed 
novel translational-coupling devices with different coupling efficiencies. These coupling-devices 
can therefore expand the utility of the used antibiotic resistance genes. Finally, we designed the 
translational-coupling devices in such a way that no artificial extension of the protein of interest is 
necessary.  
 
The six tested antibiotic resistance genes confer resistance to the most commonly used laboratory 
antibiotics. Five of these antibiotics encode cytosolic proteins that target the ribosome and therefore 
interfere with protein biosynthesis41. Ampicillin inhibits periplasmic proteins which are required 
for peptidoglycan synthesis. The protein that confers resistance, β-lactamase, is secreted into the 
periplasm via the Sec translocon42. Our analysis identified β-lactamase as the most suitable 
resistance marker for selection despite the requirement for secretion. This may reflect the mode of 
action of ampicillin, being the only tested antibiotic not acting on protein synthesis. It would be 
interesting to explore more antibiotics that are not acting on protein biosynthesis for this purpose 
since β-lactamase could saturate the secretory machinery when expressing recombinant proteins 
that also utilize the Sec translocon, such as membrane proteins and periplasmic proteins. Indeed, 
when performing whole cell fluorescence measurements for the selected high expressing NarK-
GFP and AraH-GFP variants, we noticed a significant decrease in fluorescence when the 
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translational coupling cassette was added (on average six- and three-fold, Supplementary Fig. S2a 
and S2b). A similar effect was not observed when using the spectinomycin resistance gene instead 
of the ampicillin resistance gene in the antibiotic selection system. Therefore, it may be worth 
removing the selection device after identification of a high expressing gene variant, especially 
when working with a membrane or secreted protein.  
The choice of β-lactamase as the most suitable candidate in a growth-based selection system might 
not be surprising. Previously β-lactamase was used as a growth-based sensor for protein 
stability43,44 and very recently it was used in a survival assay that linked extracellular protein 
secretion to ampicillin resistance45. Reasons for the abrupt plateauing of the chloramphenicol 
resistance gene at 1 mg/mL chloramphenicol might be caused by too high ethanol concentrations 
in the medium (due to chloramphenicol stock solution being dissolved in 100% v/v ethanol) or is 
result of a limitation in the tuneable range of the system. To avoid the latter one could use a weaker 
variant of our translational coupling device. The general limitation of tetracycline-based selection, 
due to its extremely narrow dynamic range of action, may be related to the resistance gene used 
(tetC), and growth at higher concentration might be achieved by using the tetracycline transporter 
TetA instead. Here, it should be taken into account that it was previously observed that over-
expression of a membrane proteins like the tetracycline transporter can have toxic effects on the 
cell 46 and can lead to impaired growth by affecting the cell’s membrane potential47. 
 
In addition to our two model membrane proteins, we demonstrated that the translational coupling 
cassette facilitated the identification of optimized TIRs for the production of a Nanobody® and an 
Affibody®. The Nanobody® was increased from virtually no expression to an estimated 1 g/L scale 
yield. Previous studies reported a yield of 10-15 mg/L of culture48, albeit under different growth 
conditions. With the optimization of the TIR sequence in our expression vector, the obtained yield 
was more than 65-fold higher. The production of the Affibody® was doubled in a fed-batch 
fermentation at >10 g/L industrial scale. The latter example demonstrates that even highly 
optimized production scenarios at industrial titres can benefit from TIR optimization and selection. 
Furthermore, these examples highlight the importance of the extended coupling device toolbox to 
enable antibiotic selection at many different production levels.  
 
The optimization of the two pharmaceutically relevant proteins also demonstrates the strength of 
our developed hairpin structures in the selection system. These enable translational coupling of a 
gene of interest without any modification to the protein sequence, such as the addition of an 
 103 
expression tag. This is particularly important for industrially- or pharmacologically-relevant 
proteins, where modifications to the protein sequence are not tolerable for downstream 
applications.  
 
Methods 
Strains, media and growth conditions 
The strains used in this study are listed in Supplementary Table S1. Escherichia coli NEB5α (New 
England Biolabs, Ipswich, MA, USA) was used for cloning and propagation of plasmids. For 
library constructions the E. coli strain MC1061 was used. Expression experiments were performed 
in E. coli BL21(DE3) pLysS (Novagen, Merck KGaA, Darmstadt, Germany). E. coli MG1655 was 
used for testing combinations of RNA hairpin structures and antibiotic resistance genes. 
Chemically competent cells of NEB5α, MG1655 and MC1061 were obtained as described 
elsewhere49. Bacteria were cultivated in lysogeny broth (LB) with shaking (250 rpm) at 37 °C. 
Cultures were supplemented with antibiotics when required. Unless otherwise stated, antibiotics 
were used in the following concentrations: ampicillin and carbenicillin (100 µg/ml), kanamycin (50 
µg/ml), chloramphenicol (34 µg/ml), spectinomycin (50 µg/ml), tetracycline (10 µg/ml) and 
gentamicin (10 µg/ml).  
 
Plasmid and strain construction 
All plasmid manipulations were performed using uracil excision cloning as described elsewhere50. 
The plasmids used in this study are listed in Supplementary Table S2. PCR was carried out with 
PfuX7 polymerase as previously described51 and Phusion U Hot Start polymerase (Thermo Fisher 
Scientific, Waltham, MA, USA). Oligonucleotides were received from Integrated DNA 
technologies (IDT, Coralville, IA, USA) (Supplementary Table S3). For comparing different 
translationally-coupled antibiotic resistance genes and different RNA hairpin structures, the 
pACYC-DasherGFP-hp-AbR series was constructed using the resistance genes of different vector 
backbones (Supplementary Table S2) and a plasmid encoding the DasherGFP protein under 
control of a rhamnose inducible promoter (ATUM Bio, Newark, CA, USA). The various hairpin 
sequences were introduced by PCR with oligonucleotides. For validation of the selection system 
the hp-bla and hp-aadA module were cloned into a pET28a(+) backbone already encoding known 
expression variants of AraH-GFP and NarK-GFP. For optimization of the GFP-Nanobody® the 
gene encoding the Nanobody®, as well as translational coupling element and bla gene, were 
cloned into the pET28a(+) backbone (Novagen, Merck KGaA, Darmstadt, Germany). All plasmids 
 104 
were isolated using the QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany) and PCR products 
were purified using the NucleoSpin® Gel and PCR Clean-up Kit (Macherey-Nagel, Düren, 
Germany). 
 
Library design and construction 
TIR libraries were constructed using a degenerated forward primer specific for each gene of 
interest. In each degenerated forward primer the six nucleotides upstream of the start codon were 
changed to all possible combinations and the six nucleotides downstream of the start codon were 
changed to all possible synonymous codon combinations. For plasmid library constructions Q5 
polymerase was used (New England Biolabs, Ipswich, MA, USA). Library construction was 
performed as described elsewhere14.  
 
Expression and selection 
For expression of individual clones, overnight cultures were prepared by inoculating a single 
colony in 800 µL LB media supplemented with respective antibiotics and incubated in a 2.2 ml 96-
deep well plate (EnzyScreen, Heemstede, The Netherlands) at 37 °C with shaking. Cultures were 
then back-diluted (1:50) into 5 mL of LB media containing appropriate antibiotics in a 24-deep well 
plate and incubated at 37 °C. At an OD600 of approximately 0.3 expression was induced with 1.0 
mM IPTG. For membrane protein expression the temperature was lowered to 25 °C. 
 
For expression and selection from clone libraries ca. 1 µg of plasmid library was transformed into 
100 µl BL21(DE3)pLysS using a standard protocol. The transformation was transferred to 5 ml LB 
media supplemented with respective antibiotics and grown overnight at 37 °C. Cultures were then 
back-diluted (1:50) into 5 mL LB media containing the appropriate antibiotics in a 24-deep well 
plate (EnzyScreen, Heemstede, The Netherlands) and incubated at 37 °C. At an OD600 of 
approximately 0.3 expression was induced with 1.0 mM IPTG. For membrane protein expression 
the temperature was lowered to 25 °C. 2 h after induction, OD600 was measured and 0.2 OD units 
of cells were then plated on LB agar plates containing 1 mM IPTG and different concentrations of 
ampicillin and incubated overnight at 37 °C. Selected expression variants were sequenced. To 
exclude other reasons than an optimized translation initiation region for higher expression levels, 
the selected TIR sequences were re-cloned into a clean expression vector for further 
characterization.  
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MIC determination 
To test translationally coupled antibiotic resistance genes and different hairpins, the pACYC-
DasherGFP-hp-AbR series were transformed into E. coli MG1655 using a standard protocol. 
Overnight cultures were prepared by inoculating a single colony in 3 mL 2xYT media containing 
the appropriate antibiotic and incubated at 37 °C. Cultures were then back-diluted (1:100) into 2 
mL 2xYT media containing the appropriate antibiotic and different concentrations of rhamnose as 
inducer (0 mM, 0.625 mM, 1.25 mM, 2.5 mM, 5 mM, 10 mM, 20 mM, 40 mM rhamnose) in a 24-
deep well plate (EnzyScreen, Heemstede, The Netherlands). Cultures were incubated at 37 °C with 
shaking. After 4 h, 10 µL of each culture was transferred to a 96 well plate (Greiner, Kremsmünster, 
Austria) containing 100 µL 2xYT media (ca. 5x105 cfu/mL), a serial dilution of the antibiotic and 
respective concentrations of rhamnose as inducer. Plates were incubated for 18 h. For end-point 
MIC determination fluorescence (Ex: 485 nm, Em: 512 nm for GFP; Ex:, 512 nm Em: 520 nm for 
DasherGFP) and OD600 were measured in an MX plate reader (Biotek, Winooski, VT, USA). A 
culture containing none of the inducible antibiotic served as positive control, media containing no 
culture served as negative control. For each antibiotic the MIC value was defined as the lowest 
antibiotic concentration at which the final OD600 represented less than 10% of the entire population 
after background correction. Each MIC experiment was conducted with biological triplicates.  
 
To assess protein production, constructs were transformed into E. coli BL21(DE3) pLysS (Novagen, 
Merck KGaA, Darmstadt, Germany) using a standard protocol. Cultures were prepared and 
expression was performed as described above. After induction, cultures were incubated for 2 h. 
For MIC determination a dilution series of the translationally coupled antibiotic was prepared in a 
96 well plate (Greiner, Kremsmünster, Austria). Subsequently, 10 µL of each culture was 
transferred to the 96 well plate. 
 
Flow cytometry 
For flow cytometry measurements, cultures were prepared and expression was performed as 
described above. Expression cultures were grown overnight after induction and then back-diluted 
(1:100) in 1x PBS for analysis. Flow cytometry measurements were performed on a FACS Aria 
(Becton–Dickinson, San Jose, CA, USA) with excitation at 488 nm from a blue solid-state laser. 
FlowJo (Treestar, Ashland, OR, USA) was used for data analysis. 
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Western Blot analysis 
For Western Blot analysis, cultures were prepared and expression was performed as described 
above. Cultures were grown for 5 h after induction. Cells were resuspended to a final concentration 
of 0.025 ODU/µl in CelLytic B (Sigma Aldrich, St. Louis, MO, USA) supplemented with lysozyme, 
egg white (Amresco, Solon, OH, USA), Benzonase nuclease (≥250 units/µL, Sigma Aldrich, St. 
Louis, MO, USA) and Roche cOmplete™ Protease Inhibitor Cocktail (Sigma Aldrich, St. Louis, MO, 
USA) and incubated for 1 h before the sample was mixed with the same volume of 5x reducing 
sample buffer and heated to 95°C for 5 min for protein denaturation. 0.05 ODU of the samples were 
loaded onto a 4-20 % Mini-PROTEAN-TGX gel (BioRad, Hercules, CA, USA) and run for 35 min at 
175 V. Proteins were transferred to a nitrocellulose membrane using the iBlot® dry blotting system 
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) at 25 V for 7 min. The proteins were 
detected using antigen-specific antibodies. The following antibodies were used: anti-His (1:1000; 
Merck Millipore, Merck KGaA, Darmstadt, Germany), anti-Lep (1:1000; a generous gift from 
IngMarie Nilsson and Gunnar von Heijne, Stockholm University). Primary antibodies were diluted 
in 5% w/v skim milk in TBS-T (20 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.1 % v/v Tween-20), 
secondary antibodies were diluted in TBS-T. The secondary antibody was visualized using 
Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare, Chicago, IL, USA). The 
chemoluminescence signal was detected using G:Box bioimager (Syngene, Cambridge, UK). The 
resulting images were analyzed by densitometry using the Fiji software52. 
 
Analyses of expression levels of Nanobody® molecules 
Cell pellets of 10 mL cultures were resuspended in 600 µL CelLytic B (Sigma Aldrich, St. Louis, 
MO, USA) supplemented with lysozyme, egg white (Amresco, Solon, OH, USA), Benzonase 
nuclease (≥250 units/µL, Sigma Aldrich, St. Louis, MO, USA) and Roche cOmplete™ Protease 
Inhibitor Cocktail (Sigma Aldrich, St. Louis, MO, USA) and incubated for 1 h on ice. Lysates were 
centrifuged for 20 min at 12,000 x g and the soluble fraction was loaded on a Ni-NTA Spin Column 
(Qiagen, Hilden, Germany). The spin column was washed twice with wash buffer (600 µL of 50 
mM NaH2PO4, pH 7.4, 300 mM NaCl and 20 mM imidazole) and then eluted twice with 300 µl of 
elution buffer (50 mM Tris-Cl pH 7.4, 300 mM NaCl, 250 mM imidazole). The two eluates were 
pooled. Protein concentration in the 600 uL eluate were estimated by densiometric analysis in 
accordance to a standard curve of known protein concentration using the Fiji software52. 
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In-Gel fluorescence measurements 
For In-Gel fluorescence measurements, cultures were prepared and expression was performed as 
described above. Cultures were grown for 5 h after induction. Cells were resuspended to a final 
concentration of 0.05 ODU/µl in CelLytic B (Sigma Aldrich, St. Louis, MO, USA) supplemented 
with lysozyme, egg white (Amresco, Solon, OH, USA), Benzonase nuclease (≥250 units/µL, Sigma 
Aldrich, St. Louis, MO, USA) and Roche cOmplete™ Protease Inhibitor Cocktail (Sigma Aldrich, 
St. Louis, MO, USA) buffer and incubated for 20 min on ice. Subsequently, cells were mixed with 
0.2 mg/mL GFP (final concentration 0.1 mg/ml). Cells and GFP were incubated for 20 min at 30 °C 
and 250 rpm. 10 µl of the GFP-cell-mixture were mixed with 5 µl 2× Laemmli sample buffer and 
the whole sample was loaded onto a 4-20 % Mini-PROTEAN-TGX gel (BioRad, Hercules, CA, USA) 
and run for 35 min at 175 V. The fluorescence signal was detected using G:Box bioimager (Syngene, 
Cambridge, UK). The resulting images were analysed by densitometry using the Fiji software52. 
 
Expression of Affibody® molecules 
Pre-inoculi were made from fresh colonies on selective agar using TSB+YE-medium supplemented 
with 50 mg/mL kanamycin. After 5 h incubation at 37 °C part of the pre-inoculi were used to 
inoculate a YNB-based defined shake-flask medium. This culture was incubated at 30 °C for 22 h. 
A defined synthetic fermentor medium was inoculated to an OD of 0.112. The fermentations were 
run at 37 °C using a glucose feeding strategy to control the growth rate, using a Greta 
Multifermentor System (Belach Bioteknik AB, Skogås, Sweden). pH was controlled at 7, through 
the automatic titration with 25 % NH4OH. After 18 h, the fermentations were induced with 0.5 mM 
IPTG. The fermentations were harvested after 30 h total cultivation time. Cell pellet samples were 
collected through centrifugation. 
 
Analyses of expression levels and purity of Affibody® molecules 
Cell pellets were treated with CelLytic (Sigma, St. Louis, MO, USA) and purified on product 
specific affinity chromatography matrices. The absorbance at 280 nm of the eluate was measured, 
and the product concentration could be calculated. The purity was analysed using an LC/MS 
method.  
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Abbreviations 
aadA   gene encoding streptomycin 3''-adenylyltransferase 
ABD   albumin binding domain 
acc3   gene encoding aminoglycoside N(3)-acetyltransferase 
aphA1   gene encoding aminoglycoside 3'-phosphotransferase 
bla   gene encoding β-lactamase 
cat   gene encoding chloramphenicol acetyltransferase 
cds   coding sequence 
FACS   fluorescence-activated cell sorting 
GFP   green fluorescent protein 
HER3   human epidermal growth factor receptor 3 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
LB   lysogeny broth 
MIC   minimum inhibitory concentration 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
rRNA   ribosomal RNA 
SD   Shine Dalgarno 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
tetC   gene encoding TetC, tetracycline resistance protein, class C 
TIR   translation initiation region 
TSB   tryptic soy broth 
YE   yeast extract 
YNB   yeast nitrogen base 
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Supplementary information for: 
TARSyn: Tuneable antibiotic resistance devices enabling bacterial 
synthetic evolution and protein production 
 
Supplementary Figure S1. The β-lactamase gene can be used as a sensor for high protein production levels. (a) 
A translational coupling device and the ampicillin resistance conferring gene (bla, red) were cloned into a pET28a(+) 
vector encoding NarK-GFP and AraH-GFP. (b) Known expression variants of the translational coupled NarK-GFP 
and AraH-GFP constructs were tested in minimum inhibitory concentration (MIC) assays and compared to non-
coupled NarK-GFP and AraH-GFP expression levels, estimated by fluorescence. (C) Translationally coupled NarK-
GFP and AraH-GFP TIR libraries grown with different ampicillin concentrations on agar plates. Ten individual 
colonies were picked from each plate and expression levels were estimated. 
 
 
Supplementary Figure S2. Assessment of effects of the co-production of an antibiotic resistance marker. narK-
gfp (a) and araH-gfp (b) expression levels were analysed in regards to co-expression of the translationally coupled 
ampicillin resistance conferring gene bla (AmpR marker) and the spectinomycin resistance conferring gene aadA1 
(SpecR marker). The wild type (wt; black), two low expressing (L1, L2; red) and two high expressing (H1, H2; blue) 
variants from a TIR library in a pET28a(+) backbone (KanR) were analysed.  
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Supplementary Figure S3. Assessment of Nanobody® expression levels. (a) A standard curve (upper panel) was 
used to estimate concentration of purified Nanobody® protein by densitometry (lower panel). (b) Nanobody® 
production levels were calculated for the two synthetically evolved library variants (TIRSynEvo1 and TIRSynEvo2) in 
comparison to the original construct (TIROrig) and plotted as product per cell mass against product per culture 
volume. 
 
Table S1. Strains used in this study 
Strain Genotype Source/Reference 
E. coli NEB5α fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
a 
E. coli MC1061 araD139, Δ(ara, leu)7697, ΔlacX74, galU-, galK-, hsr-, hsm+, strA  In house 
E.  coli BL21(DE3) pLysS F– ompT hsdSB(rB- mB-) gal dcm (DE3) pLysS (CmR) b 
E. coli MG1655 K-12 F– λ– ilvG– rfb-50 rph-1 c 
aNEB, Ipswich, MA, USA; b Novagen, Merck KGaA, Darmstadt, Germany; cATCC, Manassas, VA, USA 
 
Table S2. Plasmids used in this study 
Plasmid Property Source/Reference 
DasherGFP vector encoding dasher, KmR d 
pACYCDuet-1 Cloning and expression vector, CmR b 
pCDF-Duet Cloning and expression vector, SpR b 
pET PfuX7 Cloning and expression vector, AmpR 4 
pSEVA551 Cloning and expression vector, TetR 5 
pSEVA614 Cloning and expression vector, GmR 5 
pET28a(+) Cloning and expression vector, KmR b 
pACYC-pRha-dasher-hp-bla Cloning and expression vector with rhamnose promoter, CmR, p15A origin  This study 
pACYC-pRha-dasher-hp-aphA1 Cloning and expression vector, CmR This study 
pACYC-pRha-dasher-hp-aadA Cloning and expression vector, CmR This study 
pACYC-pRha-dasher-hp-cat3 Cloning and expression vector, AmpR This study 
pACYC-pRha-dasher-hp-acc3 Cloning and expression vector, CmR This study 
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pACYC-pRha-dasher-hp-tetA Cloning and expression vector, CmR This study 
pACYC-pRha-dasher-hpAUU-bla Cloning and expression vector, CmR This study 
pACYC-pRha-dasher-hpAUU-SD2-bla Cloning and expression vector, CmR This study 
pET28a-narKWT  narK-gfp-tev-his8 with T7 promoter, Km
R, 
pBR322/ROP origin 6 
pET28a-narKP3-3  narK-gfp-tev-his8 with T7 promoter, Km
R, 
pBR322/ROP origin 6 
pET28a-narKP4-4 narK-gfp-tev-his8 with T7 promoter, Km
R, 
pBR322/ROP origin 6 
pET28a-narKP7-1 narK-gfp-tev-his8 with T7 promoter, Km
R, 
pBR322/ROP origin 6 
pET28a-narKP7-6 narK-gfp-tev-his8 with T7 promoter, Km
R, 
pBR322/ROP origin 6 
pET28a-araHWT araH-gfp-tev-his8 with T7 promoter, Km
R, 
pBR322/ROP origin 6 
pET28a-araHP2-2 araH-gfp-tev-his8 with T7 promoter, Km
R, 
pBR322/ROP origin 6 
pET28a-araHP2-3 araH-gfp-tev-his8 with T7 promoter, Km
R, 
pBR322/ROP origin 6 
pET28a-araHP7-4 araH-gfp-tev-his8 with T7 promoter, Km
R, 
pBR322/ROP origin 6 
pET28a-araHopt araH-gfp-tev-his8 with T7 promoter, Km
R, 
pBR322/ROP origin 7 
pET28a-narKWT-bla  narK-gfp-tev-his8-hp-bla with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-narKP3-3 -bla  narK-gfp-tev-his8-hp-bla with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-narKP4-4-bla  narK-gfp-tev-his8-hp-bla with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-narKP7-1-bla  narK-gfp-tev-his8-hp-bla with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-narKP7-6-bla  narK-gfp-tev-his8-hp-bla with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-araHWT-bla  araH-gfp-tev-his8-hp-bla with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-araHP2-2-bla  araH-gfp-tev-his8-hp-bla with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-araHP2-3-bla  araH-gfp-tev-his8-hp-bla with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-araHP7-4-bla  araH-gfp-tev-his8-hp-bla with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-araHopt-bla araH-gfp-tev-his8-hp-bla with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-narKWT-aadA narK-gfp-tev-his8-hp-aadA with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-narKP3-3-aadA  narK-gfp-tev-his8-hp-aadA with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-narKP4-4-aadA  narK-gfp-tev-his8-hp-aadA with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-narKP7-1-aadA  narK-gfp-tev-his8-hp-aadA with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-narKP7-6-aadA  narK-gfp-tev-his8-hp-aadA with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-araHWT-aadA  araH-gfp-tev-his8-hp-aadA with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-araHP2-2-aadA  araH-gfp-tev-his8-hp-aadA with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-araHP2-3-aadA  araH-gfp-tev-his8-hp-aadA with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-araHP7-4-aadA  araH-gfp-tev-his8-hp-aadA with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-araHopt-aadA araH-gfp-tev-his8-hp-aadA with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-Nanobody®-hp-bla Nanobody®-his6-hp-bla with T7 promoter, Km
R, 
pBR322/ROP origin 
This study 
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pET28a-Nanobody®-hpAUU-bla Nanobody®-his6-hpAUU-bla with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-Nanobody®-TIRSynEvo1 SynEvo1-Nanobody®-his6 with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-Nanobody®-TIRSynEvo2 SynEvo2-Nanobody®-his6 with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-Nanobody®-TIRBCD BCD-Nanobody®-his6 with T7 promoter, Km
R, 
pBR322/ROP origin This study 
pET28a-Nanobody®-TIRRBSopt RBSopt-Nanobody®-his6 with T7 promoter, KmR, pBR322/ROP origin This study 
pET28a-Nanobody®-TIRUTRopt UTRopt-Nanobody®-his6 with T7 promoter, KmR, pBR322/ROP origin This study 
bNovagen, Merck KGaA, Darmstadt, Germany; dATUM, Newark, CA, USA 
 
Table 3. Oligonucleotides used in this study 
Name Sequence (5' --> 3') 
Cloning oligonucleotides   
pET28a-backbone_fwd ATC CGG CUG CTA ACA AAG CCC GAA AG 
pET28a-backbone_rev ATC CTC GAG UCT CCT TCT TAA AG 
Amp-pET28a_rev AGC CGG AUC TCA TTA CCA ATG CTT AAT C 
Spec-pET28a_rev  AGC CGG AUC TCA TTA TTT GCC GAC TAC CTT GGT GAT CTC G 
pACYC_backbone_rev AGG TAT CCU CAG CCG CGC GCG CGT C 
pACYC_backbone_fwd AGG TTA CCU CAG CGG CCG GCC CCT G 
pRhaDasher_fwd AGG ATA CCU CAG CCA CCA CAA TTC AGC AAA TTG TG 
pRhaDasher_hp_rev ACC TCC TAU GTC ACT GAT ACG TGT CCA GAT CAA CCG C 
pRhaDasher_hpAUU_rev ACC TCC TAU TTC ACT GAT ACG TGT CCA GAT CAA CCG C 
pRhaDasher_hpAUU_SD2_rev ACC AGG AAU TTC ACT GAT ACG TGT CCA GAT CAA CCG C 
Amp_hp_fwd ATA GGA GGU CCT CCT ATG TCA ATT CAA CAT TTC CGT GTC 
Amp_hpAUU_fwd ATA GGA GGU CCT CCT ATT TCA ATT CAA CAT TTC CGT GTC 
Amp_hpAUU_SD2_fwd ATT CCT GGU CCA GGA ATT TCA ATT CAA CAT TTC CGT GTC 
Spec_hp_fwd ATA GGA GGU CCT CCT ATG TCA AGG GAA GCG GTG ATC GC 
Kan_hp_fwd ATA GGA GGU CCT CCT ATG TCA CAT ATT CAA CGG GAA AC 
Cm_hp_fwd ATA GGA GGU CCT CCT ATG TCA GAG AAA AAA ATC ACT GG 
Tet_hp_fwd ATA GGA GGU CCT CCT ATG TCA AAA TCT AAC AAT GCG CTC 
Gm_hp_fwd ATA GGA GGU CCT CCT ATG TCA TTA CGC AGC AGC AAC 
Tet_ rev AGG TAA CCU CAG CTC AGG TCG AGG TGG CCC GGC TC 
Cm_ rev AGG TAA CCU CAG CTT ACG CCC CGC CCT GCC AC 
Kan_ rev AGG TAA CCU CAG CTT AGA AAA ACT CAT CGA GCA TCA AAT G 
Spec_ rev AGG TAA CCU CAG CTT ATT TGC CGA CTA CCT TGG TGA TCT C 
Gm_ rev AGG TAA CCU CAG CTT AGG TGG CGG TAC TTG GGT C 
Nanobody®_fwd ACT CGA GGA UGG CTC AGG TCC AAC 
Nanobody®_hpAUU_rev ACC TCC TAU TTC AGT GGT GGT GGT GG 
Nanobody®_hp_rev ACC TCC TAU GTC AGT GGT GGT GGT GG 
Nanobody®_var1_fwd ACT TTA AGA AGG AGA CTG GTA AAT GGC CCA AGT CCA ACT GGT 
CGA ATC AG 
Nanobody®_var2_fwd ACT TTA AGA AGG AGA CGA ATA TAT GGC TCA AGT CCA ACT GGT 
CGA ATC AG 
Nanobody®_RBSopt_fwd ATT CCC CTC UAG AAT AAT AGA GAC GTA ATA AGT AAT AAG GAG 
GTA AAC ATG GCT CAG GTC CAA CTG GTC GAA TCA G 
Nanobody®_UTRopt_fwd ATT CCC CTC UAG AAT AAT GTC ACA ATG CAA AGG AGA ATA TAC 
AAT GGC TCA GGT CCA ACT GGT CGA ATC AG 
Nanobody®_RBS_rev AGA GGG GAA UTG TTA TCC GCT CAC AAT TCC CCT ATA GTG AGT 
CGT ATT A 
Nanobody®_BCD_fwd AAA CAT CTT AAU CAT GCT AAG GAG GTT TTC TAA TGG CTC AGG 
TCC AAC TGG TCG AAT C 
Nanobody®_BCD_rev ATT AAG ATG TTU CAG TAC GAA AAT TGC TTT CAT CCT CGA GTC 
TCC TTC TTA AAG TTA AAC 
Bla_loopout_fwd ATA GGA GGU TGA GAT CCG GCT GCT AAC AAA G 
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Sequencing oligonucleotides   
hp-Amp_seq_fwd GAC AAC GAT CGG AGG ACC GAA G 
hp-Amp_seq_rev GAT CAA GGC GAG TTA CAT GAT C 
T7P_seq_fwd TAA TAC GAC TCA CTA TAG GGG AAT TG 
Dasher-hp_seq_fwd CAT CCG CGT TGA GTT CAA CC 
T7T_seq_rev GCT CAG CGG TGG CAG CAG CCA ACT CAG CTT 
Duet_colPCR_fwd GCG ACT CCT GCA TTA GGA AA 
Duet_colPCR_rev ACC CCT CAA GAC CCG TTT AG 
 
 
Table S4. Nanobody TIR sequences identified in this study. 
TIRorig TCGAGGATGGCTCAG 
TIRSynEvo1 TGGTAAATGGCCCAA 
TIRSynEvo2 GAATATATGGCTCAA 
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Summary 
Strategies to select highly expressed variants of a protein coding sequence are usually based on 
trial and error approaches, which are time-consuming and expensive. We address this problem 
using translationally-coupled antibiotic resistance markers. The system requires that the target 
gene can be fused at the 3’-end with a translational coupling element and an antibiotic resistance 
gene. Highly expressed target genes can then be selected using a fast and simple whole cell survival 
assay in the presence of high antibiotic concentrations. Herein we show that the system can be used 
to select highly expressing clones from libraries sampling translation initiation sites. 
 
Keywords: gene expression, protein production optimization, selection, library screening, antibiotic 
resistance, translational coupling 
 
1. Introduction 
Bacterial production of recombinant proteins is highly important in the construction of cell 
factories, and for basic studies on the function, interactions and structure of proteins. 
Unfortunately, yields are often low, particularly in heterologous hosts, and optimisation of the 
coding sequence is necessary. Coding sequence optimisations frequently utilise randomised 
libraries combined with screening approaches to pick out the coding sequence that expresses to 
the highest level. Whilst the randomised libraries are simple and inexpensive to make, the 
screening steps are usually costly and time-consuming1.  
Translational coupling is a natural phenomenon in bacteria, where initiation of translation is 
dependent on the successful translation of an upstream sequence, e.g. in the tryptophan operon of 
E. coli between the trpB and trpA genes2 or in the tightly controlled stoichiometric expression of 
genes in the ATP operon encoding the subunits of the ATP synthase complex3. This mechanism 
has been exploited to synthetically connect the translation of a target gene to a reporter gene 
without creating protein fusions4. In this elegant study, Mendez-Perez and co-workers designed 
synthetic translational-coupling devices using the knowledge that mRNA secondary structure can 
mask a Shine-Dalgarno (SD) site, but may re-fold into a less inhibitory structure by the action of an 
upstream translating ribosome4. Applying similar design principles, we created an extended 
toolbox of sequences that couple with different efficiency and to different antibiotic resistance 
markers (unpublished data). Those reporters, when coupled to the production of a protein of 
interest, offer specific growth advantages to the host organism and, therefore, represent a highly 
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attractive alternative to e.g. fluorescent proteins, enabling screening of very large libraries5-7. The 
extended toolbox of coupling devices enables the selection of gene expression variants from 
virtually no expression to g/L industrial scale (unpublished data). 
 
 
 
Figure 1. Schematic illustration of protein production optimization with the translationally-coupled antibiotic 
selection system. (A) Selection plasmid construct with beta-lactamase gene (bla) encoding the ampicillin selection 
marker. (B) Selection of high-expressing variants by plating on LB agar plates containing 0.25 mg/mL, 0.5 mg/mL 
and 1 mg/mL ampicillin (Amp). (C) Western blot analysis of the selected optimized variants, on 1 mg/ml ampicillin 
and expression level estimation of the high-expressing variants. 
 
In this chapter we present our protocols for plasmid construction and selection of high-expressing 
clones using these translationally-coupled antibiotic resistance markers. An overview of the 
method is presented in Figure 1. In the first three days the selection plasmid is constructed and 
isolated using uracil excision DNA assembly (Figure 1A). The plasmid will contain the coding 
sequence to be expressed (termed expression variant) fused to a region encoding the translational-
coupling device (depicted as an mRNA hairpin) and finally, a region encoding for the antibiotic 
resistance marker (shown is the coding region for ß-lactamase). In the following four days a 
plasmid library is constructed and each plasmid variant is tested by antibiotic sensitivity (Figure 
1B). The library is constructed in a simple PCR reaction using degenerate primers that randomise 
either the Translation Initiation Region (TIR) or the coding sequence8,11. The entire library is 
isolated and transformed into a standard E. coli expression strain and gene expression is induced 
in liquid cultures. Bacteria are plated on LB agar plates containing different concentrations of the 
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selectable antibiotic and high-expressing clones can be selected by their ability to withstand the 
antibiotics. When we applied the protocol to a plasmid encoding a secreted single-chain antibody 
fragment we were able select a number of gene variants that expressed to higher levels than the 
wild type coding sequence (Figure 1C). These gene variants differed only in the TIR8. Shown are 
Western blots decorated with the corresponding antibody anti-sera (top panel) and a loading 
control anti-sera (bottom panel). The protocol enables the selection of the high-expressing clones 
in one week starting from initial cloning and using an absolute minimum of resources and only 
standard molecular biology equipment.  
 
2. Materials  
2.1 Components for plasmid construction 
1. A set of oligonucleotides to integrate the translational coupling element and the antibiotic 
resistance gene into the desired expression plasmid (see Note 1 for design). 
2. PfuX7 DNA polymerase with 10X reaction buffer (see Note 2). 
3. dNTP mix (10 mM each), sterile H2O and MgCl2 (final concentration 50 mM) (see Note 3). 
4. 0.2 mL PCR tubes (VWR). 
5. Thermocycler (BioRad). 
6. DpnI restriction enzyme (New England Biolabs) (see Note 4). 
7. 1x TAE buffer. Prepare from 50x stock solution (Life Technologies) with H2O. Can be stored 
at room temperature.  
8. SeaKem® LE Agarose (Lonza). 
9. RedSafe Nucleic Acid Staining Solution (iNtRON Biotechnology). 
10. NucleoSpin® Gel and PCR Clean-up Kit (Macherey-Nagel) or any other PCR Clean-up Kit. 
11. NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Scientific). 
12. 100 ng of each PCR fragment, USER enzyme (New England Biolabs) and provided reaction 
buffer (see Note 5). 
 
2.2 Components for transformation and plasmid propagation 
1. Escherichia coli strain NEB5α for cloning. Chemically competent cells of NEB5α are obtained 
as described elsewhere (9).  
2. Bacteria are cultivated in Luria-Bertani broth (20 g/L in H2O) (Sigma Aldrich) and plated on 
Luria-Bertani agar (35 g/L in H2O) (Sigma Aldrich).  
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3. Antibiotics: 100 µg/mL ampicillin, 50 µg/mL kanamycin, 34 µg/mL chloramphenicol, 50 
µg/mL spectinomycin and 10 µg/mL gentamycin (see Note 6). 
4. 1.5 mL microfuge tubes (Eppendorf). 
5. Thermomixer (Eppendorf). 
6. 50 mL reaction tubes (Sarstedt). 
7. Shaking incubator at 37 °C for 50 ml reaction tubes. 
8. Plate incubator at 37 °C. 
9. QIAprep Spin Miniprep Kit (Qiagen) or any other plasmid DNA purification Kit.  
 
2.3 Components for expression and selection 
1. For library expression and selection we use the chemically competent E. coli strain 
BL21(DE3) pLysS (Novagen) (see Note 7).  
2. Bacteria are cultivated in Luria-Bertani broth (20 g/L in H2O) (Sigma Aldrich) and plated on 
Luria-Bertani agar (35 g/L in H2O) (Sigma Aldrich).  
3. 1M Isopropyl β-D-1-thiogalactopyranoside (IPTG) stock solution in H2O (see Note 8). 
4. Antibiotics for selection: ampicillin, kanamycin, chloramphenicol or spectinomycin (see Note 
9). 
5. 50 mL reaction tubes (Sarstedt). 
6. Shaking incubator at 37 °C for 50 mL reaction tubes. 
7. Plate incubator at 37 °C. 
 
3. Methods 
3.1 Primer design and selection set-up 
1. Before constructing the selection plasmid, the expression level of the target gene needs to be 
evaluated carefully. We have developed a set of different translational coupling devices that 
vary in their coupling efficiency (Figure 2). For low expressed target genes we recommend the 
strong coupling device. For genes already expressing to decent levels, a weaker coupling 
device is advisable. This way the use of very high antibiotic concentrations for selection is 
avoided and the dynamic range of the selection system is better exploited (see Note 10). The 
coupling device is introduced with PCR oligonucleotides - the major part with a “forward” 
oligonucleotide for amplification of the antibiotic resistance gene (here denoted AbR gene 
fwd). The reverse oligonucleotide for amplifying the target gene introduces the second part of 
the coupling device (here denoted target gene rev.) (Figure 3). 
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Figure 2. Different modules can be combined for optimal antibiotic selection via translational coupling. (A) The 
antibiotic selection system optimizes the expression of untagged, N-terminal tagged or C-terminal tagged genes. 
The target gene (green box) is combined with one out of three translational coupling devices (grey box). The three 
different hairpins vary in their coupling efficiency due to altered start codons (shaded purple regions) and Shine-
Dalgarno (SD) sequences (shaded grey regions). Four different antibiotic resistance genes (AbR, purple box) can be 
used as reporters. (B) Illustration of the principle of translational coupling; if the mRNA from the target gene (green) 
is not translated, the ribosome-binding site (black) for the reporter gene (purple, AbR gene) is not accessible. If the 
target gene is translated, the ribosome will melt the hairpin structure and enable a ribosome to bind to the SD 
sequence of the reporter gene mRNA and start translation. 
 
2. The target gene can either be amplified together with the backbone or can be cloned into a 
new backbone. When amplified with the backbone primer set 1 is not needed (Figure 3). In 
case that primer set 1 is needed, the design will be similar to primer set 3. The reverse primer 
for amplifying the target gene introduces parts of the coupling device (target gene rev.) and 
the only necessary modification to the gene of interest ensures that TGA is used as a stop 
codon. Moreover, the reverse primer for amplifying the target gene should ideally anneal with 
a melting temperature of ca. 60 °C to the sequence upstream from the stop codon. Typically, 
this takes roughly 20 nucleotides for the anneal part resulting in a total oligonucleotide size of 
ca. 36. 
3. The major part of the translational coupling device is introduced with the forward primer for 
amplification of the antibiotic resistance gene (AbR gene fwd.). Besides encoding the device, 
the primer should anneal with a melting temperature if ca. 60 °C to sequence downstream 
from the start codon. This will typically result in oligonucleotide size of ca. 40 nucleotides. 
Note that the first amino acid after the start codon is still part of the coupling device and will 
always be TCA (encoding for serine). The ampicillin and kanamycin resistance genes, bla and 
aphA1, already encode serine as the second amino acid. For the spectinomycin and 
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chloramphenicol resistance genes, aadA1 and cat, the addition of serine in this position does 
not influence functionality (see Note 11). 
4. Following the PCR, cohesive ends with a melting temperature of ca. 23 °C are formed by uracil 
excision (see Note 12) and the resulting nicked circular DNA can be transformed into 
chemically competent E. coli. Details about uracil excision DNA assembly can be found 
elsewhere (10).  
 
 
 
Figure 3. Illustration of the design of oligonucleotides that introduce a translational coupling device and an 
antibiotic resistance gene for selection. Primer pairs denoted in boxes 1, 2 and 3 have complementary 5´ ends as 
exemplified with sequence detail in box 2. 
 
3.2 Plasmid construction and propagation 
1. Mix all reagents for a 50 µL PCR reaction in a 0.2 ml PCR tube: 5 µL of 10X reaction buffer, 5 
µL of forward primer, 5 µL of reverse primer, 2 µL dNTP mix (40 mM), 1.2 µL 2M MgCl2, 1 
µL PfuX7 DNA polymerase, 100 ng of template DNA, fill up to 50 µL with sterile H2O. 
2. Amplify the different fragments in a Thermocycler using a Touchdown-PCR program (95 °C 
for 5 min, 10 cycles of 95 °C for 45 sec, 55-65 °C for 45 sec (increment 1 °C in each cycle), 72 °C 
for 5 min, followed by 20 cycles of 95 °C for 45 sec, 55 °C for 45 sec, 72 °C for 5 min and one 
final elongation step for 8 min at 72 °C (see Note 13). 
3. Prepare a 1% agarose gel by heating up 1 g of agarose in 100 ml of 1 x TAE buffer. Add DNA 
stain. Analyze 5 µlLof the PCR product by agarose gel electrophoresis (e.g. 90 V, 30 min). 
4. Add 2 µL DpnI to the reaction mix to digest the original plasmid at 37 °C for at least 1 h. 
Inactivate DpnI for 5 min at 80 °C. 
 126 
5. Purify the PCR fragments using a PCR Clean-up Kit, following the manufacturer’s 
instructions. 
6. Mix 100 ng of each fragment. Add 1 µL of USER enzyme and 1 µL of buffer. Fill up with sterile 
H2O to a final volume of 10 µL.  
7. Start the USER reaction in a Thermocycler: 37 °C for 15 min, 23 °C for 15 min, 10 °C for 15 min 
(see Note 14).  
8. Mix the whole USER reaction with 100 µL of chemically competent E. coli cells. Use a cloning 
strain, such as NEB5α. 
9. Incubate on ice for 30 min. 
10. Heat shock for 1 min at 42 °C. 
11. Incubate on ice for 3 min. 
12. Add 0.9 mL of LB broth without antibiotics for recovery and incubate at 37 °C with shaking 
for 1 h.  
13. Plate 0.1 mL (10%) of the transformation mix on a LB agar plate containing the appropriate 
antibiotics. 
14. Harvest the rest of the transformation mix by centrifugation at 4000 x g in a tabletop centrifuge 
and plate on an LB agar plate containing the appropriate antibiotics. 
15. Incubate for 16 h at 37 °C. 
16. Inoculate 5 mL LB media containing the appropriate antibiotics (in a 50 ml reaction tube) with 
a single colony from the transformation plates and incubate for 16 h at 37 °C with shaking.  
17. Harvest the cells at 6500 x g and purify the plasmid using a plasmid DNA purification Kit (e.g. 
QIAprep Spin Miniprep Kit), follow the manufacturer’s instructions. 
18. Prepare an expression library (see Note 15). 
 
3.3 Expression and selection 
1. Transform the library and the wild type plasmid into an expression strain, e.g. E. coli 
BL21(DE3) pLysS. To do so, follow steps 7-11 in section 3.2. Transform ca. 5 µL of library into 
50 µL of commercially competent cells, and 1 µL of wild type plasmid into 15 µL of 
commercially competent cells. Heat shock for 45 sec at 42 °C. 
2. After 1 h of recovery transfer the transformation mix to a 50 mL reaction tube containing 5 ml 
of LB media with appropriate antibiotics and incubate for 16 h at 37 °C with shaking. 
3. Prepare plates for selection. Use LB agar containing the inducing agent, we use IPTG in a final 
concentration of 1 mM, and different concentrations of the selective antibiotic (see Note 16). 
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We recommend preparing selection plates with at least 5 different antibiotic concentrations. 
Remember to prepare two plates of each concentration, one for the library and one for the wild 
type. 
4. After 16 h, start an expression culture by inoculating 5 mL fresh LB medium containing 
appropriate antibiotics with 100 µL of over night culture (1:50). Incubate at 37 °C with shaking. 
5. Grow the culture to an OD600 of 0.3 – 0.5 (ca. 2 h) and induce expression with IPTG (final 
concentration 1 mM) of any other agent needed to induce expression. Incubate at 37 °C with 
shaking. 
6. After 2 h of expression, plate 0.2 ODU (ca. 100 µL) on each selection plate. Incubate for up to 
40 h at 37 °C. On antibiotic concentrations where no growth can be seen for the wild type, high 
expressing variants can be selected. 
7. Select variants and check with sequencing (see Note 17).  
8. Re-transform the selected variants to confirm the selection of a highly translated variant. 
Follow steps 1-5 (skip step 3) and check for expression levels, e.g. by western blot analysis.  
 
4. Notes 
1. The forward primer of the target gene and the reverse primer of the antibiotic resistance gene 
form the translational coupling device. Oligonucleotides contain an incorporated uracil for 
USER cloning. 
2. Alternatively, Phusion U Hot Start DNA Polymerase (Thermo Scientific) can be used. 
3. If Phusion U Hot Start DNA Polymerase is used, 1.5 µL of 1 M DMSO is added to a 50 µL 
reaction. 
4. 2 µl FastDigest DpnI (Thermo Scientific) were added directly to a 50 µL PCR mix after PCR 
reaction, since DpnI works effectively in the reaction buffers used for PCR. 
5. We recommend a ligation step after the USER reaction, if electro-competent cells are used. In 
this case, we recommend using T4 ligase buffer for the USER reaction. 
6. Antibiotic concentrations indicated are those that should be used for the backbone antibiotic 
resistance. Make sure that the backbone resistance and the resistance used for selection are 
different. 
7. Be aware that when using a plasmid with chloramphenicol resistance, either in the backbone 
or as selection module, BL21(DE3) without pLysS needs to be used, as the pLysS plasmid (and 
derivatives) confer resistance to chloramphenicol. 
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8. The type of inducing agent depends on the promoter used. We are using a (DE3) T7 promoter 
and therefore typically use IPTG for induction. 
9. Concentrations depend on the target gene expression level and the chosen coupling efficiency. 
10. The coupling device can be changed easily in a one-PCR step followed by a one fragment 
USER reaction.  
11. Note that the chosen resistance gene for selection should not be present as a backbone 
resistance gene on any other plasmid transformed. We obtained the best results when using 
the ampicillin resistance gene for selection. 
12. We recommend choosing a USER cloning overlap in the backbone sequence, as it facilitates 
the exchange of the antibiotic resistance gene, if necessary.  
13. Note that the extension time depends on the size of the PCR product and the processivity of 
the DNA polymerase that is used. 
14. When using electro-competent cells, add 1.5 µL of T4 ligase and incubate for 15 min at room 
temperature prior to transformation. 
15. Library construction is not part of this protocol. Sequence variation may be sampled 
throughout the gene coding sequence or expression vector. We construct libraries based on 
the protocol “Codon optimizing for increased membrane protein production: A minimalist 
approach” (11). Additionally, we expand the library by also randomizing the six nucleotides 
upstream of the start codon (8).  
16. Make sure that the LB agar has cooled down to at 60 °C before adding the inducing agent and 
antibiotics. 
17. Sequencing after selection is of outmost importance. It can occur that the cell starts mutating 
in ways to favour the expression and usage of the antibiotic resistance gene and a false positive 
is selected.  
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Abstract 
 
Background 
The market for recombinant proteins is on the rise, and Gram-positive strains are widely exploited 
for this purpose. Bacillus subtilis is a profitable host for protein production thanks to its ability to 
secrete large amounts of proteins, and Lactococcus lactis is an attractive production organism with 
a long history in food fermentation.  
 
Results 
We have developed a synbio approach for increasing gene expression in two Gram-positive 
bacteria. First of all, the gene of interest was coupled to an antibiotic resistance gene to create a 
growth-based selection system. We then randomised the translation initiation region (TIR) 
preceding the gene of interest and selected clones that produced high protein titres, as judged by 
their ability to survive on high concentrations of antibiotic. Using this approach, we were able to 
significantly increase production of two industrially relevant proteins; sialidase in B. subtilis and 
tyrosine ammonia lyase in L. lactis. 
  
Conclusion 
Gram-positive bacteria are widely used to produce industrial enzymes. High titres are necessary 
to make the production economically feasible. The synbio approach presented here is a simple and 
inexpensive way to increase protein titres, which can be carried out in any laboratory within a few 
days. It could also be implemented as a tool for applications beyond TIR libraries, such as screening 
of synthetic, homologous or domain-shuffled genes.  
 
Background 
The advent of recombinant protein technology has enabled commercial applications for 
biopharmaceutical proteins and industrial biocatalysts not possible when the only option was to 
extract proteins from their original hosts. The enzyme market in particular has bloomed as a result 
of the production costs approaching those of the chemical industry1. To achieve low costs, enzymes 
are produced in large quantities by exploiting cell factories and large-scale bioreactors, but 
continuous improvements in the design of cell factories are needed to keep the production 
competitive and open markets for new products2. 
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Various rational engineering approaches for cell factories are routinely employed to improve 
production. In the initial process a suitable expression host needs to be selected. Despite the 
documented role of Escherichia coli in molecular biology, other bacterial expression systems have 
been explored in biotechnology, taking advantage of divergent metabolism, secretion capability 
and biosafety of their protein-based products3,4. Amongst them, various Gram-positive bacteria are 
of great interest due to e.g. their highly efficient protein secretion and GRAS status. Bacillus subtilis 
is routinely used industrially for its ability to secrete large amount of enzymes, which simplifies 
protein recovery and purification, leading to yields up to 20-25 g/L5. Lactococcus lactis has a long 
history of use in food microbiology and in the dairy industry6, and it has lately risen as an emerging 
alternative for production of membrane proteins7,8, secreted proteins9,10 and plant-based proteins 
and secondary metabolites11-13.  
 
Previously we have shown that protein production in Gram-negative bacteria can be significantly 
increased by synthetically evolving a part of the translation initiation region (TIR)14. In expression 
clones the TIR extends from the region upstream of the Shine-Dalgarno (SD) sequence to the 5th 
or 6th codon of the gene of interest15. Whilst most TIRs function, they can support higher 
production titres if they are evolved with an appropriate selection pressure. For example, the TIR 
can be optimised by creating large libraries of randomised TIRs and selecting one that produces 
the most protein16,17.  
 
Yet screening approaches for those libraries are limited. High throughput screening methods like 
fluorescence activated cell sorting (FACS) or droplet microfluidics enable the assessment of large 
libraries18-20 but their use is restricted to phenotypes associated with a fluorophore to effectively 
screen for e.g. increased protein production21. Fusions with reporter proteins, such as fluorescent 
proteins, can also compromise the expression, solubility and bioactivity of a protein and are not 
suitable in industrial set-ups22,23. The availability of other types of biosensors is limited and 
developing one for a new target is a laborious and time consuming process24.   
 
For this purpose, we have established a phenotypic screening approach for screening TIR libraries 
in E. coli25. The approach utilises an antibiotic resistance gene that is translationally coupled to the 
gene of interest. In the bicistronic mRNA design, a hairpin-like structure separates an upstream 
gene of interest from a downstream antibiotic selection marker, thereby sequestering the SD site of 
the latter. Only upon efficient translation of the upstream gene, antibiotic resistance is obtained 
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because the helicase activity of the translating ribosome allows expression of the downstream 
resistance gene (Figure 1A). In this study we set out to determine if the same synbio approach for 
optimising and selecting TIRs, would lead to increased production levels in industrially relevant 
Gram-positive bacteria.  
 
Results 
Characterization of a translational coupling device in Gram-positive hosts 
We first set out to explore the applicability of a translational coupling design that was previously 
developed in E. coli25. To this end we constructed a plasmid for L. lactis and B. subtilis that contained 
the gene encoding green fluorescent protein (gfp), coupled by a sequence with hairpin-forming 
(hp) propensity to a chloramphenicol resistance gene (gfp-hp-CmR) (Figure 1A).  
 
 
 
Figure 1: Testing of a translational coupling device in Bacillus subtilis and Lactococcus lactis. (A) To asses the 
efficacy of a specific translational coupling device in B. subtilis and L. lactis an mRNA hairpin structure was 
sandwiched between the gene encoding green fluorescent protein (gfp, green) and the chloramphenicol resistance 
gene (CmR, orange). Left side: Shown is the predicted structure of the translational coupling device. Presumably, 
the stem of the mRNA hairpin structure consists of 11 nucleotide pairs comprising the stop codon of the upstream 
gene (red box) and the start codon of the downstream gene (green box). The ribosome binding site (black box) of 
the downstream gene is designed to be masked by the secondary mRNA structure. Upper right side: When the 
upstream gene (green, gfp) is not translated, the mRNA hairpin structure will not be resolved and the ribosome 
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binding site of the downstream gene (orange, CmR) remains inaccessible for the ribosome. Therefore, there is no 
translation of the downstream gene. Lower right side: When a ribosome translates gfp, the ribosome’s helicase 
activity will melt the secondary mRNA structure which makes the ribosome binding site accessible and the 
chloramphenicol resistance gene can be translated. The correlation between protein production, determined as 
fluorescence normalized for cell density, and chloramphenicol resistance, determined as minimal inhibitory 
concentration (MIC), was determined for genome-based expression in B. subtilis (B) and for plasmid-based 
expression in L. lactis (C). 
 
The gfp-hp-CmR construct was expressed from the nisin-inducible promoter PnisA on a pNZ8048 
vector in L. lactis26. In B. subtilis a set of four different constitutive promoters of increasing strength 
(PJ23101, PliaG, PlepA and Pveg27) were used and the constructs were integrated into the amyE locus on 
the chromosome28. L. lactis cultures were grown overnight, diluted in the morning and induced 
with variable concentrations of nisin (0.25-10 ng/mL); B. subtilis cultures were treated the same 
way, but did not require induction. Fluorescence was measured when the cultures reached late 
exponential phase and was normalized by cell density. At the same time resistance was assessed 
by plating on different concentrations of chloramphenicol. In both L. lactis and B. subtilis 
fluorescence levels showed a linear correlation (R2 > 0.9) with resistance to chloramphenicol, the 
latter measured as the minimum inhibitory concentration (MIC) (Figure 1B, C). This demonstrates 
that the translational coupling device in combination with a chloramphenicol resistance gene can 
work over a broad range as a reporter of gene expression in these two Gram-positive model 
bacteria. 
 
Characterization of translation initiation region libraries in L. lactis and B. subtilis 
Next we introduced sequence diversity in a specific part of the translation initiation region (TIR) – 
an approach that has proven successful for expression optimization in E. coli14. In this experiment 
the six nucleotides upstream of the start codon are randomized and the second and third codon of 
the open reading frame are concurrently substituted with synonymous codons (Figure 2A). 
Depending on the nature of the 2nd and 3rd amino acid in the protein sequence, this system 
generates a maximum library size of about 150,000 variants and up to 1000-fold variation in gene 
expression levels14.  
 
In the case of gfp, a library with about 50,000 variants was constructed in both hosts. In B. subtilis 
we chose a strong constitutive promoter (Pveg) to drive expression of gfp. The library was integrated 
into the amyE locus on the chromosome using an integrative vector propagated in E. coli. In L. lactis 
we used the pNZ8048 plasmid with the inducible nisin promoter controlling the expression of gfp. 
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Both libraries were based on the constructs used for the initial characterization of the translational 
coupling device gfp-hp-CmR. Variability was introduced by PCR using degenerate 
oligonucleotides that randomized the TIRs. The TIR region of five arbitrary clones from each 
library were sequenced to validate diversity in the libraries. A total of 96 clones were randomly 
picked and cultivated. Cultures were back-diluted after overnight incubation, induced when 
required and expression levels were assayed after five hours. The fluorescence levels varied greatly 
amongst the clones with the highest and the lowest gfp-expressing clones differing by up to 1000-
fold (Figure 2B and C). This observation confirms that this part of the TIR is an important 
determinant of expression levels in a broad range of bacterial species. 
 
 
 
Figure 2: A part of the translation initiation region (TIR) affects expression in Bacillus subtilis and Lactococcus 
lactis. (A) TIR libraries (NNNNNNATGN*N*N*N*N*N*, see main text for further details) were constructed by 
PCR, transformed into the host strains and individual library clones were grown to asses the expression level ranges 
in B. subtilis and L. lactis. Fluorescence normalized by cell density was determined for 96 library clones for B. subtilis 
(B) and L. lactis (C). The B. subtilis library was expressed from the genome whereas the L. lactis library was expressed 
from a plasmid. 
 
Antibiotic-based selection of high-producing variants from TIR libraries 
To select for the best TIRs, libraries were plated on solid media with increasing concentrations of 
chloramphenicol. The amount of colonies appearing on the plates decreased whereas the average 
fluorescence intensity increased with rising concentrations of antibiotic (Figure 3A). Clones were 
randomly picked from the plates, recovered and grown overnight without antibiotic selection 
before measuring the fluorescence in a microplate reader (Figure 3B). This analysis showed that 
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the likelihood of isolating a highly fluorescent clone increased with increasing concentrations of 
antibiotics (Figure 3C). In contrast to the plate- based selection setup, we were unable to enrich for 
high expressing clones in liquid media supplemented with different concentrations of 
chloramphenicol (data not shown). 
 
 
Figure 3: Antibiotic selection of maximal protein production in a Gram-positive bacterium. (A) B. subtilis TIR 
libraries expressing gfp were grown on agar plates with different chloramphenicol concentrations. GFP production 
levels on the different antibiotic concentrations were assayed by exposing agar plates to long-wave UV light. Five 
individual colonies were randomly picked from these plates and assayed for expression levels assessed by 
fluorescence per cell density in a microplate reader (B-C).  
 
Optimization of industrially relevant proteins 
Finally, we explored optimization of clones for production of different industrially relevant 
proteins in the two Gram-positive hosts. For L. lactis we chose to optimize expression of a tyrosine 
ammonia lyase (TAL) from Flavobacterium johnsoniae, which is expressed in the cytoplasm and 
converts tyrosine into p-coumaric acid in a single enzymatic step29.  For B. subtilis we chose to target 
a Micromonospora viridifaciens sialidase (SIA), a hydrolase that cleaves the sialic residues of 
glycans30. In both cases well established expression set-ups were used that already resulted in high 
expression levels. 
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We first integrated the selection module hp-CmR downstream of the genes-of-interest into the 
plasmids used in the previous studies for the corresponding enzyme production29,30. In these 
experiments, cytoplasmic expression of tal in L. lactis was driven by the inducible PnisA promoter in 
a pNZ8048 vector; however, we had to exchange the original chloramphenicol cassette of the vector 
backbone for an erythromycin resistance gene, to be able to utilize the hp-CmR device for selection. 
Expression of sia in B. subitilis was under control of the strong constitutive P32 promoter and 
secreted by the aid of a CGTase signal peptide encoded in the replicative pDP66K plasmid. In both 
experiments, we refer to the TIR in the original constructs as the TIRorig. 
 
The TIRorig was then randomized by PCR using degenerate oligonucleotides, employing the same 
strategy as with the gfp-hp-CmR library. After transformation into the hosts and overnight recovery 
with the appropriate vector backbone antibiotics in liquid culture, both libraries were back-diluted, 
induced when required and after five hours plated on solid media with increasing concentrations 
of chloramphenicol. We then determined the Colony Forming Units (CFUs) of each library at 
different concentrations of chloramphenicol, and compared it with the TIRorig. In both cases we 
observed that the library produced more CFUs at higher chloramphenicol concentrations than the 
original construct (Figure 4A, B). As expected, we also observed a reduction in the amount of 
colonies appearing on the plates as the antibiotic concentration increased. 
 
Colonies were recovered on 75 µg/mL chloramphenicol for B. subtilis and 25 µg/mL 
chloramphenicol for L. lactis. Protein levels were assessed by Western blotting using a His-tag 
antiserum for sialidase and Strep-tag antiserum for TAL (Figure 4C, D). In both cases, the clones 
isolated at the highest antibiotic concentration displayed a higher protein production compared to 
the TIRorig. Production of TAL in L. lactis was improved by 8-fold (Figure 4D) and production of 
sialidase in B. subtilis was doubled (Figure 4C) from 1 g/L to approximately 2 g/L (Figure 4E). In 
both cases, activity of the enzymes originating from the optimized TIRopt variants was not 
compromised by the high level of production (Supplementary Figure 1A, B). 
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Figure 4: Production optimization of the industrially relevant proteins tyrosine ammonia lyase (TAL) and 
sialidase (SIA). (A) A His-tagged sialidase-encoding sequence was translationally coupled to the chloramphenicol 
resistance gene. A TIR library was constructed, transformed into B. subtilis and grown with different 
chloramphenicol concentrations on agar plates. Colony forming units (CFUs) were counted for all concentrations 
for the library (TIRlib) and the original, non-randomized clone (TIROrig) as control. (B) A STREP-tagged tal-encoding 
sequence was translationally coupled to the chloramphenicol resistance gene. A TIR library was constructed, 
transformed into L. lactis and grown with different chloramphenicol concentrations on agar plates. CFUs were 
counted for all concentrations for the library (TIRlib) and the original, non-randomized clone (TIRorig) as control. (C) 
Sialidase production level in the culture supernatant of the best performing clone (TIRopt) was analyzed by Western 
blot, using an antibody against a His-tag (left panel). The increase in production was analyzed by densitometry and 
plotted as the relative protein production compared to the original clone (right panel). (D) TAL production level of 
the best performing clone (TIRopt) was analyzed by Western blotting using an antibody against Strep-tag (left 
panel). The increase in production was analyzed by densitometry and plotted as the relative protein production 
compared to the original clone (right panel). (E) Sialidase (TIRopt) was purified via a Ni2+-NTA column and 
purified product concentration was estimated using a BCA assay (left panel). Product per cell mass and per culture 
volume was calculated (right panel). The original construct (TIRorig) was used for comparison. 
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Discussion 
A wide range of industrial applications use enzymes as a sustainable alternative to chemical 
catalysts. These applications include, but are not limited to, the manufacturing of food, paper, 
detergents and biofuels31. However, refinement in production titres rely on enzyme discovery and 
gene and strain engineering, which are time consuming and labour intensive processes. Existing 
methods for high throughput screening of gene expression are based on e.g. droplet microfluidics 
or flow cytometry18,20. Despite being extremely efficient and effective, these platforms are 
expensive to purchase and operate and their availability is limited to large-scale operations. Other 
screening methods rely on protein fusions, which might alter parameters such as expression, 
solubility and/or turnover rate22. To address this issue, we developed a simple growth based 
selection system based on translational coupling of an antibiotic resistance gene with the upstream 
gene sequence that leaves the protein of interest unaltered. Different from previous attempts, our 
system focuses on Gram-positive bacteria25, works on genomically integrated targets and does not 
require tagging of the protein of interest32. Nonetheless, tags can be purposefully added to the 
protein if desired.  
 
We first evaluated the correlation between gene expression and antibiotic resistance. A lack of 
correlation would be indicative of either poor folding or poor melting of the mRNA hairpin. 
Instead the correlation coefficient was strong in both hosts, which demonstrates that antibiotic 
sensitivity is tuneable and that the system responds linearly to all gene expression levels tested.  
Differences in the dynamic range of screenable chloramphenicol concentrations were observed 
between the two hosts; presumably the cause for a smaller dynamic range in B. subtilis may be due 
to the initial choice of a poor-performing TIR for gfp. The expression was very low, even when 
driven by a strong promoter. Once we built a combinatorial library randomizing the TIR, the best 
expressing variants improved in protein production by 8 fold over the variant we used to 
characterize the mRNA hairpin. 
 
Protein production constructs are often assembled in replicative or integrative plasmids. Previous 
work has shown that the junction created between the vector and the coding sequence can result 
in different levels of expression depending on e.g. the restriction site used14. The variability is not 
completely explained by the free energy (∆G) associated with mRNA folding and seems to be 
context specific, meaning that the cloning scar will affect the levels of expression in a manner that 
is not entirely computationally predictable. The creation of a TIR library circumvents the problem 
 141 
by optimizing the expression of a gene directly in the system in which it will be expressed. Here 
we demonstrate the effectiveness of removing the cloning scar bias by improving the production 
of two industrially relevant proteins. We chose to optimize TAL in L. lactis, due to the wide range 
of compounds of biotechnological interest that are produced from the intermediate p-coumaric 
acid; these include for example the flavonoid naringenin or the stilbene resveratrol11,29. For B. 
subtilis we optimized the production of a sialidase, as their enzymatic activity gained interest in 
relation to treatment of spinal cord injuries and there was a recent attempt to improve their activity 
and production using B. subtilis30. Both genes were cloned into their vectors using traditional 
restriction enzyme based cloning and were already expressed with high yield. After creating a 
combinatorial library that modifies the TIR, we could select variants that produced 2-8 fold more 
protein than the original clones. Most importantly, the sialidase production level in B. subtilis 
increased from 1 to 2 g/L in a 50 mL shake flask experiment, demonstrating that the specific TIR 
optimization and selection tool can achieve high yields, in the range of industrial titer levels, even 
when carried out in low density cultures. A substantial increase in yield is expected in industrial 
fed-batch fermentations. 
The tool we developed has the potential to be easily translatable to other less amenable members 
of the Bacillus or Lactococcus families. With decreasing cost of DNA synthesis and the increasing 
interest in Gram-positive cell factories, different types of combinatorial libraries can be coupled 
with this selection system to screen for variants that produce a protein. Some examples are error 
prone PCR, DNA shuffling or any other in vitro and in vivo methodologies that generate genetic 
variability. The screening process is simple, inexpensive and can be carried out in a few days in 
any laboratory and therefore presents an attractive alternative to advanced screening 
methodologies. 
 
Conclusion 
We developed a selection-based system to screen for synthetically evolved TIRs Gram-positive 
hosts. The system responds linearly to increasing concentrations of antibiotic by preventing growth 
of non optimized library variants. Using our selection tool, we demonstrate improved expression 
of industrially relevant proteins in two cell factory hosts, namely TAL in L. lactis and a sialidase in 
B. subtilis.  
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Methods 
 
Bacterial strains, media and growth conditions 
Bacterial strains used in this study are listed in Supplementary Table S1. 
Lactococcus lactis strain NZ9000 ∆ hsd was used for all experimental procedures. Cells were grown 
at 30 °C in M17 broth (BD Difco, San Jose, CA, USA) supplemented with 1% glucose (GM17), 
without shaking. Electro competent cells were prepared as previously described33. Cultures were 
supplemented with 5 µg/mL erythromycin or 5 µg/mL chloramphenicol to select for plasmid 
presence, unless otherwise stated. Cultures were induced with 1.5 ng/mL nisin, unless otherwise 
stated. 
 
Bacillus subtilis strain SCK6 (1A976 http://www.bgsc.org) was used for expression experiments. 
Cloning, library construction and propagation of plasmids were performed in E. coli NEB5α (New 
England Biolabs, Ipswich, MA, USA). B. subtilis was grown in lysogeny broth (LB) at 37 °C shaking 
(250 rpm). The antibiotics neomycin (5 µg/mL), kanamycin (50 µg/mL) and erythromycin (5 
µg/mL) were supplemented when necessary. Transformation of integration vectors into B. subtilis 
was performed with chemically competent cells as previously described34. Correct genome 
integrations were confirmed by colony PCR and sequencing. 
 
Plasmids and strain construction 
Plasmids and oligonucleotides used in this study are listed in Supplementary Tables S2 and S3. All 
constructs were made with uracil excision cloning as previously described35. 
Plasmids used in L. lactis are based on pNZ8048 from the NIsin Controlled gene Expression (NICE) 
system26 and expression was controlled by the inducible nisin promoter. Translationally coupled 
versions were constructed using the standard chloramphenicol acetyltransferase resistance gene 
derived from pNZ804826. Hairpins were introduced by USER cloning using overlapping 
oligonucleotide tails coding for the hairpin33,36. The resulting plasmids pNZ-tal-hp-CmR was built 
by adding the hp-CmR module to the pNZ_FjTAL described previously29. The plasmid pNZ-gfp-
hp-CmR was built in two steps: first by cloning a GFP folding reporter37 into pNZ8048, using 
primers 1 and 2. In a second step the module hp-CmR was added to the vector.  
B. subtilis plasmids were constructed in E. coli NEB5α (New England Biolabs, Ipswich, MA, USA), 
purified and subsequently transformed and integrated into B. subtilis. Integration vectors were 
based on the pDG268 plasmid, with integration in the amyE locus. Transcription was controlled by 
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four different constitutive promoters of increasing strength: PJ23101, PliaG, PlepA, and Pveg27. All four 
promoter variants were used to construct pDG-gfp-hp-CmR. Promoters were amplified from the B. 
subtilis genome. The synthetic promoter PJ23101 was inserted into the plasmid using two overlapping 
oligonucleotides by PCR. 
The replicating vector pDP66K-SIA-hp-CmR was constructed by adding the hp-CmR module to 
the plasmid pDP66K-Mv30 which uses the promoter P32 to drive transcription. 
 
Library construction 
For the construction of TIR libraries a degenerated forward oligonucleotide specific for the gene of 
interest was designed. The six nucleotides upstream of the start codon were changed to all possible 
combinations whereas the six nucleotides downstream the start codon were changes to all possible 
synonymous codons. 
 
Libraries for L. lactis were constructed by amplification of the whole pNZ-derived plasmid using 
the degenerated forward oligonucleotide and a reverse oligonucleotide with a pairing USER 
cloning overlap. The plasmid library was built by amplifying the template plasmid containing gfp, 
gfp-hp-CmR or tal-hp-CmR with the degenerate oligonucleotides and circularized using USER 
cloning as described elsewhere35. Libraries were transformed directly into L. lactis with no 
intermediate steps. The reference construct for the tal gene, here referred to as the TIRorig clone, was 
previously described29.  
 
Libraries for B. subtilis were constructed in E. coli MC1061 by amplification of the whole 
pDG268neo or pDP66K-Mv plasmids using degenerated forward oligonucleotides and reverse 
oligonucleotides sharing 15 nucleotide homology with the forward oligonucleotide. Q5 
polymerase (New England Biolabs, Ipswich, MA, USA) was used to amplify the template plasmid 
containing gfp, gfp-hp-CmR or sia-hp-CmR. Library construction was performed as described 
before14. The reference construct for the sia gene, here referred to as the TIRorig clone, was previous 
described30.  
 
Expression and selection 
Expression of individual L. lactis clones, were assayed using overnight cultures prepared by 
inoculating a single colony in 5 mL GM17 supplemented with respective antibiotics and incubated 
at 30 °C without shaking. Cultures were then back-diluted (1:50) into 5 mL of GM17 media 
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containing the appropriate antibiotics and incubated at 30 °C without shaking. At OD600 0.3-0.6, 
cultures were induced with 1.5 ng/mL nisin and incubated for 3 h.  
For the assessment of individual clones, B. subtilis overnight cultures were prepared by inoculating 
a single colony in 5 mL LB media supplemented with the appropriate antibiotics and incubated at 
37 °C with shaking. Cultures were then back-diluted (1:50) into 5 mL of LB media containing the 
appropriate antibiotics and incubated at 37 °C with shaking for 5 h or 23 h. 
 
Ca. 1 µg of plasmid library was transformed into L. lactis or B. subtilis using standard protocols33,34. 
Cells were recovered for 1h after transformation in GM17MC or LB media, transferred to GM17 or 
LB media supplemented with antibiotics and grown overnight at 30 °C for L. lactis and 37 °C for B. 
subtilis.  
L. lactis cultures were then back-diluted (1:50) into 10 mL GM17 media containing the appropriate 
antibiotics and incubated at 30 °C. Cultures were induced at OD600 0.3-0.6 and after 5h 0.2 OD units 
were plated on GM17 plates with increasing concentrations of chloramphenicol and incubated at 
30 °C overnight.  
After overnight incubation, B. subtilis cultures were back-diluted (1:50) into 5 mL LB media 
containing the appropriate antibiotics and incubated at 37 °C with shaking. 5 h after dilution, OD600 
was measured and 0.2 OD units of cells were then plated on LB agar plates containing different 
concentrations of chloramphenicol and incubated overnight at 37 °C.  
Selection was performed as previously described36. Selected expression variants were sequenced.  
 
MIC determination 
For L. lactis MIC determinations, 5 mL GM17 media with 5µg/mL erythromycin were inoculated 
with a single colony containing pNZGFP-hp-CmR and grown overnight at 30 °C. Cultures were 
then back-diluted (1:50) into 10 mL GM17 media supplemented with 5µg/mL erythromycin, and 
their growth monitored. At OD 0.3 the culture was split into 8 different 2 mL eppendorf tubes and 
induced with different concentrations of nisin (0; 0.25; 0.5; 0.75; 1; 1.5; 5 or 10 ng/mL). Cultures 
were incubated at 30 °C for 2 h and 0.01 ODU of each culture was transferred to a 96 wells plate 
(Greiner, Kremsmünster, Austria) containing 200 µL GM17 media (ca. 5x106 cfu/mL), and a serial 
dilution of chloramphenicol and respective concentrations of nisin as inducer. Plates were 
incubated for 15 h at 30 °C.  
B. subtilis MIC determinations were performed in 5 mL LB media that were inoculated with 4 
strains that constitutively expressed gfp-hp-CmR and grown overnight at 37 °C with shaking. 
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Cultures were then back-diluted (1:100) into 5 mL LB media containing the appropriate antibiotic 
in a 24-deep well plate (EnzyScreen, Heemstede, Netherlands). Cultures were incubated at 37 °C 
with shaking. After 2 h, 10 µL of each culture was transferred to a 96 well plate (Greiner, Austria) 
containing 100 µL LB media (ca. 5x105 cfu/mL) and a serial dilution of chloramphenicol. Plates 
were incubated for 18 h. 
 
To assess translational coupling, fluorescence (Ex: 485 nm, Em: 516 nm for GFP) and OD600 were 
measured in an MX plate reader (Biotek, Winooski, VT, USA). The MIC value was defined as the 
lowest antibiotic concentration at which the final OD600 represented less than 10% of the entire 
population after background correction. Each MIC experiment was conducted with biological 
triplicates. 
 
Protein detection and quantification 
Western Blot analysis was performed by resuspending L. lactis grown as described above in 50% 
volume of CelLytic B (Sigma Aldrich, St. Louis, MO, USA) supplemented with lysozyme, egg white 
(Amresco, Solon, OH, USA), benzonase nuclease (≥250 units/µL, Sigma Aldrich, St. Louis, MO, 
USA) and Roche cOmplete™ Protease Inhibitor Cocktail (Sigma Aldrich, St. Louis, MO, USA) and 
incubated for 1 h before the samples were sonicated. An aliquot of 20µL of each sample was 
incubated for 1 hour with 1µL of a 1:10 dilution of CY5 dye (Amersham quick stain, GE healthcare, 
Chicago, IL, USA) for total protein quantification. The sample was then mixed with the same 
volume of 5x reducing sample buffer and heated to 95°C for 5 min for protein denaturation. 0.05 
ODU of the samples were loaded onto a 4-20 % Mini-PROTEAN-TGX gel (BioRad, Hercules, CA, 
USA) and run for 35 min at 175 V.  
 
For B. subtilis 10 µL of supernatant were mixed with 5 µL of 5x reducing sample buffer and heated 
to 95°C for 5 min for protein denaturation. 10 µL of the samples were loaded onto a 4-20 % Mini-
PROTEAN-TGX gel (BioRad, Hercules, CA, USA) and run for 35 min at 175 V. 
 
Proteins were transferred from the protein gel to a nitrocellulose membrane using the iBlot® dry 
blotting system (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) at 25 V for 7 min. The 
proteins were detected with the help of antigen-specific antibodies.  
For B. subtilis sialidase an anti-His antibody (1:1000; Merck Millipore, Merck KGaA, Darmstadt, 
Germany) was used. The antibody was diluted in 5% w/v skim milk in TBS-T (20 mM Tris-HCl pH 
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7.6, 150 mM NaCl, 0.1 % v/v Tween-20), the secondary antibody was diluted in TBS-T. For L. lactis 
an anti-STREP (1:10000, Biorad, Hercules, CA, USA) directly coupled to HRP was used.  
The HRP-coupled antibody was visualized using Amersham ECL Prime Western Blotting 
Detection Reagent (GE Healthcare, Chicago, IL, USA). The chemoluminescence signal was 
detected using a G:Box bioimager (Syngene, Cambridge, UK). The resulting images were analysed 
by densitometry using the Fiji software38. 
 
Sialidase protein purification 
50 mL LB broth supplemented with 50 µg/mL kanamycin was inoculated with an overnight culture 
of B. subtilis SCK6 transformed with pDP66K-SIA-hp-CmR to an OD600 of 0.05. Cells were grown 
for 23 hours at 37°C with shaking (250 rpm). After 23 hours the supernatant was harvested by 
centrifugation at 5,000 x g for 15 min and 4°C and passed through a 0.45 µm filter (Frisenette ApS, 
Knebel, Denmark) and a 0.20 µm filter (Sartorius AG, Göttingen, Germany).  The filtered 
supernatant was then concentrated using a 10K Amicon concentrator (Merck, Darmstadt, 
Germany), mixed with 10 mL purification buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM 
imidazole, pH 8.0) and again concentrated. The final concentrate was subjected to a Ni-NTA spin 
column (Qiagen, Hilden, Germany). The column was washed twice with 600 µL of washing buffer 
(50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0) and finally protein was eluted twice 
with 300 µL elution buffer (50 mM NaH2PO4, 300 mM NaCl, 500 mM imidazole, pH 8.0). To reduce 
imidazole concentration several cycles of concentrating and diluting in storage buffer (20 mM 
NaH2PO4, 100 mM NaCl and 10% glycerol, pH 7.4) were performed using a 10K Amicon 
concentrator (Merck, Darmstadt, Germany). The final volume was adjusted to 200 µL and protein 
concentration was estimated using BCA assay (Merck, Darmstadt, Germany). BSA was used as 
standard. 
 
Sialidase activity assay 
To determine activity of the sialidase, supernatant and concentrated supernatant of expression 
cultures of the original and optimized clones and purified proteins were diluted in 50 mM 
phosphate-citrate buffer pH 7.0. The enzymatic reaction was started by addition of the substrate 
pNP-Neu5Ac (Sigma Aldrich, St. Louis, MO, USA) at a concentration of 0.75 mM in a 100 µL 
reaction. Absorbance at 410 nm was monitored continuously for 1 h in an MX plate reader (Biotek, 
USA). The reaction rate was calculated from the slope of the initial linear section of the curve.  
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TAL activity assay  
The TAL activity was measured as described by Jendersen and colleagues29. Briefly, expression of 
tal was induced with 1.5 ng/mL nisin in chemically defined media (CDM) as described above. 
Cultures were grown at 30°C for 16 hours, harvested at 13000g and the supernatant was recovered. 
The concentration of p-coumarate was measured by HPLC using a gradient method with two 
solvents (0.1% ammonium formate and acetonitrile) and quantified measuring absorbance at 290 
nm. 
 
List of abbreviations 
Cm chloramphenicol 
HRP horse radish peroxidase 
LB lysogeny broth 
NICE NIsin Controlled gene Expression 
OD600 Optical density at 600 nm  
SIA sialidase 
SD Shine Dalgarno 
TAL tyrosine ammonia lyase 
TIR translation initiation region 
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Figure S1: Activity assessment of selected library clones. To assure that optimized variants are still active, activity 
assays for sialidase and TAL were performed. (A) Activity of the optimized sialidase clone was measured as 
absorbance at 410 nm per minute. Activity for culture supernatant, concentrated culture supernatant and purified 
protein were assessed. pNP-Neu5Ac was used as substrate. The negative control (NC) contained buffer and 
substrate but no enzyme was supplemented. (B) Activity of the optimized TAL clone was measured as product 
formation in µM by HPLC. 
 
 Table S1. Strains used in this study 
Strain Genotype Source/Reference 
L. lactis NZ9000 -  ∆ hsd ∆ hsd, pepN::nisRK Dudnik, not published 
B. subtilis SCK6 Em, his, nprE18, aprE3, eglSΔ102, bglT/bglSΔEV, 
lacA::PxylA-comK 1 
B. subtilis SCK6 Pveg-
gfp 
Em, his, nprE18, aprE3, eglSΔ102, bglT/bglSΔEV, 
lacA::PxylA-comK, amyE::Pveg-gfp-hp-CmR This study 
B. subtilis SCK6 PlepA-
gfp 
Em, his, nprE18, aprE3, eglSΔ102, bglT/bglSΔEV, 
lacA::PxylA-comK, amyE::PlepA-gfp-hp-CmR This study 
B. subtilis SCK6 PliaG-
gfp 
Em, his, nprE18, aprE3, eglSΔ102, bglT/bglSΔEV, 
lacA::PxylA-comK, amyE::PliaG-gfp-hp-CmR This study 
B. subtilis SCK6 
PJ23101-gfp 
Em, his, nprE18, aprE3, eglSΔ102, bglT/bglSΔEV, 
lacA::PxylA-comK, amyE::PJ23101-gfp-hp-CmR This study 
E. coli NEB5α fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
New England Biolabs, 
USA 
E. coli MC1061 araD139, Δ(ara, leu)7697, ΔlacX74, galU-, galK-, hsr-, 
hsm+, strA  In house 
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Table S2. Plasmids used in this study 
Plasmid Property Source/Reference 
pNZ8048 L. lactis gene expression vector, CmR, 
PnisA  
 
2 
pNZ_FjTAL Pnz8048 vector with PnisA-tal insert - 
CmR 
3 
pNZ-TAL-hp-CmR Pnz8048 vector ErmR, with PnisA-tal-hp-
CmR insert 
This study 
pNZ-GFP-hp-CmR Pnz8048 vector, ErmR, with PnisA-gfp-hp-
CmR insert 
This study 
pDG268-neo Shuttle vector, ColE1 origin, AmpR, MCS 
for integration into amyE locus with NeoR 
4 
pDG-Pveg-GFP-hp-CmR Shuttle vector, ColE1 origin, AmpR, for 
integration of P
veg
-gfp-hp-CmR into amyE 
locus 
This study 
pDG-PlepA-GFP-hp-CmR Shuttle vector, ColE1 origin, AmpR, for 
integration of P
lepA
-gfp-hp-CmR into amyE 
locus 
This study 
pDG-PliaG-GFP-hp-CmR Shuttle vector, ColE1 origin, AmpR, for 
integration of P
liaG
-gfp-hp-CmR into amyE 
locus 
This study 
pDG-PJ23101-GFP-hp-CmR Shuttle vector, ColE1 origin, AmpR, for 
integration of P
J23101
-gfp-hp-CmR into amyE 
locus 
This study 
pDP66K-Mv Cloning and expression vector, KmR, 
encodes P32-sp-sia 
5 
pDP66K-SIA-hp-CmR Cloning and expression vector, KmR, 
encodes P32-sp-sia-hp-CmR 
This study 
 
Table 3. Oligonucleotides used in this study 
Name Sequence (5' --> 3') 
Cloning oligonucleotides 
2995_pDGneo_fwd AAAAGCAUTAGTGTATCAACAAGC 
2989_pDGneo_rev AGCTATTUCAGCTGCGCTTTTTCCATTATGTACTATTTCGATCAGAC 
2993_CmR_fwd ATAGGAGGUCCTCCTatgTCAaactttaataaaattgatttagacaattg 
2994_CmR_rev AAATAGCUGCGCTTTTTTGTGTCATAAttataaaagccagtcattaggc 
2999_pVeg_fwd ATGCTTTUGGAGTTCTGAGAATTGGTATG 
3000_pVeg_rev ACAGTAGUACTACATTTATTGTACAACACGAGC 
3001_pLepA_fwd ACAGTAGUACTATTAAACGCAAAATACACTAGC 
3002_pLepA_rev ATGCTTTUAGTCAATGTATGAATGGATACGG 
3003_pLiaI_fwd ACAGTAGUTCGTTTTCCTTGTCTTCATCT 
3004_pLiaI_rev ATGCTTTUATTGGCCAAAGCAGAAAG 
3005_pLiaG_rev ATGCTTTUCAAAAATCAGACCAGACAAAAG 
3006_pLiaG_fwd ACAGTAGUTCATTCATTCTATTATAAAGGAAAAGC 
3044_pJ23101_fwd ACAGTAGUgctagcataatacctaggactgagctagctgtaaaGGATCCTAGAAGCT
TATCGA 
3135_ GFPsf_rev ACCTCCTAUGTCAttTgtatagttcatccatgcc 
3136 _GFPsf_fwd AGGatgcgUaaaggagaagaactt 
3137_pDG_CmR_rev ATAGGAGGUCCTCctatgtcaa 
3138 _pDG_Pveg_fwd acgcatCCUCGAGcctcctA 
3206_pDG_pVeg-GFP-lib_fwd ACTACTGUaggaggCNNNNNNatgcgNaaRggagaagaacttttcactgg 
3474_pDP66K_fwd AGGATCCUGCCTGCGAT 
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3475_sia-His_rev ACCTCCTAUGTCAATGATGGTGGTGATGG 
3476_Term_CmR_rev AGGATCCUAAAAAGCGCAGCTGAAA 
3489_pDP66K-P32-Sia-lib_fwd ACGATTACATAGGAGGNNNNNNATGAARAARTTTCTGAAATCGACAGC
TGC 
3490_pDP66K-lib_rev CTCCTATGTAATCGTTTGAATTCCAGGCTTGTCCGCTGTCGCCGGATC
C 
  
1_GFPfr_fwd actcaccaUGTCCAAAGGAGAAGAACTT 
2_GFPfr_rev aacCTTTGUAGAGCTCATCCATGC 
3a_hpCmR_rev ACCTCCTAUGTCATTTTTCAAATTGTGGATGGC 
3_CmR_fwd ATAGGAGGUCCTCCTatgTCAaactttaataaaattgatttagacaattg 
4_CmR+histag_rev ATGATGAUGGGCCGCAAGCTTtaaaagccagtcattaggcctatc 
4b_Backbone_HIS_fwd ATCATCAUCACCACCACCACCACtaatcaattgaaatggcaattaaac 
5_RND-GFPfr_fwd ataaattaUaaggaggcactcaccATGTCNAARGGAGAAGAACTTTTCACTGG 
6_RND-GFP-fr_rev ATAATTTAUTTTGTAGTTCCTTCG 
7_ TAL_Strep_fwd ATCCACAAUTTGAAAAATAAtctagagagctcaagctttct 
8_ TAL_Strep_rev ATTGTGGAUGGCTCCAGCTTTTAGAACCattgttaatcaggtggtcttttac 
9_ ERMSwap_fwd attgaaUGCTTCAGTTGTCTTATTTCTAGATCT 
10_ERMSwap_rev atctcataUTATTTCCTCCCGTTAAATAATAGATA 
11_ BB-ERM_rev attcaaUaatccctcctctca 
12_ BB-ERM_fwd atatgagaUaatgccgactgt 
13_TALRndlib_fwd ATAAATTAUAAGGAGGCANNNNNNatgAAYACNatcaacgaatatctgagcc 
14_TALRndlib_rev ATAATTTAUTTTGTAGTTCCTTCG 
 
Sequencing oligonucleotides 
3052_AmyE_SeqS_rev TGCCTGAACGAGAAGCTAT 
3051_AmyE_SeqL_rev TATATAAACCATTTAGCACGTAATCA 
2990_pDGseq_rev TGTATCAAGATAAGAAAGAACAAGTTC 
3064_AmyE_SeqL_fwd ATGTTTGCAAAACGATTCA 
3015_pDGseq_fwd CCAATGAGGTTAAGAGTATTCC 
3528_P32_seq_fwd gatatgataagattaatagt 
3529_Sialidase_seq_rev GTTGGGCGGCCGTCGTATGA 
3530_KanR_seq_fwd aagcctgattgggagaaaat 
TalSeq_fwd gattaccattgttcaggcg 
TalSeq_rev acaaaccggactcagcg 
FW_insert_seq actaacctgccccgttagt 
RV insert seq ATTCCTTGGUCCTTTAATTGGTGGACA 
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Abstract 
DNA vectors serve to maintain and select recombinant DNA in cell factories, and as design 
complexity increases, there is a greater need for well-characterized parts and methods for their 
assembly. Standards in synthetic biology are top priority, but standardizing molecular cloning 
contrasts flexibility, and different researchers prefer and master different molecular technologies. 
Here, we describe a new, highly versatile and automatable standard “SEVA linkers” for vector 
exchange. SEVA linkers enable backbone swapping with 20 combinations of classical enzymatic 
restriction/ligation, Gibson isothermal assembly, uracil excision cloning, and a nicking enzyme-
based methodology we term SEVA cloning. SEVA cloning is a simplistic one-tube protocol for 
backbone swapping directly from plasmid stock solutions. We demonstrate the different 
performance of 30 plasmid backbones for small molecule and protein production and obtain more 
than 10-fold improvement from a four-gene biosynthetic pathway and 430-fold improvement with 
a difficult-to-express membrane protein. The standardized linkers and protocols add to the 
Standard European Vectors Architecture (SEVA) resource and are freely available to the synthetic 
biology community. 
 
Keywords: synthetic biology standards, plasmid backbone exchange, standard parts characterization, cell 
factory design 
 
Introduction 
The early steps in engineering of microbial cell factories typically involve a choice of vector for 
gene expression. This vector enables maintenance (replication) of the genetic elements of interest, 
e.g., by containing an origin of replication or elements ensuring transfer to the microbial genome, 
and often includes a selectable trait, in bacteria typically in the form of antibiotic resistance. These 
initial choices can have a major impact on the performance of the cell factory, and balancing these 
factors is imperative to optimize production.1,2 
 
Plasmids are extrachromosomal DNA elements that are nonessential, can replicate autonomously 
and are easily modified in vitro and thus represent an extremely powerful toolbox for molecular 
biology. The number of plasmid molecules in a single cell specifies the amount of gene copies 
available for expression, and this copy number is determined by different genetic elements at the 
origin of replication.3 Toxicity of plasmid-encoded proteins is usually the highest metabolic burden 
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for a production host,4 and gene overexpression is a stress for the organism that needs to cope with 
this metabolic overload and prevent the system’s breakdown.2 Moreover, extra DNA elements and 
gene expression will likely compete with the native DNA for essential resources, e.g., the native 
RNA polymerase.5,6 
 
In a typical laboratory setup, horizontal gene transfer events are selected for with the aid of 
antibiotic resistance genes. Antibiotics either inhibit bacterial cell growth (bacteriostatics) or cause 
bacterial cell death (bactericidals).7 Thus, antibiotic selection is inherently linked to metabolic 
burden, fitness costs and physiological changes 8−11  
 
Most synthetic biology and metabolic engineering projects require a first step of DNA 
assembly,12−14 and with increasingly advanced design requirements, simple methods for genetic 
elements exchange are highly attractive. Struggling to find the best-suited assembly and exchange 
strategies is common among researchers since all of the described DNA cloning methods possess 
different limitations. Moreover, a consensus method- ology is hard to agree on: best exemplified 
with the paradoxical high number of assembly strategies available at the Registry of Standard 
Biological Parts.15 Nevertheless, standardized genetic parts and methods for their assembly are 
very important for continuous progress in the synthetic biology field.16,17 For example, standards 
surely will enable more systematic and reliable approaches to assay the performance and 
robustness of genetic elements. 
 
Here we attempt to address the standardization paradox by designing small multifunctional DNA 
fragments designed to link together genetic elements often used in bacterial cell factories. The 
resulting linkers contain elements enabling continuous reassembly with several of the most 
common DNA assembly methodologies (e.g., restriction enzymes, Gibson assembly and uracil 
excision cloning) and with a new extraordinary simple protocol for plasmid backbone exchange. 
Finally, we demonstrate the usefulness of this resource by systematically comparing bacterial 
production of the membrane protein NarK and the food coloring pigment β-carotene produced 
from a four-gene biosynthetic pathway, each with a total of 30 combinations of origins of 
replication and antibiotic resistance markers. 
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Results and Discussion 
In the Standard European Vector Architecture (SEVA),18,19 different rare restriction sites flank three 
basic genetic elements: (1) antibiotic selection markers, (2) origins of replication and (3) the so-
called cargo that contains the genetic elements necessary for the end-application of the cell factory 
(very often a promoter driving expression of a gene, Figure S1). Importantly, these genetic elements 
have well-defined borders that are useful for parts exchange and a catalogue of all 54 combinations 
of nine origins of replication with six antibiotic resistance markers is available. 
 
To make this great resource compatible with a range of state- of-the-art DNA assembly methods, 
we designed two multi- functional SEVA linker sequences that hosted five and four additional rare 
restriction sites, respectively (PacI, NotI, AscI, SgrDI, MauBI on one side and FseI, Sbf II, MreI, SpeI 
on the other side, Figure 1a). This enables backbone swapping with a total of 20 combinations of 
these enzymes. Additionally, all cargo elements, flanked with these linkers, are easily inserted in 
the existing SEVA system using the outermost PacI and SpeI sites (but violates the SEVA design 
rules by reusing the FseI and AscI sites, Figure S1). The saturation with rare restriction sites means 
that it should always be possible to find a suitable pair of restriction enzymes for backbone 
swapping. In other words this minimizes the consequence of “forbidden sites” in the cargo. 
Moreover, these unique linkers sequences make it possible to design highly specific 
oligonucleotides (for examples see Supporting Information Table S1) that anneal in these regions, 
while hosting features compatible with state-of-the-art DNA assembly methods such as Gibson 
isothermal assembly20 and uracil excision21 (Supporting Information Table S1, Figure S2). Such 
oligonucleotides can be performance benchmarked and kept in the freezer for continuous reuse 
when assembling new parts with these technologies. 
 
Another recently popularized assembly method is Golden Gate cloning.22 One of the biggest 
advantages of Golden Gate cloning is that DNA can be exchanged directly from (compatible) 
plasmid stock solutions with a simple protocol, whereas a drawback is the frequent occurrence of 
the type IIS restriction sites typically used: “forbidden sites”. Inspired by some of the features in 
Golden Gate cloning, we designed an extension to the SEVA linkers enabling backbone exchange 
with a very simple protocol directly from plasmid stocks. Instead of type IIS restriction sites, our 
design uses two pairs of nicking restriction sites (Figure 1a) that together form two different 7 bp 
cohesive ends (Figure 1a and Supporting Information Figure S3). We initially used the Nb.BtsI 
nicking enzyme, but changed to Nt.BbvCI because the recognition site is 7 bp and only occurs 
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rarely in standard sized DNA constructs. Furthermore, because the mutant enzyme only cuts one 
strand, occurrences outside the SEVA linker will probably not affect cloning efficiency 
significantly. This solves the forbidden site issue. 
 
We designed two SEVA-linker-flanked cargo elements, one expressing lacZ and one expressing 
gfp, with different antibiotic selection markers, and checked their ability to recombine by mixing 
the plasmids together with the nicking enzyme and plating on media with the different antibiotics 
(Supporting Information Figure S4). Ultimately, the idea is that a cargo “donor” plasmid should 
be transferred to a backbone “acceptor” plasmid at high efficiency and specificity. To this end, we 
incorporated the toxic ccdB gene23 in the backbone acceptor and selected recombinants by 
transforming constructs into standard (i.e., ccdB-incompatible) cloning strains with the backbone-
defined antibiotic selection (Figure 1a). As an initial proof of concept, we examined gfp flanked by 
the two SEVA linkers in the commercially available pCDF backbone (CloDF13 origin and 
spectinomycin resistance) transferred to an acceptor plasmid containing ccdB in the pACYC 
backbone (p15A origin and chloramphenicol resistance). We then observed fluorescent colonies 
forming on chloramphenicol- containing plates with high efficiency (Figure 1b). Optimization of 
the ratio of donor and acceptor plasmids in the reaction increased efficiency approximately 2-fold, 
whereas adding T4 DNA ligase to the mixture enhanced efficiency more than 10- fold (Figure 1b). 
The optimized and simple protocol is described in detail in the Supporting Information. Notably, 
rather than getting it right the first time, several similar nicking enzyme-based designs were tested 
for efficiency and specificity before we settled on the sequence presented here (see Supporting 
Information Figure S5). 
 
We based our further work on the comprehensive pSEVA collection as a backbone acceptor series. 
By combining five origins of replication (pBBR1: #3, p15A: #6, pSC101: #7, pUC: #8, pBR322/ROP: 
#9) and six antibiotic resistance markers (ampicillin: #1, kanamycin: #2, chloramphenicol: #3, 
spectino- mycin: #4, tetracycline: #5, gentamycin: #6), we created 30 different backbone acceptors 
with the counter-selection marker ccdB flanked by SEVA linkers as the initial cargo. 
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Figure 1. Illustration and optimization of SEVA-linker-based backbone exchange. (a) The cargo, here illustrated 
with a plasmid-encoded gfp, is flanked by two multifunctional linker sequences altogether hosting a total of nine 
rare restriction sites and four Nt.BbvcI nicking enzyme recognition sites (see expanded view). When mixed with 
the Nt.BbvcI enzyme and a backbone acceptor plasmid, hosting the toxic ccdB gene flanked with the same linkers, 
the recombined cargo can be selected on the antibiotic defined by the acceptor backbone. The expanded view of the 
reaction shows all assembly possibilities. (b) Left panel: efficiency of recombination with different ratios of 
backbone acceptor and cargo donor plasmids, and with the addition of T4 DNA ligase to the mixture. Right panel: 
representative picture showing the efficient recombination of a gfp-expressing cargo into a new backbone acceptor 
plasmid. 
 
To assay the performance of our 30 standardized plasmid backbones in two typical, cell 
factory-type experimental settings, we swapped-in the four-gene crtEBIY biosynthetic 
pathway for β-carotene from Pantoea ananatis and the membrane protein-encoding narK-gfp in 
all 30 constructs. crtEBIY is industrially relevant and a convenient model pathway mainly due 
to the simple product output (orange color), but also because the robustness of the phenotype 
 161 
seems sensitive to the cell factory design parameters.24 Indeed, we were unable to obtain 
surviving colonies by swapping the pathway into vectors with the high-copy pUC origin of 
replication and we obtained highly variable phenotypes when T7 polymerase was used to 
drive expression from the construct in comparison with the weaker K1F variant (Figure 2a).24−26 
Overall, we observed a 10-fold difference in the β-carotene product titers, from the lowest to 
the highest performing cell factories (Supporting Information Table S3) and several of the 
combinations showed clear toxicity and population bias effects (e.g., pBR322/ROP in 
combination with chloramphenicol or pSC101 in combination with tetracycline, Figure 2a). In 
contrast, the pBR322/ROP origin in combination with both ampicillin and tetracycline was 
highly performing in both expression strains. With the membrane protein NarK,27 the 
variation in expression yield was even more prominent (Figure 2b); the difference between the 
highest and the lowest performing combination of parts was in this case an impressive 430-
fold (Supporting Information Table S3). Generally, using tetracycline selection, gentamycin 
selection or the high copy pUC origin had a negative impact on narK expression, whereas the 
p15A origin (low copy number) and spectinomycin selection seemed to positively impact the 
expression level. 
 
Comparing the two different test cases, small molecule and protein production, showcases the 
value of a synthetic biology approach (i.e., systematic studies with standardized parts) and 
provides future design guidelines and a toolbox for similar experiments. For example, the high 
copy pUC origin of replication is likely a poor choice for anything but DNA production. The 
negative impact of the tetracycline selection may in contrast only reflect the fact that the 
resistance gene encodes a membrane protein that could compete for factors involved in 
membrane translocation important for production of NarK, and thus may be a particularly 
poor choice for membrane protein production. In many cases we observed clear population 
bias effects by simple visual inspection on agar plates, and the different robustness of the T7- 
and the K1F- based bacterial hosts highlights the value of adding promoter tuning as an extra 
dimension in the cell factory performance screen. These observations could be supported by 
an array of omics studies leading to a highly informed theoretical framework for rational cell 
factory design. 
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Figure 2. Production of β-carotene and the membrane protein NarK with 30 different combinations of origins 
of replication and antibiotic resistance markers. (a) Upper panel: illustration of the cargo with T7 promoter driven 
expression of the four-gene crtEBIY biosynthetic pathway. Lower left panel: colony phenotypes of the crtEBIY cargo 
combined with ampicillin (Ap), kanamycin (Km), chloramphenicol (Cm), spectinomycin/ streptomycin (Sm/Sp), 
tetracycline (Tc) or gentamycin selection; and the pBBR1, p15A, pSC101 or pBR322/ROP origins of replication. All 
30 combinations were transformed into both E. coli NEB5α::T7* (left side) and NEB5α::K1F (right side) hosting two 
different variants of the T7 RNA polymerase. No combinations with the high copy pUC origin of replication yielded 
surviving colonies. Lower right panel: heat map representation of carotenoid levels measured by acetone extraction 
and absorbance at 453 nm on the 24 viable backbones variants in NEB5α::T7* and NEB5α::K1F. (b) Left panel: 
illustration of the NarK-GFP protein (based on the pdb files: 1EMA and 4U4V) and cargo constructs. Middle panel: 
Fluorescence from E. coli BL21 (DE3) transformed with 30 different backbones in combination with the T7-narK-
gfp cargo. Right panel: heat map representation of fluorescence levels quantified in a microplate reader after four 
and 24 h expression. 
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Materials and Methods 
Strains, media and plasmids 
Escherichia coli NEB5α (New England Biolabs, Ipswich, MA, USA) was used for propagation of 
plasmids, backbone swapping optimization and as a general cloning host except when E. coli DB3.1 
(Thermo Fisher Scientific, Invitrogen, Waltham, MA, USA) was used for handling of ccdB-
containing plasmids. NEB5α::T7* and NEB5α::K1F1 were used for β-carotene production. SOC 
media was used as a recovery media after transformation. Bacteria were propagated in Luria-
Bertani (LB) liquid media or agar plates supplemented with ampicillin (100 µg/ml), kanamycin (50 
µg/ml), chloramphenicol (50 µg/ml), spectinomycin (50 µg/ml), tetracycline (10 µg/ml), or 
gentamycin (10 µg/ml) when required. In most cases LB media was used for liquid cultures except 
for carotenoid production assessment that was accomplished in 2×YT media supplemented with 
0.5% glycerol. 
 
Molecular biology reagents 
T4 DNA ligase and restriction enzymes were purchased from Thermo Fischer Scientific (Waltham, 
MA, USA). Nicking enzymes were purchased from New England Biolabs (Ipswich, MA, USA). 
Plasmids were isolated using the QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany). PCR 
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products were purified using a PureLinkTM Quick Gel Extraction and PCR Purification Combo 
Kit (Life Technologies, Foster City, USA). Buffers for PCR and cloning reactions were purchased 
from Agilent Technologies (Santa Clara, CA, USA) and Thermo Fischer Scientific (Wilmington, 
USA). PCR was performed with the proofreading PfuX7 polymerase as previously described.3 
 
Plasmid constructions 
SEVA linker sequences (version #1, see Supporting Information Figure S3) were introduced into 
pACYCDuet-1 and pCDFDuet-1 (for references to plasmids see Supporting Information Table S2) 
by amplifying the backbones with oligonucleotides #1 and #2 (for numbering and sequences of 
oligonucleotides see Supporting Information Table S1), gfp from pETDuet-1-gfp with the 
oligonucleotides #3 and #4 and lacZα from pBluescript II KS (+) with oligonucleotides #5 and #6, 
followed by assembly by uracil excision as described previously.1, 2 This created pACYC-sl1- gfp 
and pCDF-sl1-gfp. 
The ccdB gene was amplified from pOSIP-KT using oligonucleotides #7 and #8 and mixed with a 
pACYC-sl1 fragment obtained from Nb.BtsI-digested pACYC- sl1-gfp creating pACYC-sl1-ccdB 
upon transformation into E. coli. 
pCDF-sl2-gfp was constructed by amplifying the vector backbone and gfp insert from pCDF-sl1-
gfp with oligonucleotides #9 and #10, and #11 and #12, respectively, treating the PCR products with 
Nb.BtsI and transforming the fragments into E. coli. pACYC-sl2-ccdB was similarly obtained by 
combining Nb.BtsI-digested pACYC-sl1-ccdB with a backbone fragment amplified from pACYC-
sl1-ccdB with oligonucleotides #9 and #10. 
pCDF-sl3-gfp and pACYC-sl3-ccdB were created by amplifying the corresponding sl2 versions 
with oligonucleotides #13 and #14, gfp with #15 and #16, and ccdB with #17 and #18, followed by 
Nt.BbvCI-treatment and transformation. 
pCDF-sl4-gfp and pACYC-sl4-ccdB were created by amplifying the corresponding sl2 versions 
with the oligonucleotides #19 and #20, gfp with #21 and #22, and ccdB with #23 and #24 followed 
by uracil excision cloning. 
pSEVAXX-sl3-ccdB series was constructed by combining five origins of replication (pBBR1; #3, 
p15A; #6, pSC101; #7, pUC; #8, pBR322/ROP; #9), prepared by digestion with PacI and PshAI from 
the corresponding parts in the pSEVA collection, and six antibiotic resistance markers (ampicillin; 
#1, kanamycin; #2, chloramphenicol; #3, spectinomycin; #4, tetracycline; #5, gentamycin; #6), 
prepared by digestion with PshAI and SpeI from the corresponding parts in the pSEVA collection, 
with the sl3-ccdB cargo isolated after digestion by PacI and SpeI from pACYC-sl3-ccdB. 
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The β-carotene biosynthetic pathway was introduced into pACYC-sl3 by SEVA cloning (see below) 
after amplifying the crtEBIY operon from pSIJ31B with the oligonucleotides #25 and #26, creating 
pACYC-sl3-T7-crtEBIY. Combining pACYC-sl3-T7-crtEBIY with the pSEVAXX-sl3-ccdB series as 
described below created the pSEVAXX-sl3-T7-crtEBIY series. 
The T7-narK-gfp cargo was amplified from pET28a-narKWTP7-6 using oligonucleotides #29 and 
#30, and mixed with a pSEVAXX-sl3 backbone amplified with oligonucleotides #27 and #28 
followed by uracil excision cloning. Combining the initial pSEVAXX-sl3-T7-narK-gfp clone with 
the pSEVAXX-sl3-ccdB series created the complete pSEVAXX-sl3- T7-narK-gfp series. 
 
Nicking enzyme mediated one-tube backbone exchange (SEVA cloning) 
0.06 pmol of each plasmid were added to a 10 or 20 µl total reaction volume containing CutSmart® 
buffer (New England Biolabs, Ipswich, MA, USA) and five units of Nt.BbvCI. Mixtures were kept 
at 37°C for 1 h, followed by 25°C for 15 min, 10°C for 10 min, then incubation at 0°C using a C1000 
TouchTM Thermal Cycler (Bio-Rad, Hercules, CA, USA). 2.5 U of T4 DNA ligase and buffer were 
added, followed by incubation at room temperature for 15 min and storage on ice prior to 
transformation. 
 
Gibson assembly- and uracil excision-based backbone exchange 
The GFP cargo was PCR amplified from pCDF-sl3-gfp using the oligonucleotides #31 and #32 for 
Gibson assembly and #35 and #36 for uracil excision; and the backbone was amplified from 
pACYC-sl3-ccdB using the oligonucleotides #33 and #34 (Gibson) or #37 and #38 (uracil excision). 
After PCR, DpnI treatment was done at 37°C for 40 min followed by gel purification. Insert and 
vector ratio of 2:1 was applied for both methods. Gibson assembly was performed with 2X Gibson 
Assembly Master Mix (New England Biolabs, Ipswich, MA, USA) following the manufacturer ́s 
instructions. Assembly by uracil excision was as described previously.1, 2 
 
Production and relative quantification of β-carotene 
The NEB5αT7* and NEB5αK1F strains1 were used to compare β-carotene productivity in the 
pSEVA-crtEBIY series. Corresponding strains with the pathway integrated in one copy on the 
genome (NEB5αT7*::EBIY and NEB5αK1F::EBIY) were used as reference strains.1 Cells were 
grown in 2×YT media supplemented with 0.5% glycerol at 30°C for 72 hours with 300 rpm. 1 ml of 
each culture was harvested by centrifugation at 13000 rpm for 5 min. After discarding the 
supernatant, cells were washed once with 1 ml of water. 1 ml of acetone was added and the pellets 
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re- suspended vigorously by vortexing, followed by incubation at 55°C for 20 min at 1000 rpm 
using a tabletop shaker. The remaining cell debris were removed by centrifugation (13000 rpm, 5 
min) and absorbance at 453 nm was measured in a UV- 1600PC spectrophotometer (VWR 
International, Radnor, PA, USA) on 500 µl extract using a quartz cuvette. The equation for 
calculating β-carotene production titers is	"	#	$%& '( 	#	)*+,-	./-	%  where A is the UV/Vis absorbance at 453 
nm and 𝐸)	2')	%  is the specific absorption coefficient (𝐸)	2')	% , β-carotene=2503). 
 
Production and quantification of NarK-GFP 
The pSEVAXX-sl3- T7-narK-gfp series was transformed into BL21 (DE3) (Novagen, Madison, WI, 
USA) using a standard protocol. Overnight cultures were prepared by inoculating a single colony 
in 800 µL of LB liquid media containing the different pSEVA-defined antibiotics (100 µg/ml 
ampicillin; 50 µg/ml kanamycin; 34 µg/ml chloramphenicol; 50 µg/ml spectinomycin; 10 µg/ml 
tetracycline; 10 µg/ml gentamycin) in 96-deep well plates at 37 °C and 300 rpm in an Innova 44 
incubator (Thermo Scientific, Waltham, MA, USA). For expression measurements, overnight 
cultures were back-diluted 1:50 in 3 ml LB media containing the different antibiotics in 24-well 
plates at 37 °C and 300 rpm. When exponential phase (an OD600 of approximately 0.5) was 
reached, expression was induced by addition of 1 mM IPTG and incubated at 25 °C and 300 rpm 
for 2 hours. Subsequently, 1 ml of culture was harvested at 2270 x g for 20 min, resuspended in a 
buffer (50 mM TrisŊHCl (pH 8.0), 200 mM NaCl, and 15 mM EDTA) and incubated for 2 hours at 
room temperature. Fluorescence was measured in a 96-well plate in a SynergyTM Mx plate reader 
(BioTek) (excitation wavelength 485 nm; emission wavelength 512 nm). The amount of protein 
produced was estimated from a GFP standard curve. The standard curve was obtained from 
purified GFP mixed with BL21 (DE3) cells to account for quenching effects. 22 h after induction the 
remaining culture was harvested, resuspended in buffer, incubated for 2 hours and fluorescence 
measured as described above. 
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Figure S1. Illustration of the Standard European Vector Architecture (SEVA) system and the relationship to the 
SEVA linkers and plasmids described here. Left panel: In the original SEVA system, rare restriction sites flank the 
three basic components: origins of replication, antibiotic selection markers and the cargo. This basic design enables 
exchange of the basic components using classical restriction enzyme molecular cloning. Right panel: The new SEVA 
linkers enable simple, one-pot backbone shuffling by introducing two multifunctional linker sequences 
(highlighted in yellow and orange color) flanking the cargo in the SEVA system. In this example, the ccdB 
counterselection marker is the cargo. Any cargo that is flanked by SEVA linkers can be converted to the SEVA 
system by utilizing the PacI and SpeI restriction sites, but also by a range of other molecular cloning technologies 
(see main text). The SEVA linkers violate the basic SEVA design rules by reusing the AscI and FseI sites (highlighted 
in blue and red font). 
 
 
 
 
Figure S2. Demonstration of amplification and reassembly 
of SEVA linker flanked cargo and backbone with Gibson 
assembly and uracil excision cloning. (a) Agarose gel 
showing PCR amplified cargoes and backbones 
compatible with Gibson assembly or uracil excision 
cloning. In the cargo, SEVA linkers flanked a 
transcriptional unit (a leaky Ptrc promoter driving 
expression of gfp). For details on the protocol see Materials 
and Methods. (b) PCR-amplified cargo and backbone was 
reassembled with Gibson and uracil excision cloning and 
plated on agar plates supplemented with the antibiotic 
corresponding to the backbone selection marker. Green 
fluorescent colonies demonstrate the presence of the cargo. 
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Figure S3. Exchange of DNA fragments using four Nt.BbvCI- nicking enzyme- sites in the SEVA linkers. Yellow 
and orange boxes mark the four Nt.BbvCI recognition sites. The two three-nucleotide spacers between the two 
double nicking sites are different from each other, thereby ensuring specificity and directionality in the parts 
exchange. Any cargo (light blue box) of choice can replace the ccdB (red box) counterselection marker. 
 
 
 
 
 
Figure S4. Demonstration of parts exchange 
between two plasmids that contain SEVA linkers. (a) 
Illustration of a gfp expressing SEVA linker cargo in 
a plasmid that confers chloramphenicol resistance, 
mixed with a lacZα expressing SEVA linker cargo in 
a plasmid conferring spectinomycin resistance, 
leading to four different recombinant plasmids. (b) 
Left panel: The two different plasmids were 
transformed into NEB5α and plated on LB agar 
supplemented with X-gal combined with 
spectinomycin or chloramphenicol. Right panel: The 
two plasmids were mixed with the nicking enzyme 
Nb.BtsI, transformed into NEB5α and plated on LB 
X-gal agar. 
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Figure S5. Different types of nicking enzyme-based linkers that were tested for cloning efficiency and accuracy. 
Version #2 outperforms version #1 in simplicity, but the Nb.BtsI-based designs generally performed poorly, 
probably due to the frequent occurrence of the six-nucleotide recognition sites outside the SEVA linkers. Version 
#4 likewise performed poorly, probably because the single-strand overhangs formed by the Nt.BspQI sites were 
too stable. Version #3 clearly outperformed the other designs in terms of cloning efficiency and accuracy and was 
the preferred choice for the SEVA linkers. 
 
Table S1. Oligonucleotides used in this study 
No. NAME SEQUENCE 
1 Duet-sl1-rev ATCGCGAUCACTGCCGCGCGCGCGTCGACGGGCGCGCCGCGGCCGCTTAATTAACAAAATTATTTCTACAGGGGAATTGTTATCCGCTC 
2 Duet-sl1-fwd AGAGCGAUCGCACTCACTGCGGCCGGCCCCTGCAGGCGCCGGCGACTAGTCCTAGGCTGCTGCCACCGCTG 
3 Sl1-PtrcGFP_fwd ATCGCGAUCGCTCTTCATATATCGCGATCACTGCTTGACAATTAATCATCCGGCTCGTATAATG 
4 Sl1-PtrcGFP_rev ATCGCTCUTCATATATCGCGATCACTGCTTATTTGTAGAGCTCATCCATGCCATGTG 
5 Sl1-lacZa_fwd ATCGCGAUCGCTCTTCATATATCGCGATCACTGCACCAGTGGNTCATCTCCAAGCAGTGGTTCGCGCAACGCAATTAATGTGAG 
6 Sl1-lacZa_rev AGTGCGAUCGCTCTTCATATAGTGCGATCACTGCACCAGTGCTACCTCCTGAACCAC 
7 Sl1-ccdB_fwd ATC GCG AUC GCT CTT CAT ATA TCG CGA TCA CTG CTA CTA AAA GCC AGA TAA CAG TAT GCG TAT 
8 Sl1-ccdB_rev AGT GCG AUC GCT CTT CAT ATA GTG CGA TCA CTG CCG GGT TAT TAT ATT CCC CAG AAC ATC AG 
9 Nb.BtsI_SL_F (vector) ATCGCactCACTGCGGCCGGCCCCTG 
10 Nb.BtsI_SL_R (vector) ATCGCgatCACTGCCGCGCGCGCGTC 
11 Nb.BtsI_PtrcGFP_F ATCGCGATCACTGCTTGACAATTAATCATCCGGCTCGTATAATG 
12 Nb.BtsI_PtrcGFP_R AGTGCGATCACTGCTTATTTGTAGAGCTCATCCATGCCATGTG 
13 Nt.BbvCI_V_F GGTCGCCTCAGCGGCCGGCCCCTGCAGGCG 
14 Nt.BbvCI_V_R GGTATCCTCAGCCGCGCGCGCGTCGACGGG 
15 Nt.BbvCI_GFP_F GGATACCTCAGCTTGACAATTAATCATCCGGC 
16 Nt.BbvCI_GFP_R GGCGACCTCAGCTTATTTGTAGAGCTCATCCATGC 
17 Nt.BbvCI_CCDB_F GGATACCTCAGCTACTAAAAGCCAGATAACAGTATGC 
18 Nt.BbvCI_CCDB_R GGCGACCTCAGCCGGGTTATTATATTCCCCAG 
19 Nt.BspQ1_V_R_U AGA AGA GCT CTT CUC GCG CGC GCG TCG ACG GG 
20 Nt.BspQ1_V_F_U  AGAAGAGCGCTCTTCUGGCCGGCCCCTGCAGGCG 
21 Nt.BspQ1_GFP_F_U  AGAAGAGCTCTTCUTTGACAATTAATCATCCGGC 
22 Nt.BspQ1_GFP_R_U  AGA AGA GCG CTC TTC UTT ATT TGT AGA GCT CAT CCA TGC 
23 Nt.BspQ1_ccdB_F_U  AGAAGAGCTCTTCUtactaaaagccagataacagtatgc 
24 Nt.BspQ1_ccdB_R_U  AGA AGA GCG CTC TTC UCG GGT TAT TAT ATT CCC CAG AAC ATC AG 
25 Nt.BbvCI_EBIY_F GGATACCTCAGCGGATCTCGACGCTCTCCC 
26 Nt.BbvCI_EBIY_R GGCGACCTCAGCGATTATGCGG 
27 SL3-backbone_rev AGGTATCCUCAGCCGCGCG 
28 SL3-backbone_fwd AGCTGAGGUCGCCTCAGC 
29 NarK-sl3_fwd AGGATACCUCAGCTAATACGACTCACTATAGGG 
30 NarK-sl3_rev ACCTCAGCUCAGTGGTGGTGG 
31 SL-Gibson_ifwd TTAATTAAGCGGCCGCGGCGCGCCCGTCGA 
32 SL-Gibson_irev ACTAGTCGCCGGCGCCTGCAGGGGCCGGCC 
33 SL-Gibson_bbfwd GGCCGGCCCCTGCAGGCGCCGGCGACTAGT 
34 SL-Gibson_bbrev TCGACGGGCGCGCCGCGGCCGCTTAATTAA 
35 SL3m-Ptrc_U_F AGGATACCUCAGCTTGACAATTAATC 
36 SL3m-GFP_U_R ACCTCAGCUTATTTGTAGAGCTC 
37 pCDF_BB_U_F AGCTGAGGUCGCCTCAGC 
38 pCDF_BB_U_R AGGTATCCUCAGCCGCGCG 
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Table S2. Strains and plasmids used in this study 
Strain/plasmid Property Source/Reference 
Strains   
E. coli NEB5α fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17 
NEB 
E. coli DB3.1 F- gyrA462 endA1 glnV44 Δ(sr1-recA) mcrB mrr hsdS20(rB-, 
mB-) ara14 galK2 lacY1 proA2 rpsL20(Smr) xyl5 Δleu mtl1 
Thermo Fisher 
Scientific 
NEB5α::T7* NEB5α with a T7* RNA polymerase integrated  (1) 
NEB5α::K1F NEB5α with a T7*(K1F) RNA polymerase integrated (1) 
BL21 (DE3) F– ompT gal dcm lon hsdSB(rB- mB-) λ(DE3 [lacI lacUV5-T7 gene 
1 ind1 sam7 nin5]) 
Novagen 
   
Plasmids   
pCDFDuet-1 Cloning and expression vector, SpR Novagen 
pACYCDuet-1 Cloning and expression vector, CmR Novagen 
pETDuet-1-gfp Constitutively expressed GFP, AmpR (1) 
pBluescript II 
KS(+) 
lacZa expressed from lac promoter Agilent Technology 
pCDF-sl1- lacZa  lacZα fragment flanked by SEVA linker ver1, SpR, CloDF13 
origin from pCDFDuet-1  
This study 
pACYC-sl1-gfp gfp flanked by SEVA linker ver1, CmR, p15A origin from 
pACYCDuet-1 
This study 
   
pCDF-sl2-gfp gfp flanked by SEVA linker ver2, SpR, CloDF13 origin from 
pCDFDuet-1 
This study 
pACYC-sl2-ccdB ccdB flanked by SEVA linker ver2, CmR, p15A origin from 
pACYCDuet-1 
This study 
pCDF-sl3- gfp gfp flanked by SEVA linker ver3, SpR, CloDF13 origin from 
pCDFDuet-1 
This study 
pACYC-sl3-ccdB ccdB flanked by SEVA linker ver3, CmR, p15A origin from 
pACYCDuet-1 
This study 
pCDF-sl4- gfp gfp flanked by SEVA linker ver4, SpR, CloDF13 origin from 
pCDFDuet-1 
This study 
pACYC-sl4-ccdB ccdB flanked by SEVA linker ver4, CmR, p15A origin from 
pACYCDuet-1 
This study 
pSIJ31B P. ananatis crtEBIY operon, SpR, CloDF13 origin Unpublished 
pOSIP-KT P21 Integration module, ccdB, KmR, pUC origin  (5) 
pET28a-
narKWTP7-6 P7-6 
narK-gfp with T7 promoter, KmR, pBR322/ROP origin (6) 
pSEVA13-sl3-
ccdB 
ccdB flanked by SEVA linkers, AmpR, pBBR1 origin This study 
pSEVA16-sl3-
ccdB 
ccdB flanked by SEVA linkers, AmpR, p15A origin This study 
pSEVA17-sl3-
ccdB 
ccdB flanked by SEVA linkers, AmpR, pSC101 origin This study 
pSEVA18-sl3-
ccdB 
ccdB flanked by SEVA linkers, AmpR, pUC origin This study 
pSEVA19-sl3-
ccdB 
ccdB flanked by SEVAlinkers, AmpR, pBR322/ROP origin This study 
pSEVA23-sl3-
ccdB 
ccdB flanked by SEVA linkers, KmR, pBBR1 origin This study 
pSEVA26-sl3-
ccdB 
ccdB flanked by SEVA linkers, KmR, p15A origin This study 
pSEVA27-sl3-
ccdB 
ccdB flanked by SEVA linkers, KmR, pSC101 origin This study 
pSEVA28-sl3-
ccdB 
ccdB flanked by SEVA linkers, KmR, pUC origin This study 
pSEVA29-sl3-
ccdB 
ccdB flanked by SEVA linkers, KmR, pBR322/ROP origin This study 
pSEVA33-sl3-
ccdB 
ccdB flanked by SEVA linkers, CmR, pBBR1 origin This study 
pSEVA36-sl3-
ccdB 
ccdB flanked by SEVA linkers, CmR, p15A origin This study 
pSEVA37-sl3-
ccdB 
ccdB flanked by SEVA linkers, CmR, pSC101 origin This study 
pSEVA38-sl3-
ccdB 
ccdB flanked by SEVA linkers, CmR, pUC origin This study 
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pSEVA39-sl3-
ccdB 
ccdB flanked by SEVA linkers, CmR, pBR322/ROP origin This study 
pSEVA43-sl3-
ccdB 
ccdB flanked by SEVA linkers, SpR, pBBR1 origin This study 
pSEVA46-sl3-
ccdB 
ccdB flanked by SEVA linkers, SpR, p15A origin This study 
pSEVA47-sl3-
ccdB 
ccdB flanked by SEVA linkers, SpR, pSC101 origin This study 
pSEVA48-sl3-
ccdB 
ccdB flanked by SEVA linkers, SpR, pUC origin This study 
pSEVA49-sl3-
ccdB 
ccdB flanked by SEVA linkers, SpR, pBR322/ROP origin This study 
pSEVA53-sl3-
ccdB 
ccdB flanked by SEVA linkers, TetR, pBBR1 origin This study 
pSEVA56-sl3-
ccdB 
ccdB flanked by SEVA linkers, TetR, p15A origin This study 
pSEVA57-sl3-
ccdB 
ccdB flanked by SEVA linkers, TetR, pSC101 origin This study 
pSEVA58-sl3-
ccdB 
ccdB flanked by SEVA linkers, TetR, pUC origin This study 
pSEVA59-sl3-
ccdB 
ccdB flanked by SEVA linkers, TetR, pBR322/ROP origin This study 
pSEVA63-sl3-
ccdB 
ccdB flanked by SEVA linkers, GmR, pBBR1 origin This study 
pSEVA66-sl3-
ccdB 
ccdB flanked by SEVA linkers, GmR, p15A origin This study 
pSEVA67-sl3-
ccdB 
ccdB flanked by SEVA linkers, GmR, pSC101 origin This study 
pSEVA68-sl3-
ccdB 
ccdB flanked by SEVA linkers, GmR, pUC origin This study 
pSEVA69-sl3-
ccdB 
ccdB flanked by SEVA linkers, GmR, pBR322/ROP origin This study 
pSEVA13-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, AmpR, pBBR1 origin This study 
pSEVA16-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, AmpR, p15A origin This study 
pSEVA17-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, AmpR, pSC101 origin This study 
pSEVA19-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, AmpR, pBR322/ROP 
origin 
This study 
pSEVA23-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, KmR, pBBR1 origin This study 
pSEVA26-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, KmR, p15A origin This study 
pSEVA27-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, KmR, pSC101 origin This study 
pSEVA29-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, KmR, pBR322/ROP 
origin 
This study 
pSEVA33-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, CmR, pBBR1 origin This study 
pSEVA36-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, CmR, p15A origin This study 
pSEVA37-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, CmR, pSC101 origin This study 
pSEVA39-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, CmR, pBR322/ROP 
origin 
This study 
pSEVA43-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, SpR, pBBR1 origin This study 
pSEVA46-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, SpR, p15A origin This study 
pSEVA47-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, SpR, pSC101 origin This study 
pSEVA49-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, SpR, pBR322/ROP 
origin 
This study 
pSEVA53-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, TetR, pBBR1 origin This study 
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pSEVA56-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, TetR, p15A origin This study 
pSEVA57-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, TetR, pSC101 origin This study 
pSEVA59-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, TetR, pBR322/ROP 
origin 
This study 
pSEVA63-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, GmR, pBBR1 origin This study 
pSEVA66-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, GmR, p15A origin This study 
pSEVA67-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, GmR, pSC101 origin This study 
pSEVA69-sl3-T7-
crtEBIY 
crtEBIY operon flanked by SEVA linkers, GmR, pBR322/ROP 
origin 
This study 
pSEVA13NarK/GF
P 
narK-gfp flanked by SEVA linkers, AmpR, pBBR1 origin This study 
pSEVA16-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, AmpR, p15A origin This study 
pSEVA17-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, AmpR, pSC101 origin This study 
pSEVA18-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, AmpR, pUC origin This study 
pSEVA19-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, AmpR, pBR322/ROP origin This study 
pSEVA23-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, KmR, pBBR1 origin This study 
pSEVA26-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, KmR, p15A origin This study 
pSEVA27-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, KmR, pSC101 origin This study 
pSEVA28-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, KmR, pUC origin This study 
pSEVA29-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, KmR, pBR322/ROP origin This study 
pSEVA33-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, CmR, pBBR1 origin This study 
pSEVA36-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, CmR, p15A origin This study 
pSEVA37-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, CmR, pSC101 origin This study 
pSEVA38-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, CmR, pUC origin This study 
pSEVA39-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, CmR, pBR322/ROP origin This study 
pSEVA43-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, SpR, pBBR1 origin This study 
pSEVA46-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, SpR, p15A origin This study 
pSEVA47-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, SpR, pSC101 origin This study 
pSEVA48-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, SpR, pUC origin This study 
pSEVA49-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, SpR, pBR322/ROP origin This study 
pSEVA53 -sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, TetR, pBBR1 origin This study 
pSEVA56 -sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, TetR, p15A origin This study 
pSEVA57-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, TetR, pSC101 origin This study 
pSEVA58-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, TetR, pUC origin This study 
pSEVA59-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, TetR, pBR322/ROP origin This study 
pSEVA63-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, GmR, pBBR1 origin This study 
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pSEVA66-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, GmR, p15A origin This study 
pSEVA67-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, GmR, pSC101 origin This study 
pSEVA68-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, GmR, pUC origin This study 
pSEVA69-sl3- T7-
narK-gfp 
narK-gfp flanked by SEVA linkers, GmR, pBR322/ROP origin This study 
 
 
Table S3. β-carotene and NarK production overview 
Strain/pSEVA construct Resistance/origin Production (mg/L) 
NEB5α::T7*  /genome 1.29 
NEB5α::T7*::KmR Km/genome 1.30 
13 Amp/pBBR1 0.64 
16 Amp/p15A 1.56 
17 Amp/pSC101 0.54 
19 Amp/pBR322/ROP 3.69 
23 Km/pBBR1 0.97 
26 Km/p15A 1.37 
27 Km/pSC101 0.61 
29 Km/pBR322/ROP 0.38 
33 Cm/pBBR1 1.24 
36 Cm/p15A 1.70 
37 Cm/pSC101 0.63 
39 Cm/pBR322/ROP 0.31 
43 Sp/pBBR1 1.54 
46 Sp/p15A 1.91 
47 Sp/pSC101 1.03 
49 Sp/pBR322/ROP 0.67 
53 Tet/pBBR1 0.95 
56 Tet/p15A 1.51 
57 Tet/pSC101 0.66 
59 Tet/pBR322/ROP 2.69 
63 Gm/pBBR1 1.72 
66 Gm/p15A 3.16 
67 Gm/pSC101 0.51 
69 Gm/pBR322/ROP 0.59 
NEB5α::K1F   
13 Amp/pBBR1 2.58 
16 Amp/p15A 3.15 
17 Amp/pSC101 2.08 
19 Amp/pBR322/ROP 3.03 
23 Km/pBBR1 3.28 
26 Km/p15A 2.72 
27 Km/pSC101 2.33 
29 Km/pBR322/ROP 0.43 
33 Cm/pBBR1 3.46 
36 Cm/p15A 2.97 
37 Cm/pSC101 2.07 
39 Cm/pBR322/ROP 2.36 
43 Sp/pBBR1 3.41 
46 Sp/p15A 3.13 
47 Sp/pSC101 2.11 
49 Sp/pBR322/ROP 1.83 
53 Tet/pBBR1 3.51 
56 Tet/p15A 3.17 
57 Tet/pSC101 1.53 
59 Tet/pBR322/ROP 4.10 
63 Gm/pBBR1 3.31 
66 Gm/p15A 4.15 
67 Gm/pSC101 1.85 
69 Gm/pBR322/ROP 1.73 
BL21 (DE3), 4hr   
13 Amp/pBBR1 9.32 
16 Amp/p15A 11.84 
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17 Amp/pSC101 17.21 
18 Amp/pUC 0.64 
19 Amp/pBR322/ROP 19.43 
23 Km/pBBR1 5.50 
26 Km/p15A 6.26 
27 Km/pSC101 3.49 
28 Km/pUC 0.21 
29 Km/pBR322/ROP 0.54 
33 Cm/pBBR1 8.76 
36 Cm/p15A 10.46 
37 Cm/pSC101 1.70 
38 Cm/pUC 7.13 
39 Cm/pBR322/ROP 10.91 
43 Sp/pBBR1 9.25 
46 Sp/p15A 9.08 
47 Sp/pSC101 11.34 
48 Sp/pUC 11.79 
49 Sp/pBR322/ROP 1.92 
53 Tet/pBBR1 2.48 
56 Tet/p15A 2.28 
57 Tet/pSC101 4.72 
58 Tet/pUC 0.55 
59 Tet/pBR322/ROP 0.70 
63 Gm/pBBR1 2.52 
66 Gm/p15A 5.61 
67 Gm/pSC101 2.37 
68 Gm/pUC 1.39 
69 Gm/pBR322/ROP 3.77 
BL21 (DE3), 24hr   
13 Amp/pBBR1 24.29 
16 Amp/p15A 26.68 
17 Amp/pSC101 36.69 
18 Amp/pUC 0.95 
19 Amp/pBR322/ROP 21.08 
23 Km/pBBR1 15.94 
26 Km/p15A 35.15 
27 Km/pSC101 11.36 
28 Km/pUC 0.47 
29 Km/pBR322/ROP 0.72 
33 Cm/pBBR1 22.26 
36 Cm/p15A 34.44 
37 Cm/pSC101 2.71 
38 Cm/pUC 0.88 
39 Cm/pBR322/ROP 42.22 
43 Sp/pBBR1 91.58 
46 Sp/p15A 78.48 
47 Sp/pSC101 32.66 
48 Sp/pUC 57.18 
49 Sp/pBR322/ROP 3.16 
53 Tet/pBBR1 9.63 
56 Tet/p15A 9.29 
57 Tet/pSC101 27.03 
58 Tet/pUC 0.75 
59 Tet/pBR322/ROP 0.96 
63 Gm/pBBR1 35.26 
66 Gm/p15A 25.26 
67 Gm/pSC101 5.80 
68 Gm/pUC 5.96 
69 Gm/pBR322/ROP 23.14 
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Appendix 1. Application of TIR optimization and selection for 
biosynthetic production pathway 
 
 
Increased production of L-serine from an optimized synthetic operon in E. coli. (A) Glycolytic 3-phospho-
glycerate (3PG) is converted in three steps into L-serine. SerA catalyzes the oxidation of 3PG to 3-phosphohydroxy 
pyruvate (3PHP). SerC converts 3PHP into 3-Phosphoserine (3PS). SerB catalyzes the hydrolysis of 3PS. (B) 
Assembly of SerACB in a synthetic operon. Start and stop codons are indicated in green and red, respectively. The 
Shine-Dalgarno sequence is marked in orange. (C) KM values for SerA, SerB and SerC. Data was taken from the 
Sabio-RK database. SerA conducts the rate-limiting step. (D) SerAmut (feedback inhibition removed) was taken 
from the synthetic operon and then translationally coupled to the ampicillin resistance gene (bla). Sequence 
variation was introduced (for more details, see Chapter 3.3.4) (NNNNNNATGN*N*N*N*N*N*) and optimized 
variants selected on increasing concentrations of ampicillin. Hereafter, the biosynthetic pathway for L-serine was 
re-assembled in an operon with the optimized SerAmut as the first gene (serAmut-opt-serCB). (E) L-serine 
production was measured over time for the assembled synthetic operon (grey) and the operon with an optimized 
serAmut TIR (blue). L-serine production was measured after 3, 4, 6, 9 and 23 hours. (F) Endpoint L-serine production 
was compared. Optimization of SerAmut increased production titers from 0.13 g/L to 0.4 g/L, a 3-fold improvement. 
(G) In a proteomic analysis, expression levels of the three pathway genes in the original operon and in the optimized 
operon were compared. Optimized translation of the first gene, serA (dark grey), resulted in elevated expression of 
the second gene, serC (grey) and also in elevated expression of the third gene, serB (light grey). Data is derived from 
a manuscript in preparation, which is not included as an article in this thesis. 
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Appendix 2. Application of TIR optimization and selection on 
the genome of E. coli 
 
 
 
Optimized production of GFP in genome-based expression libraries in E. coli (A) The gene encoding the green 
fluorescent protein GFP (green) was translationally coupled with the bla gene (red). For this reason, hp-bla was 
integrated down stream of genomically encoded gfp using CRISPR/Cas9 mediated λ–Red recombineering. 
Subsequently an expression library was constructed. Expression was controlled by a constitutive promoter (PJ23100). 
(B) A TIR library (NNNNNNATGN*N*N*N*N*N*) (for more details, see Chapter 3.3.4) was constructed with 
CRISPR/Cas9-mediated MAGE and 96 clones were assayed for their GFP levels to assure that sequence variation 
in the translation initiation region on the genome leads to differences in expression levels. (C) The PJ23100-GFP TIR 
library was grown with different ampicillin concentrations on agar plates. Seven individual colonies were picked 
from each plate and expression levels were estimated by fluorescence. (D) The library constructed with 
clonetegration was grown with different ampicillin concentrations directly in liquid culture. Expression levels of 
the different populations were assayed by flow cytometry. (E) A TIR library of gfp-hp-bla under control of an IPTG 
inducible promoter (Ptrc) was assembled in pOSIP-KT and integrated into the genome. High expressing variants 
were then selected in liquid cultures with increasing ampicillin concentrations. Data is derived from the patent 
application EP17186000.0. 
 
